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Abstract 
Discovering Novel Regulators of Nucleolar Form and Function 
Lisa Ogawa McLean 
2021 
 
Nucleoli are dynamic nuclear condensates in eukaryotic cells that originate 
through ribosome biogenesis at loci that harbor the ribosomal DNA. These loci are 
known as nucleolar organizer regions and there are 10 in a human diploid genome. While 
there are 10 nucleolar organizer regions however, the number of nucleoli observed in 
cells is variable. Furthermore, changes in number are associated with disease, with 
increased numbers and size common in aggressive cancers. In the near-diploid human 
breast epithelial cell line, MCF10A, the most frequently observed number of nucleoli is 
2-3 per cell. While ribosome biogenesis is an essential biological process that is common 
among all life forms, studies that elaborate on the complexities of ribosome biogenesis in 
higher eukaryotes, like humans, are few. In this dissertation, to identify novel regulators 
of ribosome biogenesis in higher eukaryotes, I used quantitative imaging of MCF10A 
cells to perform a high-throughput siRNA screen for proteins that, when depleted, 
increase the percentage of nuclei with ≥5 nucleoli. Unexpectedly, this screening approach 
led to the identification of proteins associated with the cell cycle. Functional analysis on a 
subset of hits further revealed not only proteins required for progression through S and 
G2/M phase, but also proteins required explicitly for the regulation of RNA polymerase I 
transcription and protein synthesis. Thus, results from this screen for increased nucleolar 
number highlight the significance of the nucleolus in human cell cycle regulation, linking 
RNA polymerase I transcription to cell cycle progression.  
ii 
In this dissertation, I also applied this high-throughput screening approach to 
cancer drug discovery. Because ribosome biogenesis is essential for cell growth and is 
linked to the pathogenesis of cancer, targeting the nucleolus has become an attractive 
target for the development of novel therapies. Screening a library of ~4,000 FDA-
approved drugs revealed over 100 compounds that regulate nucleolar number, with 
antineoplastic agents being the most common identified. Expanding the search to a 
library of ~25,000 novel, synthetic compounds also revealed additional regulators of 
nucleolar number that are structurally distinct from the FDA-approved drugs and harbor 
promise as putative new cancer therapies. The discoveries described herein broaden our 
understanding of nucleolar biology in higher eukaryotes and will provide a foundation for 





















Presented to the Faculty of the Graduate School 
of 
Yale University 
In Candidacy for the Degree of 
















Lisa Ogawa McLean 
 
 















© 2021 by Lisa Ogawa McLean 





Table of Contents Page 
 
Abstract ............................................................................................................................... i 
Title.................................................................................................................................... iii 
List of Figures and Tables ............................................................................................. viii 
List of Abbreviations ....................................................................................................... xi 
 
Chapter 1: Ribosome biogenesis, the nucleolus, and disease .........................................1 
Introduction ..........................................................................................................................2 
Nucleolar assembly and the cell cycle .................................................................................6 
Nucleolar dynamics during mitosis .........................................................................7 
Liquid-liquid phase separation in nucleolar assembly .............................................9 
The nucleolar response to cellular stress ...........................................................................13 
Crosstalk between the nucleolus and the DNA damage response .........................14 
Ribosome biogenesis and disease ......................................................................................22 
Ribosomopathies ....................................................................................................22 
Aging and related diseases .....................................................................................28 
The nucleolus and cancer .......................................................................................33 
 
Chapter 2: Genome-wide RNAi screen for increased nucleolar number reveals 
regulators of cell cycle progression ................................................................................37 
Introduction ........................................................................................................................38 
Results ................................................................................................................................40 
 siRNA screen for increased nucleolar number reveals 113 hits ............................40   
Bioinformatic analysis reveals a unique subset of proteins ...................................47 
Screen validation by oligonucleotide deconvolution .............................................58 
Nuclear area is significantly larger in nuclei with ≥5 nucleoli ..............................74 
 Cell cycle analysis reveals proteins required for S and G2/M phase progression .83 
 Inhibition of DNA replication and mitosis increase nucleolar number .................94 
Discussion ..........................................................................................................................97 
Materials and Methods .....................................................................................................102 
 




Rationale for the selection of hits ........................................................................112 
72 hr depletion by siRNA pools yields effective knockdown of hits ..................112 
11/14 screen hits are required for RNA polymerase I transcription ....................115 
1/14 screen hits are required for pre-rRNA processing .......................................118 
 13/14 screen hits are required for global protein synthesis ..................................128 
 Depletion of 2/14 screen hits results in p53 stabilization ....................................132 
Discussion ........................................................................................................................136 
Materials and Methods .....................................................................................................139 
 
vi 
Chapter 4: High-throughput screen for nucleolar-targeted cancer therapies reveals 
small molecule regulators of nucleolar number ..........................................................144 
Introduction ......................................................................................................................145 
Results ..............................................................................................................................148 
Identification of small molecule positive controls for high-throughput screening
..........................................................................................................................................148 
 Pilot screen of FDA-approved drugs revealed 140 compounds ..........................157 
 Bioinformatic analysis of screen hits reveals known cancer therapeutics ...........167 
 Screen of synthetic library of drug-like small molecules identified 234 hits ......174 
 Re-screening revealed 185 compounds high confidence hits ..............................182 
 Cluster analysis reveals diverse structures among the high confidence hits .......188 
Discussion ........................................................................................................................192 
Materials and Methods .....................................................................................................196 
 
Chapter 5: Perspectives and Future Directions ..........................................................201 
Introduction ......................................................................................................................202 
Increased nucleolar number reflects changes in RNAPI transcription ............................203 
What mechanism underlies the increase in nucleolar number? .......................................220 
What mechanism underlies the increased nucleolar number observed when DNA 
replication, recombination, and repair factors are depleted? ..............................223 
What mechanism underlies the increased nucleolar number observed when 
mitosis factors are depleted? ..............................................................................229 




Appendix I: DNA repair proteins that localize to the nucleolus ...............................260 
 
Appendix II: The 113 high confidence screen hits that, when depleted, caused an 
increase in the percentage of nuclei with ≥5 nucleoli..................................................269 
 
Appendix III: Cell cycle analysis of screen hits selected for validation by 
oligonucleotide deconvolution. ......................................................................................274 
 
Appendix IV: Effect on nucleolar number of 25 candidate compounds screened in 
positive control search for a high-throughput screen .................................................290  
 
Appendix V: The 110 FDA-approved drugs that caused a decrease in nucleolar 
number ............................................................................................................................300 
 
Appendix VI: The 30 FDA-approved drugs that caused an increase in nucleolar 
number ............................................................................................................................311 
 
Appendix VII: The 234 synthetic, drug-like compounds that yielded either an 
increase or decrease in nucleolar number ...................................................................315 
 
vii 
Appendix VIII: The 185 high confidence compounds that regulate nucleolar 
number from both the FDA-approved drug screen and screen of synthetic, drug-like 
compounds ......................................................................................................................327 
 




List of Figures and Tables Page 
 
Figures for Chapter 1 
1-1. Ribosome biogenesis is a complex, stepwise and modular process that 
initiates in the membraneless nuclear organelle called the nucleolus..........5 
1-2. Nucleolar dynamics during mitosis ...........................................................12 
1-3. Nucleolar response to DNA damage ..........................................................20 
1-4. Tissue specific clinical manifestation of ribosomopathies ........................27 
1-5. A working model for the association between the nucleolus and aging ....32 
 
Tables for Chapter 1 
1-1. Human nucleolar proteomes include proteins involved in DNA repair ....19 
 
Figures for Chapter 2 
2-1. High-content, genome-wide siRNA screen in human MCF10A cells 
revealed 113 hits that increase the percentage of nuclei with ≥5 nucleoli. 43 
2-2. Representative hits showing an increase in nuclei with ≥5 nucleoli .........45 
2-3. Bioinformatic analysis on the 113 hits reveals a unique set of proteins 
required for maintaining normal nucleolar number ...................................53 
2-4. Nuclear area is significantly greater in nuclei with ≥5 nucleoli ................75 
2-5. Cell cycle analysis reveals that hits are required for progression through 
either S or G2/M phase ..............................................................................87 
2-6.  Atypical annular and semi-annular nuclei were counted both as one and 
more than one nucleus, potentially skewing estimates of nucleolar number 
per nucleus .................................................................................................90 
2-7. Atypical “stretched” nucleoli in some cases led to an overestimate of 
nucleolar number per nucleus ....................................................................91 
2-8. The observed increase in nucleolar number (NPE) is greater when 
restricting analysis to cells in G2/M phase ................................................92 
2-9. Inhibition of mitosis and DNA replication increase the percentage of 
nuclei with ≥5 nucleoli ...............................................................................96 
2-10. Northern blot analysis of pre-rRNA intermediates of MDN1 depletion by 
the pool and each individual siRNA revealed the expected large subunit 
(LSU) processing defect in all conditions ................................................106 
 
Tables for Chapter 2 
2-1. One-third (38/113) of the hits identified by increased nucleolar number in 
MCF10A cells are conserved to the yeast, Saccharomyces cerevisiae .....48 
2-2. Molecular and Cellular Function core analysis in the Ingenuity Pathway 
Analysis software (IPA; Qiagen) revealed a significant association of the 
113 hits with 23 categories ........................................................................55 
2-3. High-confidence screen hits validated by oligonucleotide deconvolution 61 
2-4. Oligonucleotide deconvolution of 20 screen hits supports validity of the 
screen approach and the identification of a unique subset of proteins ......67 
ix 
2-5. Overlap of high confidence screen hits with proteins identified in other 
screens for regulators of ribosome biogenesis reveals a unique subset of 
proteins .......................................................................................................73 
2-6. Nuclear area analysis of screen hit depletions comparing nuclei with 0-4 
nucleoli to nuclei with ≥5 nucleoli .............................................................77 
2-7. Cell cycle profiling of screen hits in bold in Table 2-3 by pooled depletion 
validate hits with G2/M phase defects .......................................................89 
2-8. ≥5 nucleoli per nucleus normalized percent effect (NPE) is greater when 
considering cells in G2/M phase only ........................................................93 
 
Figures for Chapter 3 
3-1. 72 hr depletion using siRNA pools yields effective mRNA knockdown of 
hits ............................................................................................................114 
3-2. Depletion of the selected hits reveal 11/14 significantly decrease or 
increase RNAPI transcription ..................................................................117 
3-3. Pre-rRNA processing diagram labeled with the oligonucleotide probes 
used to detect pre-rRNA intermediates ....................................................121 
3-4. Qualitative analysis of pre-rRNA intermediates reveals no obvious pre-
rRNA processing defects among the 14 selected hits ..............................122 
3-5. Quantitative analysis of the northern blots of nucleolar hits reveals 
MDN1-depletion significantly affects processing of the 12S pre-rRNA.123 
3-6. Quantitative analysis of the northern blots of non-nucleolar hits reveals 
pre-rRNA processing is not impacted ......................................................125 
3-7. Quantitative analysis of pre-rRNA intermediates relative to the 7SL RNA 
loading control reveals a general trending decrease in overall levels of pre-
rRNA intermediates .................................................................................126 
3-8. Global protein synthesis was significantly decreased upon depletion of 
13/14 of the selected screen hits ..............................................................130 
3-9. Depletion of only 2 hits results in the stabilization of the tumor suppressor 
protein, p53 ..............................................................................................133   
 
Tables for Chapter 3 
 
3-1. Summary of discoveries associated with nucleolar function upon depletion 
of a subset of screen hits, and the screen positive control, KIF11 ...........135 
 
Figures for Chapter 4 
4-1. High-throughput screen of FDA-approved drugs revealed 110 compounds 
(2.8%) that caused a decreased in nucleolar number ...............................160 
4-2. High-throughput screen of FDA-approved drugs revealed 30 compounds 
(0.8%) that caused an increase in nucleolar number ................................164 
4-3. Antineoplastic drugs were the most frequently identified compounds 
among the FDA-approved drugs that regulate nucleolar number ............170 
4-4. Several common molecular targets were identified among the FDA-
approved drugs that regulate nucleolar number .......................................172 
x 
4-5. High-throughput screen of a synthetic library of drug-like compounds 
identified 202 hits that decrease nucleolar number ..................................178 
4-6. High-throughput screen of a synthetic library of drug-like compounds 
identified 32 hits that increase nucleolar number ....................................180 
 
Tables for Chapter 4 
4-1.  Candidate compounds screened in positive control search for a high-
throughput screen to identify small molecule regulators of nucleolar 
number .....................................................................................................151 
4-2.  Screen statistics for re-screened one nucleolus per nucleus candidates ..155 
4-3.  Screen statistics for re-screened ≥5 nucleoli per nucleus candidates ......156 
4-4. Compounds identified more than once in the screen for decreased 
nucleolar number. ....................................................................................162 
4-5.  Comparison to other screens for small molecule inhibitors of ribosome 
biogenesis .................................................................................................166 
4-6. Summary statistics of candidate positive controls for increased nucleolar 
number .....................................................................................................177 
4-7.  Designated thresholds to identify hits in the validation re-screening assays
..................................................................................................................186 
4-8. Number of high confidence hits identified by re-screening all hits in 
duplicate and applying reproducibility and viability filters .....................187 
4-9. Number of compound clusters identified among the high confidence hits 
using different structure similarity thresholds .........................................191 
 
Figures for Chapter 5 
5-1.  Screen hit classification by protein class reveals several proteins involved 
in nucleic acid metabolism and transcriptional regulation ......................208 
5-2. Interaction network of high confidence screen hits that, when depleted, 
cause an increase in nucleolar number .....................................................218 
5-3. Model illustrating our current understanding of increased nucleolar 
number based on discoveries reported in this thesis ................................221 
5-4. Screen hits may be required for maintaining genome stability at the 
replication fork .........................................................................................227 
5-5. Screen hits may be required for the re-initiation of RNAPI transcription 
during mitosis...........................................................................................232 
 
Tables for Chapter 5 
5-1. Screen hits identified as nucleic acid metabolism proteins (PC00171) 
using the PANTHER classification system by protein class ...................210 
5-2. Screen hits identified as gene-specific transcription regulators (PC00264) 
using the PANTHER classification system by protein class ...................213 
5-3. Expanded summary of discoveries on the subset of screen hits that cause 
an increase in nucleolar number ..............................................................222 
5-4. Screen hits identified at the replication fork and as substrates of ATM and 
ATR kinases .............................................................................................228 
 
xi 
List of Abbreviations 
 
Abbreviation Meaning 
rRNA Ribosomal RNA 
rDNA Ribosomal DNA 
NOR Nucleolar organizer region 
RNAPI RNA polymerase I 
Pre-rRNA Precursor ribosomal RNA 
SSU Small subunit of the ribosome (40S) 
LSU Large subunit of the ribosome (60S) 
snoRNA Small nucleolar RNA 
r-protein Ribosomal protein 
FC Fibrillar center 
DFC Dense fibrillar component 
GC Granular component 
siRNA Small interfering RNA 
ETS External transcribed spacer  
ITS Internal transcribed spacer 
Chr Chromosome 
AMD Actinomycin D 
PNB Prenucleolar body 
IDR Intrinsically disordered region 
LLPS Liquid-liquid phase separation 
mRNA Messenger RNA 
snRNA Small nuclear RNA 
5S-RNP 5S ribosomal RNA ribonucleoprotein 
NOPdb Nucleolar Proteome database 
GO Gene Ontology 
NHEJ Non-homologous end joining 
BER Base excision repair 
HR Homologous recombination 
DBA Diamond-Blackfan anemia 
SDS Shwachman-Diamond syndrome 
DC Dyskeratosis congenita 
TCS Treacher Collins syndrome 
HGPS Hutchinson-Gilford progeria syndrome 
WS Werner syndrome 
CS Cockayne syndrome 
BS Bloom syndrome 
AD Alzheimer’s disease 
PD Parkinson’s disease 
MDS Myelodysplastic syndrome 
AML Acute myeloid leukemia 
RNAi RNA interference 
PE Percent effect 



















The nucleolus has fascinated scientists since it was first observed in the eighteenth 
century by bright-field microscopy. While scientists had studied this “nucleus within a 
nucleus” throughout the nineteenth century, these studies were largely observational and 
the function of this discernible nuclear body remained a mystery until the mid-1900s 
(Montgomery Jr., 1898; Pederson, 2011; Raška et al., 2006). An early discovery that 
contributed to the advancement of our current understanding of nucleolar function was 
that the nucleolus is associated with a specific chromosomal site (McClintock, 1934). It 
was not until after the discovery of the ribosome in the 1950s (Palade 1955), however, 
that the function of the nucleolus was finally ascertained. Here, several studies 
contributed to this landmark discovery, including one that found that Xenopus embryos 
lacking a nucleolus also failed to synthesize ribosomal RNA [rRNA; (Brown and 
Gurdon, 1964)]. Other studies concluded that RNA in the nucleolus was identical to the 
rRNA in the cytoplasm and hybridized specifically to repeat DNA loci within the 
nucleolus (Birnstiel et al., 1963; Chipchase and Birnstiel, 1963; Ritossa and Spiegelman, 
1965). Thus, these discoveries and others during this same period began the decades of 
research that have gone towards understanding how ribosomes are synthesized within the 
eukaryotic nucleolus (Pederson, 2011; Raška et al., 2006). Today, it is well-established 
that the nucleolus is a dynamic, subnuclear compartment in which the essential process of 
ribosome biogenesis takes place.  
Ribosome biogenesis is a modular process in which the ribosome, a megadalton 
cytoplasmic ribozyme, is synthesized and assembled as two distinct subunits comprised 
of RNA and protein. In eukaryotic organisms, the biogenesis of ribosomes initiates in 
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large membraneless nuclear organelles known as nucleoli (Figure 1-1). Nucleoli form 
around tandemly arrayed ribosomal DNA (rDNA) loci, also known as nucleolar organizer 
regions (NOR), upon initiation of transcription by RNA polymerase I (RNAPI) 
(Bersaglieri and Santoro, 2019; Grob et al., 2014; Hernandez-Verdun, 2011; McClintock, 
1934; Potapova and Gerton, 2019). In mammals, the products of RNAPI transcription are 
precursor rRNAs (pre-rRNA) that harbor 3 of the 4 mature rRNA species (18S, 5.8S, and 
28S), along with external and internal transcribed spacer sequences that are removed by 
numerous accessory factors (Aubert et al., 2018; Henras et al., 2015). The 18S is 
assembled into the small subunit of the ribosome (SSU; 40S) and the 5.8S and 28S are 
assembled into the large subunit of the ribosome (LSU; 60S), along with the RNA 
polymerase III-transcribed 5S rRNA from an extra-nucleolar locus. Additionally, pre-
rRNAs undergo nucleotide modification guided by small nucleolar RNAs (snoRNA) and 
subunit assembly with the ~80 RNA polymerase II-transcribed SSU and LSU ribosomal 
proteins [r-proteins; (Bassler and Hurt, 2019; Kiss, 2002)]. As a consequence of these 
functions, nucleoli exhibit a tripartite substructure when observed by electron microscopy 
comprising a (1) fibrillar center (FC), (2) dense fibrillar component (DFC), and a (3) 
granular component (GC), each associated with different steps in ribosome biogenesis 
(Brinkley 1965; Pederson, 2011; Sugihara and Yasuzumi, 1970). Thus, while scientists 
have observed and studied this large and charismatic organelle for centuries, advances in 
microscopy and the development of molecular tools have led to a comprehensive 
understanding of nucleolar form and function, and continues to reveal novel complexities 
of ribosome biogenesis and its connection to human disease. 
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This dissertation will focus on several novel discoveries I have made surrounding 
nucleolar form and function in higher eukaryotes. The nucleolar function of ribosome 
biogenesis is an essential biological process that is common among all life forms and can 
therefore be studied in any number of model systems. As such, many of the early studies 
to define the process and factors involved were carried out in the single-celled budding 
yeast, Saccharomyces cerevisiae (Woolford and Baserga, 2013). While studies in S. 
cerevisiae have established a solid foundation of how ribosomes are synthesized in 
eukaryotic organisms, they are unable to probe any added layers of regulation that may 
occur in more complex, multicellular organisms, like humans. Here, I asked whether 
novel factors governing ribosome biogenesis could be identified by investigating 
regulators of nucleolar number in the human breast epithelial cell line, MCF10A. In 
Chapter 1, I provide the necessary background for the research presented in the remaining 
chapters. In Chapter 2, I report on the results from a genome-wide small interfering RNA 
(siRNA) screen that was carried out to identify proteins that, when depleted, cause an 
increase in the number of nucleoli per nucleus. In Chapter 3, I tested several proteins 
identified in the siRNA screen for functional roles in ribosome biogenesis. In Chapter 4, I 
adapted our screening approach to screen for small molecule regulators of nucleolar 
number and to identify putative new nucleolus-targeting drugs for the treatment of 
cancer. In Chapter 5, I conclude by sharing my current perspective on the field of 
nucleolar biology and ribosome biogenesis and suggest future research directions 
stemming from this dissertation. Some of the text, tables and figures that appear in this 
dissertation have been published in (Farley-Barnes* and Ogawa* et al., 2019; Ogawa and 




Figure 1-1. Ribosome biogenesis is a complex, stepwise and modular process that 
initiates in the membraneless nuclear organelle called the nucleolus. Previously published 
in (Ogawa and Baserga, 2017). (Left) Flow chart of the general steps of ribosome 
biogenesis. (Right) Simplified schematic of ribosome biogenesis. Ribosome biogenesis 
initiates with the transcription of the precursor-ribosomal RNA (rRNA) by RNAPI from 
an array of tandemly repeated rDNA loci. Following transcription, the pre-rRNA 
undergoes processing to release the mature rRNAs (18S; 5.8S; 28S). The 18S is 
assembled into the small subunit (SSU; 40S) of the ribosome, and the 5.8S and 28S are 
assembled into the large subunit (LSU; 60S) of the ribosome. Additionally, nucleotide 
modification, assembly with ribosomal proteins (r-proteins) and the 5S rRNA, and rapid 
nuclear export occur. Final maturation of the SSU and LSU occur in the cytoplasm, 
where they join on messenger RNA to perform their function in translation. Blue=SSU; 
Orange=LSU. Small circles=r-proteins. 5’ETS, ITS1, ITS2, and 3’ETS=transcribed 
spacer sequences in the precursor-rRNA. Black ball and sticks=nucleotide modifications.  
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Nucleolar assembly and the cell cycle 
The nucleolus is a nuclear organelle “formed by the act of building a ribosome 
(Mélèse and Xue, 1995).” In humans, nucleoli arise from the tandemly arrayed rDNA 
loci that are present on the short arms (p arms) of the 5 human acrocentric chromosomes 
[chr 13-15, 21 and 22; (Floutsakou et al., 2013; Henderson et al., 1972). Although highly 
variable, approximately 300-400 copies of the ~45 kb rDNA locus are present in a human 
diploid cell (Gibbons et al., 2015; Gonzalez and Sylvester, 1995; McStay and Grummt, 
2008; Schmickel, 1973). Interestingly, however, only around 50% of these loci are 
actively transcribed (Conconi et al., 1989). These sites of rDNA arrays are aptly named 
nucleolar organizer regions [NORs; (McClintock, 1934), and while there are 10 NORs in 
a human diploid cell, studies in diverse model systems reveal that the actual number of 
nucleoli per cell varies. Some of the variability in nucleolar number may be dependent on 
cell cycle stage (Anastassova-Kristeva, 1977). A more recent survey, however, in 
populations of asynchronized cells reveals that the average number of nucleoli also 
differs depending on the cell line observed (Farley et al., 2015). Indeed, while not all 
NORs may be competent or actively transcribed by RNAPI (Roussel et al., 1996), it is 
also known that nucleoli fuse and will often comprise multiple NORs (Anastassova-
Kristeva, 1977; Floutsakou et al., 2013; Savino et al., 2001; van Sluis et al., 2016). 
Additionally, a recent study also suggests that not all acrocentric chromosomes may 
actually harbor rDNA (van Sluis et al., 2020). These data thus complicate the 
reconciliation of the number of NORs with the observed number of nucleoli. Taken 
together, the nucleolus is a dynamic host to the rDNA loci and embodies a complexity 
that is best highlighted by the coordinated remodeling of nucleoli during mitosis.   
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Nucleolar dynamics during mitosis 
The nucleolus disassembles and reassembles every mitosis. Since Barbara 
McClintock first observed the disappearance of chromosomally-tethered nucleoli in late 
prophase and their re-emergence in telophase [Figure 1-2; (McClintock, 1934)], efforts to 
understand the mechanisms underlying these dynamic changes have been made. It is now 
well-established that the breakdown and reformation of nucleoli is a highly ordered 
process that establishes reservoirs of pre-rRNA and processing factors to be recruited to 
competent NORs following mitosis (Hernandez-Verdun, 2011). First hints that nucleolar 
formation did not require de novo transcription of the rDNA came from studies in the 
1970s that observed nucleolar assembly upon mitotic exit even in the presence of the 
RNAPI inhibitor, actinomycin D [AMD; (Phillips and Phillips, 1973; Phillips, 1972)]. 
Later research elaborated on these early discoveries and observed, beginning in prophase, 
the ordered relocation of pre-rRNA and processing factors to the chromosome periphery 
that then migrates with the chromosomes during anaphase [Figure 1-2; (Gautier et al., 
1992; Savino et al., 2001)]. A recent high-throughput survey to define the nucleolar 
proteins localized to the mitotic perichromosomal compartment identified a total of 65 
such proteins (Stenström et al., 2020). Furthermore, it has recently been discovered that 
pre-rRNA localization to the perichromosomal compartment is dependent on the marker 
of proliferation, Ki67 (Hayashi et al., 2017). In telophase, nucleolar proteins at the 
chromosomal periphery condense to form prenucleolar bodies (PNBs) from which 
ribosome biogenesis factors are then recruited to the competent NORs where, with early 
processing factors and pre-rRNA, promote nascent nucleolar reassembly (Muro et al., 
2010). Finally, in early G1, the nascent nucleoli fuse, which leads to nucleoli that are 
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comprised of multiple NORs, both active and inactive (Anastassova-Kristeva, 1977; 
Savino et al., 2001; Sullivan et al., 2001). Nucleolar disassembly and reassembly during 
mitosis is therefore a complex and highly ordered processes that requires the coordination 
of numerous factors to successfully propagate functional nucleoli from one generation of 
cells to the next.  
 Nucleolar breakdown and reassembly, however, does not occur in a vacuum and 
requires coordination with the cell cycle by cell cycle regulators. Beginning in prophase, 
activation of the CDK1-cyclin B kinase leads to the inhibition of RNAPI transcription, 
which coincides with the disappearance of nucleoli [Figure 1-2; (Sirri  et al., 2002)]. The 
repression of RNAPI likely occurs in part through phosphorylation of selectivity factor 1 
(SL1), which impairs association with upstream binding transcription factor (UBTF) and 
the formation of the RNAPI pre-initiation complex (Heix et al., 1998; Kuhn et al., 1998). 
RNAPI transcriptional repression is then reversed in anaphase through the inhibition of 
CDK1-cyclin B activity by PP1 phosphatases, which allows for nucleolar assembly to 
initiate by telophase (Heix et al., 1998; Sirri et al., 2000). Together, these data are 
consistent with the observations that nucleolar formation requires transcription by 
RNAPI, even though initial assembly is driven by the recruitment of early processing 
factors and PNBs at mitotic exit (Dousset et al., 2000). Furthermore, essential to the re-
initiation of transcription is the expression of UBTF. In simple yet elegant studies using 
engineered pseudo- and neo-NORs, UBTF binding was shown to be required for the 
maintenance of competent NORs through mitosis and for the recruitment of RNAPI; 
however, in the absence of an rDNA array, transcription did not initiate and nucleoli did 
not form (Grob et al., 2014; Mais et al., 2005). The dynamic changes to the nucleolus 
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during mitosis are thus highly coordinated and tightly regulated by cell cycle regulators 
in order to ensure faithful cell duplication and viability. 
 While details surrounding the disassembly and reassembly of nucleoli in mitosis 
have been established, there is much left to be determined. In the recent survey 
identifying nucleolar proteins associated with the mitotic perichromosomal compartment, 
65 proteins were identified, but 36 were not previously known to localize to 
chromosomes (Stenström et al., 2020). Furthermore, the nucleolar proteins that localize 
to the perichromosomal compartment are enriched in proteins with intrinsically 
disordered regions (IDR), and this is intriguing given that IDRs are reported drivers of 
nucleolar assembly through a biophysical process known as liquid-liquid phase 
separation [LLPS; (Hyman et al., 2014; Lafontaine et al., 2020)]. The role of LLPS in 
driving nucleolar organization has gained significant attention over the past decade and 
establishing the contribution of this biophysical process will be important to gaining a 
more comprehensive understanding of nucleolar form and function. Thus, while decades 
of research have led to significant insights into nucleolar dynamics, particularly during 
mitosis, many details remain to be uncovered.   
 
Liquid-liquid phase separation in nucleolar assembly 
Nucleoli are membraneless nuclear bodies that display biophysical properties 
associated with liquids. Currently, there is significant momentum surrounding the study 
of nucleolar organization as a product of the phenomenon of LLPS (Hyman et al., 2014; 
Lafontaine et al., 2020). This body of research initiated with a study that observed liquid 
droplet-like behavior of nucleoli in Xenopus oocytes, followed by a study that observed 
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purified nucleolar proteins (FBL and NPM1, respectively) with rRNA from wheatgerm 
form distinct liquid droplets that are immiscible when mixed and crudely mimic nucleolar 
organization (Brangwynne et al., 2011; Feric et al., 2016). Although Xenopus nucleoli are 
not tethered to chromosomes as in mammals, these studies and others suggest that 
concentration-dependent physical properties of proteins, like fluidity and surface tension, 
may explain higher order organization and coalescence events observed among nucleoli. 
More recent studies have elaborated on these initial findings in human cells with 
observations of coalescence in chromosomally tethered nucleoli and through the use of 
super resolution microscopy (Caragine et al., 2018, 2019; Yao et al., 2019). In the latter, 
the authors substantiate the involvement of IDRs in promoting self-association and liquid 
droplet formation, identifying the FBL GAR domain as necessary to promote LLPS of 
FBL (Yao et al., 2019). Additionally, when self-association of FBL was impaired by 
mutants with a truncated GAR domain, so was the localization and processing of the pre-
rRNA (Yao et al., 2019). There is, however, still some skepticism surrounding the broad 
applicability of LLPS to explain the organization of membraneless cellular bodies, and 
thus the field would benefit from a set of standards for testing the hypothesis in living 
systems (Alberti et al., 2019; McSwiggen et al., 2019; Peng and Weber, 2019). 
Furthermore, because nucleoli in higher eukaryotes are tethered to multiple different 
chromosomes, additional factors like chromosomal movement and positioning within the 
nucleus are likely to also play a contributing role in nucleolar fusion and organization 
(Mangan and McStay, 2021; van Sluis et al., 2020). In conclusion, this new body of 
literature suggests that in combination with other processes, like pre-rRNA transcription 
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and higher-order chromosome organization, LLPS may contribute to the assembly of 






Figure 1-2. Nucleolar dynamics during mitosis. In every mitosis, the nucleolus 
disassembles in late prophase and reassembles in telophase. In prophase, pre-rRNA and 
processing factors relocate to the chromosomal periphery, also called the 
perichromosomal compartment. Activation of CDK1-cyclin B inhibits RNAPI 
transcription by metaphase (red). Inhibition of CDK1-cyclin B by PP1 phosphatases re-
initiates RNAPI transcription by telophase (green). In telophase, nucleolar proteins in the 
perichromosomal compartment condense into prenucleolar bodies (PNB) from which 
ribosome biogenesis factors are recruited to the competent nucleolar organizer regions 
(NORs) and, with early processing factors and pre-rRNA, promote nascent nucleolar 
formation. In early G1, nascent nucleoli fuse to from mature nucleoli. FC=fibrillar center 





The nucleolar response to cellular stress 
 The nucleolus is more than just a ribosome factory. Although the primary 
function of the nucleolus is to synthesize ribosomes, extra-ribosomal functions have also 
been attributed to this organelle. These additional functions include cell cycle regulation, 
and the processing and maturation of mRNA, snRNA, and the RNA components of 
telomerase and the signal recognition particle (Boisvert et al., 2007; Pederson, 1998). 
However, and arguably the most striking, is that it has also been defined as a sensor of 
cellular stress that results in the stabilization of the tumor suppressor protein, p53. In 
2003, Rubbi and Milner observed that common among all p53-inducing stressors is 
nucleolar disruption (Rubbi and Milner, 2003). They proceeded to define how impaired 
nucleolar function stabilizes p53 (Rubbi and Milner, 2003), which modulates 
transcriptional networks that regulate diverse cellular processes (Boutelle and Attardi, 
2021). The regulatory effects of p53 stabilization include the suppression of RNAPI 
through direct disruption of the RNAPI pre-initiation complex (Zhai and Comai, 2000). 
In subsequent studies, it was identified that p53 stabilization is mediated through the 
interaction of the p53 E3 ubiquitin ligase, MDM2/HDM2, with the 5S ribonucleoprotein 
(5S-RNP), which includes unassembled r-proteins, primarily RPL5 (uL18) and RPL11 
(uL5), and HEATR3 (Calviño et al., 2015; Dai and Lu, 2004; Fumagalli et al., 2009; 
Hannan et al., 2021; Lohrum et al., 2003; Russo and Russo, 2017). Furthermore, new 
research further supports that the nucleolus senses diverse cellular stresses, including 
stress caused by inhibition of RNA polymerases, nuclear export inhibition, and DNA 
damage, but not proteotoxic stress (Hannan et al., 2021). Additionally, since the 
discovery of the p53-mediated nucleolar stress response, several additional nucleolar 
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stress pathways independent of p53 have also been described (James et al., 2014). The 
identification of these stress response pathways has therefore positioned the nucleolus not 
only as essential in producing ribosomes, but also as a hub in the coordination of the 
cellular response to stress.    
 
Crosstalk between the nucleolus and the DNA damage response 
Discoveries made by studies employed to define the nucleolar proteome in higher 
eukaryotes have contributed substantially to our understanding of the nucleolar response 
to DNA damage. The Nucleolar Proteome Database (NOPdb3.0) is by far the most 
comprehensive attempt at defining a complete proteome. In its latest update, it included 
the identification of more than 4,500 proteins that localize to the nucleolus based on mass 
spectrometry of purified nucleoli from several experiments in different human cell lines 
(Ahmad et al., 2009; Andersen et al., 2005; Andersen et al., 2002; Leung et al., 2006; 
Scherl et al., 2002). Two other published proteomes include another mass spectrometry-
based proteome from T-cells (Jarboui et al., 2011), and a nucleolar proteome based on 
immunofluorescence microscopy (Thul et al., 2017; Thul and Lindskog, 2018). One 
analysis of nearly 700 nucleolar proteins revealed that among the functional classes 
represented were not only r-proteins, RNA-binding proteins, and RNA helicases, but also 
cell-cycle proteins, splicing related factors, and DNA replication and DNA repair 
proteins (Andersen et al., 2005). I also performed an analysis of all the nucleolar 
proteomes and uncovered a total of 166 DNA repair proteins among the datasets using 
the Gene Ontology (GO) Consortium categorization for protein identification 
[GO:0006281; Table 1-1; Appendix I; (Ogawa and Baserga, 2017). Data from these 
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studies thus support a plurifunctional role for the nucleolus in higher eukaryotes and 
lends support to the idea of the nucleolus as a sensor of DNA damage.  
 Beyond the localization of DNA repair proteins to the nucleolus, several studies 
suggest a role for the nucleolus is the sequestration of DNA repair proteins until required 
for DNA repair. In support of this proposed mechanism of coordinating the DNA damage 
response, several studies have observed large changes in the nucleolar proteome when 
treated with DNA damaging agents, like AMD (Andersen et al., 2005; Andersen et al., 
2002). In one study, treatment with UV and ionizing radiation revealed the mobilization 
of proteins associated with non-homologous end joining (NHEJ) from the nucleolus to 
the nucleoplasm (Moore et al., 2011). Similar observations have been made with the base 
excision repair (BER) enzymes APEX1 (Lirussi et al., 2012) and ALKBH2 (Li et al., 
2013a), and the Werner syndrome protein [WRN; (Blander et al., 2002; Lee et al., 2015)]. 
It is also possible, however, that DNA repair proteins that localize to the nucleolus are 
not just sequestered, but actually have yet to be defined roles in ribosome biogenesis. 
Indeed, I explored this hypothesis and identified several DNA repair proteins with roles 
in ribosome biogenesis and vice versa (Ogawa and Baserga, 2017); thus, it is likely that 
both these explanations may be accurate. Taken together, the nucleolus is a dynamic 
organelle that responds to DNA damage through the redistribution of nucleolar localized 
proteins.   
The nucleolus also responds to DNA damage through transient inhibition of 
RNAPI, although the precise mechanism underlying the response remains incomplete. 
First reported in 2007, Kruhlak and colleagues identified an ATM-mediated 
transcriptional repression of RNAPI upon DNA damage by ionizing radiation that also 
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depended on NBS1 and MDC1 (Kruhlak et al., 2007). Further, by using laser micro-
irradiation the authors also observed that RNAPI repression was locally restricted to 
nucleoli nearest the damaged chromatin (Kruhlak et al., 2007). Since this first study there 
have been several additional studies that not only validated the ATM-mediated RNAPI 
transcriptional repression, but that also further defined the mechanisms underlying this 
response [Figure 1-3, A; (Calkins et al., 2013; Ciccia et al., 2014; Korsholm et al., 2019; 
Larsen et al., 2014; Mooser et al., 2020)]. One clear discovery from these studies is the 
central role that the ribosome biogenesis factor, treacle (TCOF1), plays in mediating the 
response. TCOF1 is not only required to recruit NBS1 and possibly the rest of the MRN 
complex (MRE11 and RAD50), but has also been shown to recruit TOPBP1 which is 
required to activate ATR for the repression of RNAPI transcription [Figure 1-3, A; 
(Ciccia et al., 2014; Korsholm et al., 2019; Larsen et al., 2014; Mooser et al., 2020)]. 
Other discoveries include in one study the observed absence of RNAPI transcriptional 
repression with ionizing radiation (Moore et al., 2011), and in another the global 
silencing of nucleoli upon micro-irradiation (Larsen et al., 2014), both in contrast to 
initial findings and that suggest there are nuances in the nucleolar DNA damage response 
that remain to be elucidated. What is certain, however, is that RNAPI transcriptional 
repression upon DNA damage requires ATM-mediated recruitment of NBS1 and 
TOPBP1 by TCOF1 that triggers RNAPI repression in an ATR-dependent manner.  
DNA damage also leads to nucleolar reorganization into cap-like structures on the 
nucleolar periphery. Observed over half a century ago, treatment with DNA damaging 
agents like 4-nitroquinoline N-oxide and AMD led to nucleolar disruption and the 
formation of nucleolar “caps” (Reynolds et al., 1964; Reynolds et al., 1963). Several 
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decades later, recent studies on DNA damage specifically in the rDNA by the I-Ppol 
endonuclease have finally made progress towards defining these intriguing structures. 
Like DNA damage in nuclear chromatin, ATM-dependent RNAPI silencing is also 
observed when damage occurs in the rDNA (Franek et al., 2016; Harding et al., 2015; 
Kruhlak et al., 2007; van Sluis and McStay, 2015; Warmerdam et al., 2016). 
Interestingly, however, it was RNAPI silencing and not DNA damage specifically that 
led to the formation of nucleolar caps (Figure 1-3, B). This was ascertained because, 
remarkably, treatment with AMD at doses that inhibited RNAPI that do not cause DNA 
damage also led to cap formation, but that was independent of ATM (Harding et al., 
2015; van Sluis and McStay, 2015). Furthermore, probing the composition of caps caused 
by DNA damage suggest that damaged rDNA from the nucleolar interior retreats to the 
caps to be repaired. This is supported by the colocalization of caps with the rDNA, FC 
and DFC ribosome biogenesis proteins, γH2AX, and DNA repair factors [Figure 1-3, C; 
(Franek et al., 2016; Harding et al., 2015; Larsen et al., 2014; van Sluis and McStay, 
2015; Warmerdam et al., 2016). Taken together, these data support an ATM-dependent 
mechanism of RNAPI inhibition upon DNA damage in the rDNA; however, the purpose 
of nucleolar reorganization may differ depending on the type of damage. 
It is clear from this recent body of literature that there is a substantial crosstalk 
between the nucleolus and the DNA damage response. Questions, however, still remain 
including why the DNA damage response includes repression of RNAPI. For damage in 
the nucleolar chromatin it may be an adaptation to preserve genome integrity. As the 
most highly transcribed region in the human genome, repression of transcription during 
DNA repair would limit collision between transcription and repair machinery (Lindstrom 
 
18 
et al., 2018). Furthermore, as a highly repetitive region, prevention of double strand 
breaks is important to limit homologous recombination (HR)-mediated gain or loss of 
rDNA repeats, which has been associated with human disease (Lindstrom et al., 2018; 
Warmerdam and Wolthuis, 2019). In the nuclear chromatin, repression of RNAPI may 
represent a mechanism to coordinate DNA repair with cellular growth or with the p53 
nucleolar-mediated stress response if damage is too severe, given that ribosome 
biogenesis is an energetically costly process (Antoniali et al., 2014; Hannan et al., 2021; 
Kruhlak et al., 2007; Warner et al., 2001).  
Another outstanding question is, “What is the primary mode of DNA repair in the 
nucleolar chromatin?.” A few well-supported studies have arrived at conflicting 
conclusions regarding the predominant pathway for repair. In one study, HR-mediated 
repair was concluded (van Sluis and McStay, 2015), whereas in two others, NHEJ was 
shown as the primary mode of repair in the rDNA (Harding et al., 2015; Warmerdam et 
al., 2016), with HR actually delaying repair and leading to the loss of rDNA repeats 
(Warmerdam et al., 2016). Taken together, the nucleolus is highly responsive to cellular 






Table 1-1. Human nucleolar proteomes include proteins involved in DNA repair. Three 
databases exist on proteins that localize to the human nucleolus. Within each database, a 
subset of proteins are classified as DNA repair proteins based on Gene Ontology (GO) 
Consortium categorization (GO: 0006281). 
 
 NOPdb (Ahmad et 




et al., 2011) 
Human Protein 
Atlas subcellular 
proteome (Thul et 
al., 2017; Thul and 
Lindskog, 2018) 
Total proteins 2717 872 1153 
DNA repair 
proteins 
136 38 40 
DNA repair 
proteins with a 
yeast ortholog 






Figure 1-3. Nucleolar response to DNA damage. The nucleolus is a cellular stress sensor 
that responds to DNA damage. DNA damage in the nucleolar and nuclear chromatin both 
result in the transient inhibition of RNAPI and the formation of nucleolar caps. Created 
with BioRender.com. 
(A) Model of ATM- and ATR- dependent inhibition of RNAPI upon DNA damage. 
ATM-dependent TCOF1 recruitment of NBS1 and TOPBP1 results in the ATR-
dependent silencing of RNAPI in the nucleolus. TCOF1 may recruit the entire MRN 
complex (MRE11-RAD50-NBS1). Black lightning bolt=DNA damage. Grey=RNAPI; 
Red=silenced RNAPI.  
 
21 
(B) Nucleolar caps. The nucleolar stress response results in the transient inhibition of 
RNAPI. When RNAPI is silenced, dense nucleolar caps form on the nucleolar periphery. 
The boxed nucleolar cap is defined in C. 
(C) Nucleolar cap composition. When DNA damage, specifically double strand breaks, 
occur in the rDNA, RNAPI is silenced and nucleolar caps are formed. The caps comprise 
individual nucleolar organizer regions (NORs), γH2AX (a marker of DNA damage), 
nucleolar proteins from the fibrillar center (FC) and dense fibrillar component (DFC), 







Ribosome biogenesis and disease 
 Nucleolar dysfunction is associated with a wide range of diseases. Because the 
nucleolus is essential for growth and the cellular response to stress, it is not surprising 
that dysfunction may contribute to disease. Today, a large body of evidence implicates 
nucleolar dysfunction in a subset of congenital disorders, known as the ribosomopathies. 
The nucleolus, however, has also been linked to aging, including neurodegenerative 
diseases, and the pathogenesis of cancer. Gaining a broader understanding of the 
connection of the nucleolus and ribosome biogenesis to disease will serve to improve our 
ability to develop more targeted and effective therapeutics. While research has amassed 




The ribosomopathies are a diverse subset of congenital disorders caused by 
mutations in genes associated with ribosome biogenesis. While all ribosomopathies share 
defects in ribosome production, not all are caused by defects at the same step in the 
process (Farley-Barnes* and Ogawa* et al., 2019). Perhaps the most studied of the 
ribosomopathies are the bone marrow failure syndromes, including Diamond-Blackfan 
anemia (DBA), Shwachman-Diamond syndrome (SDS), and Dyskeratosis Congenita 
(DC), which can be caused defects in ribosome assembly (Ellis and Gleizes, 2011; 
Ruggero and Shimamura, 2014; Warren, 2018). The association of ribosome biogenesis 
with bone marrow failure was first identified in DBA (Draptchinskaia et al., 1999). DBA 
can be caused by mutations in one of at least 19 r-proteins, however, the most common 
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mutation among DBA patients is in RPS19 (Aspesi and Ellis, 2019). The consequence of 
these mutations is r-protein haploinsufficieny, which results in a reduction in the 
concentration of mature cytoplasmic ribosomes (Khajuria et al., 2018). Another well-
studied ribosomopathy is the mandibulofacial dysostosis Treacher Collins syndrome 
(TCS). In most cases TCS is caused by mutations in TCOF1, however, it has also been 
identified in patients with mutations in RNAPI subunits, POLR1B, POLR1C and 
POLR1D (Bowman et al., 2012; Dauwerse et al., 2011; Sanchez et al., 2020; Splendore et 
al., 2000; Teber et al., 2004). A related disorder, acrofacial dysostosis, Cincinnati type, 
has also been identified and is caused by mutations in POLR1A (Weaver et al., 2015). 
TCOF1 is a multifunctional protein with roles in pre-rRNA transcription, modification, 
and the nucleolar response to DNA damage (Gonzales et al., 2005; Larsen et al., 2014; 
Mooser et al., 2020; Valdez et al., 2004). However, because RNAPI subunits share the 
pathophysiology of TCS, it is likely that a reduction in pre-rRNA levels observed with 
TCS is the causative mechanism. Among the ribosomopathies, mutations have been 
identified in factors required not only for ribosome assembly and transcription, but also in 
pre-rRNA processing (Farley-Barnes* and Ogawa* et al., 2019; Warren, 2018). There are 
currently at least 21 suspected and defined ribosomopathies (Farley-Barnes* and Ogawa* 
et al., 2019; Warren, 2018), and new ribosomopathies continue to be discovered.    
 One of the most fascinating aspects of the ribosomopathies is the tissue specific 
clinical manifestations of the diseases. While tissue-specificity in disease is not unique to 
the ribosomopathies (Hekselman and Yeger-Lotem, 2020), the diversity of unique tissue 
types effected by defective ribosome biogenesis has intrigued scientists. At this time, the 
clinical manifestations of the ribosomopathies range from bone marrow failure and 
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craniofacial abnormalities to intellectual disability and cardiac deficiencies [Figure 1-4; 
(Danilova and Gazda, 2015; Farley-Barnes* and Ogawa* et al., 2019; Warren, 2018)]. 
Interestingly, however, a unifying feature of several ribosomopathies are defects in the 
tissues that arise from the neural crest cell lineage (Trainor and Merrill, 2014; Watt and 
Trainor, 2014). Neural crest cells are migratory progenitor cells that arise during early 
embryonic development and differentiate into several unique cell types including those 
that derive the skeletal structures of the face, heart, glia, peripheral nervous system, skin, 
and teeth [Figure 1-4 (Trainor and Merrill, 2014; Watt and Trainor, 2014)]. In fact, many 
ribosomopathies manifest with defects in craniofacial morphology (TCS; DBA; 
acrofacial dysostosis, Cincinnati type), and studies on TCS in animal models have 
implicated p53-mediated apoptosis of the neural crest cells in the development of the 
craniofacial phenotype (Bowen and Attardi, 2019; Rinon et al., 2011). Furthermore, p53 
inhibition, remarkably, rescues the observed craniofacial defects, linking the nucleolar-
mediated p53 stress response to the clinical manifestation of the disease (Calo et al., 
2018; Jones et al., 2008; Watt et al., 2018). Ribosomopathies, however, also manifest 
with defects in unrelated tissues, including the liver [North American Indian childhood 
cirrhosis; (Freed et al., 2012)], bone marrow [DBA; SDS; DC; (Ellis and Gleizes, 2011; 
Ruggero and Shimamura, 2014; Warren, 2018)], spleen [isolated congenital asplenia; 
(Bolze et al., 2013)], and brain [ANE syndrome, RPS23 ribosomopathy; Figure 1-4; 
(Nousbeck et al., 2008; Paolini et al., 2017)]. While there is some evidence for the role of 
p53 in the pathogenesis of some of these ribosomopathies, it is not implicated in all of 
them. The underlying mechanisms for many of the ribosomopathies therefore remain to 
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be thoroughly defined, and further research in animal models on the consequences of 
mutations in ribosome biogenesis factors will be revealing.    
 
 How tissue specific defects arise from dysfunction in a ubiquitous process has 
drawn significant recent attention. Beyond the role of p53 and the nucleolar stress 
response, other leading hypotheses have emerged to describe the mechanisms underlying 
tissue specificity in the ribosomopathies (Farley-Barnes* and Ogawa* et al., 2019). One 
hypothesis is based on the concept of ribosome heterogeneity or “specialized ribosomes,” 
and a second hypothesis is based on cellular ribosome concentration. The ribosome 
concentration hypothesis suggests that reduced production of ribosomes leads to 
increased competition among mRNA for the ribosomes that are available (Lodish, 1974; 
Mills and Green, 2017). As a consequence, a subset of proteins may not be synthesized at 
a capacity required for the normal function of a specific tissue. The most notable example 
associated with this hypothesis is with the pathogenesis of DBA and the erythroid 
specific transcription factor GATA1. GATA1 is required for erythroid cell development, 
and decreased levels of GATA1 protein have been observed in DBA patients (Khajuria et 
al., 2018; Ludwig et al., 2014). Confounding, however, is that it could then be 
hypothesized that mutations in all r-proteins could lead to bone marrow failure; however, 
this is not observed. The ribosome heterogeneity hypothesis, on the other hand, suggests 
that unique pools of ribosomes exist in different tissues that may differentially translate 
subsets of mRNAs (Genuth and Barna, 2018). This hypothesis echoes most closely the 
idea regarding tissue-specific diseases in general that a causal mutation in a protein 
disrupts interactions of that protein with a tissue specific network (Hekselman and Yeger-
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Lotem, 2020). In the case of ribosome heterogeneity this would be exemplified by the 
differential expression of r-proteins that interact with and/or recruit a specific subset of 
mRNAs (Genuth and Barna, 2018; Shi et al., 2017). It is important to note that these 
proposed mechanisms are not likely to be mutually exclusive. Both of these hypotheses, 
however, are limited in the evidentiary support for the proposed mechanisms and 
therefore require further substantiation (Farley-Barnes* and Ogawa* et al., 2019). 
Advances in technologies and further research aimed at exploring these hypotheses in 
specific disease model systems will be essential to defining the pathogenesis of the tissue 







Figure 1-4. Tissue specific clinical manifestation of ribosomopathies. Ribosomopathies 
are a diverse subset of congenital disorders that arise from defects in ribosome 
biogenesis. A unifying feature of several ribosomopathies are defects in the tissues that 
arise from the neural crest cell lineage (green), including hearing loss, craniofacial 
dysmorphology (TCS; DBA; acrofacial dysostosis, Cincinnati type), cardiac defects, and 
alterations in skin pigmentation. Ribosomopathies also manifest with defects in unrelated 
tissues (red), including neurological impairments (ANE syndrome; RPS23 
ribosomopathy), alopecia, liver cirrhosis (North American Indian childhood cirrhosis), 
asplenia (isolated congenital asplenia), and bone marrow failure (DBA; SDS; DC). Only 
the ribosomopathies discussed are included in the parenthesis. Previously published in 
(Farley-Barnes* and Ogawa* et al., 2019)   
 
28 
Aging and related diseases 
Research on longevity, premature aging disorders, and neurodegeneration support 
a connection between aging and the nucleolus. Understanding the molecular basis for 
aging has long interested scientists, yet the link between the nucleolus and aging is a 
more recent development in the history of aging research. Some of the earliest studies 
linking the nucleolus to aging began with experiments in yeast mother cells that found a 
requirement for the histone deacetylase, Sir2, in maintaining genome stability at rDNA 
loci. Additionally, loss-of-function mutants had a shorter lifespan and gain-of-function 
mutants had a longer lifespan (Gottlieb and Esposito, 1989; Guarente, 1997; Sinclair and 
Guarente, 1997). Today, genome instability in the rDNA is still one of the leading 
hypotheses for why we age (Ganley and Kobayashi, 2014; Tiku and Antebi, 2018; Turi et 
al., 2019). A recent study on mammalian SIRT7 has validated a role for sirtuins in 
maintaining rDNA heterochromatin, connecting rDNA genome stability to lifespan 
(Etchegaray and Mostoslavsky, 2018; Paredes et al., 2018). Mammalian SIRT1 has also 
been reported to regulate RNAPI transcription and rDNA stability and is a leading target 
in the development of anti-aging therapeutics, which include resveratrol and other 
synthetic agonists (Murayama et al., 2008; Stacchiotti et al., 2018; Zhou et al., 2009). 
Several lines of evidence thus support a link between rDNA genome stability and aging. 
Nucleolar form and function have also been linked to aging. In a recent study, 
smaller nucleolar size predicted longer lifespan in a C. elegans model of longevity, 
mediated by ncl-1 [TRIM2/Brat; (Tiku et al., 2017)]. This observation also extended to 
models of longevity in fly, mouse and humans, and included a concomitant observed 
decrease in ribosome biogenesis (Tiku et al., 2017). Reduced nucleolar activity as a 
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hallmark of longevity is consistent with other areas of research like the targeting of 
mTOR (mechanistic/mammalian target of rapamycin) to treat age-related diseases. 
mTOR is a kinase central to growth regulation, and inhibition is known to decrease 
ribosome biogenesis and translation (Tee, 2018; Walters and Cox, 2018). Also consistent 
with this view is the observation that the rDNA in aged mice, canids, and humans show 
increased CpG methylation (Wang and Lemos, 2019). This may suggest not only 
decreased nucleolar activity, but also perhaps a compensatory mechanism to increase 
rDNA genome stability as we age. In this same study, however, it was also observed that 
under paradigms associated with longevity (e.g. calorie restriction), methylation was 
decreased (Wang and Lemos, 2019). One possible explanation is that decreased 
methylation does not necessarily suggest increased nucleolar activity or genome 
instability. It is also possible, however, that methylation may be secondary to another 
cause for aging that is reversed in models of longevity. Taken together, the link between 
aging and nucleolar form and function is not yet well defined.  
Premature aging disorders further complicate the link between aging and the 
nucleolus. Hutchinson-Gilford progeria syndrome (HGPS) is a premature aging disorder 
caused by mutant lamin A/C. Intriguingly, however, a recent study on fibroblasts from 
HGPS patients has revealed increased nucleolar size and function that also demonstrated 
increases in rDNA transcription and translation (Buchwalter and Hetzer, 2017). In 
contrast, Werner syndrome (WS), Cockayne syndrome (CS), and Bloom syndrome (BS), 
are premature aging disorders caused by mutations in DNA repair proteins that exhibit 
decreased nucleolar activity (Karikkineth et al., 2017; Mukherjee et al., 2018). Studies on 
the proteins implicated in these syndromes have all revealed that impaired function yields 
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decreased RNAPI transcription (Bradsher et al., 2002; Grierson et al., 2012; Hannan et 
al., 2013; Lebedev et al., 2008; Lutomska et al., 2008; Okur et al., 2020; Shiratori et al., 
2002). Interestingly, WS models, like HGPS, exhibit disruption in the nuclear lamina, 
including the nuclear pores and lamin B1 (Li et al., 2013b), and lamin B2 has been shown 
to regulate nucleolar morphology and function (Sen Gupta and Sengupta, 2017) that 
together may suggest a broader link among the nuclear membrane, the nucleolus, and 
aging. Despite the discordance between HGPS and the other premature aging disorders, 
there remains a link underlying premature aging and the nucleolus. 
Neurodegenerative diseases share similar nucleolar dysfunction when compared 
to the premature aging disorders. Several lines of evidence have led to the proposal that 
nucleolar form and function are linked to the pathogenesis of neurodegenerative diseases 
(Herrmann and Parlato, 2018; Hetman and Pietrzak, 2012; Parlato and Bierhoff, 2015; 
Parlato and Kreiner, 2013; Parlato and Liss, 2014; Sia et al., 2016). In Alzheimer’s 
disease (AD), observations include reduced nucleolar size (Donmez-Altuntas et al., 2005; 
Mann et al., 1988), hypermethylation of the rDNA promoter (Pietrzak et al., 2011), 
increased rRNA oxidation (Ding et al., 2006; Honda et al., 2005), and decreased 
ribosome activity (Ding et al., 2005; Hernandez-Ortega et al., 2016; Langstrom et al., 
1989). In Parkinson’s disease (PD), nucleolar disruption has also been observed (Parlato 
and Liss, 2014). In mouse models of PD, RNAPI transcription is decreased, as was 
mouse lifespan (Evsyukov et al., 2017). In another study, when the RNAPI transcription 
factor, RRN3/TIF-1A, is depleted in mouse dopaminergic neurons, p53-dependent 
apoptosis and PD-like symptoms are exhibited (Rieker et al., 2011). This result in 
particular is intriguing given that these data suggest a link between the nucleolar stress 
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response and neurodegeneration that echoes that mechanism underlying craniofacial 
defects among a subset of ribosomopathies. Defects in ribosome recycling have also been 
shown to have impacts on nucleolar function and are also implicated in aging and 
neurodegeneration (Ishimura et al., 2014; Sudmant et al., 2018). Together, these data 
suggest that reduced nucleolar function underlies neurodegenerative diseases. A recent 
study, however, has reported that children heterozygous for a gain-of-function mutation 
in the RNAPI transcription factor, UBTF, also exhibit neurodegeneration, which 
contradicts this conclusion, yet may be consistent with increased nucleolar activity 
causing increased rDNA genome instability (Edvardson et al., 2017). Taken together, a 
link between the nucleolus and neurodegeneration is evident (Figure 1-5); however, 
informational gaps remain as they do with the association of the nucleolus with aging in 







Figure 1-5. A working model for the association between the nucleolus and aging. 
Genome instability and CpG methylation at the tandemly arrayed rDNA loci increase as 
we age. Evidence also suggests that reduced nucleolar activity is associated with aging. 
The grey dashed triangle represents normal aging. The numbers 1-3 represent specific 
diseases and are placed relative on the plot relative to normal aging. 1= Hutchinson-
Gilford progeria syndrome (HGPS) and UBTF-associated childhood neurodegeneration; 
2=Werner syndrome, Cockayne syndrome, Bloom syndrome, Alzheimer’s disease, and 







The nucleolus and cancer 
Changes in nucleolar morphology have long been associated with cancer. For 
over a century, cancer pathologists have observed changes in nucleolar size and number 
in diverse tumor types, and concluded that tumors with larger and more numerous 
nucleoli predicted a worse prognosis for the patients (Derenzini et al., 2009; Penzo et al., 
2019; Pianese, 1896). The association of the nucleolus with cancer is not surprising given 
that the nucleolus drives growth and cellular proliferation. Indeed, ribosome biogenesis is 
a highly energy-consuming process and as such is tightly regulated, and most often at the 
first step in the process, transcription (Drygin et al., 2010; Warner et al., 2001). 
Furthermore, retrospective studies on the molecular mechanisms underlying common 
chemotherapeutic agents revealed that several drugs in fact target stages of ribosome 
biogenesis, not only at the site of RNAPI transcription, but also at stages of pre-rRNA 
processing (Burger et al., 2010; Quin et al., 2014). Drugs developed specifically to target 
RNAPI transcription have since proven promising both preclinically and in clinical trials 
for solid tumors and hematological malignancies. CX-3543 (quarfloxin) and CX-5461 
have revealed few adverse events and stable disease in some trial participants (Drygin et 
al., 2011; Drygin et al., 2009; Drygin et al., 2008; Haddach et al., 2012; Hilton et al., 
2020; Khot et al., 2019; Papadopoulos et al., 2007; Sanij et al., 2020; Xu et al., 2017b). 
BMH-21 is yet another novel RNAPI inhibitor that is currently in preclinical 
development and which has shown promising antineoplastic properties in mouse 
xenograft models of melanoma and drug-resistant prostate cancer (Colis et al., 2014; Low 
et al., 2019). Taken together, nucleolar form and function are linked to pathogenesis of 
cancer and is a promising target in the development of novel cancer therapeutics.  
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Ribosomopathies are also comorbid with a predisposition to cancer. Observations 
in patients with ribosomopathies also suggest a link between nucleolar function and 
cancer pathogenesis (Ruggero and Pandolfi, 2003). This is best defined by observations 
among those with the classic bone marrow failure syndromes (DBA, SDS, and DC), 
however, it is also observed among patients with 5q minus syndrome and cartilage hair 
hypoplasia (Aspesi and Ellis, 2019; Ruggero and Pandolfi, 2003). In SDS, patients show 
an increased risk for developing myelodysplastic syndrome (MDS) and acute myeloid 
leukemia (AML). In 90% of cases, SDS is caused by mutations in the ribosome assembly 
factor SBDS, which is important in the final maturation steps of the 60S subunit by 
releasing EIF6 (Warren, 2018). While ribosomopathies can often be categorized as 
diseases of hypo-proliferation, for example of the erythroid cells in the bone marrow, 
cancer as a disease of hyper-proliferation presents a paradox (Dameshek, 1967). Several 
mechanisms have been proposed to explain the increased risk for cancer among patients 
with ribosomopathies. One of the most compelling proposals is that patients acquire 
secondary mutations to compensate for the reduced capacity to synthesize ribosomes. In a 
study of SDS patients undergoing bone marrow transplants for MDS, mutations in known 
oncogenes were observed, 19% of which were in p53 suggesting a selective pressure to 
bypass the nucleolar stress response (Lindsley et al., 2017). Acquired mutations have also 
been observed in a small longitudinal study on SDS patients, which revealed either 
duplicated SBDS or deleted EIF6 to presumably overcome ribosomal deficiencies 
(Pressato et al., 2015). Intriguingly, among these patients, none were reported to have 
developed MDS or AML yet (Pressato et al., 2015). Overcoming ribosome deficiencies 
through p53 inactivation may in fact be a common mechanism underlying the 
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predisposition for cancer. In most cases where r-proteins are mutated, mutations in p53 
are also observed (Ajore et al., 2017). Thus, there is a clear connection between the 
nucleolus and cancer and further studies aimed at validating and elaborating the 
mechanisms underlying the elevated cancer risk among ribosomopathy patients will be 
informative for better understanding the molecular basis for the link.  
 Finally, genome instability at the rDNA loci, in addition to being associated with 
aging, has also been implicated in cancer. As highly transcribed and repetitive sites, the 
rDNA repeats are not only susceptible to DNA damage, but also increased rates of 
recombination during repair that can result in the gain or loss of repeats (Lindstrom et al., 
2018). Interestingly, it has been observed that rearrangements at the rDNA loci are 
common among tumors from lung and colorectal cancer patients (Stults et al., 2009). A 
larger, more comprehensive survey of cancers supported these data by revealing that 
rDNA copy number is in fact reduced in tumors relative to adjacent normal tissue from 
the same patient (Xu et al., 2017a). At first, this is counterintuitive as fewer copies might 
suggest a decreased proliferative capacity. However, concomitant increases in copy 
number of the extra-nucleolar 5S rRNA locus were also observed, as were p53 
inactivating mutations and increased proliferative capacity (Xu et al., 2017a). 
Experiments in yeast complement these data, revealing that strains with low rDNA copy 
number exhibit an increased proportion of active to inactive rDNA repeats and increased 
rates of pre-rRNA synthesis (Ide et al., 2010). While the mechanisms underlying rDNA 
gene alterations in cancer remain unclear, genome instability at rDNA loci may have a 
selective advantage in cancer. The existence of endogenous sensors that detect and 
maintain rDNA copy number have been proposed, but evidence in higher eukaryotes is 
 
36 
limited (Nelson et al., 2019; Salim et al., 2017). While many aspects remain to be 
defined, targeting the multifaceted link between the nucleolus and cancer holds promise 



















Genome-wide RNAi screen for increased nucleolar number reveals 




Ribosome biogenesis is an essential biological process shared among all living 
organisms (Ebersberger et al., 2014). As such, for several decades, this conserved process 
in eukaryotes has been largely defined by its study in the genetically tractable single-
celled eukaryote, Saccharomyces cerevisiae (Woolford and Baserga, 2013). Humans, 
however, are multi-cellular organisms with innumerable differences including a more 
complex regulation of growth control (Miller, 2012). Furthermore, while a diploid S. 
cerevisiae cell maintains two nucleolar organizing regions and ~150 rDNA loci 
(Kobayashi et al., 1998), the diploid human genome harbors 10 nucleolar organizing 
regions and ~200-600 rDNA loci (Henderson et al., 1972; Parks et al., 2018; Stults et al., 
2008). Thus, due to this increased complexity and the growing evidence linking nucleolar 
dysfunction to human congenital diseases (Farley-Barnes* and Ogawa* et al., 2019; 
Narla and Ebert, 2010; Warren, 2018), cancer (Bursac et al., 2020; Penzo et al., 2019; 
Ruggero, 2012; Sulima et al., 2019), viral infections (Jarboui et al., 2012; Rawlinson et 
al., 2018), and aging (Hetman and Pietrzak, 2012; Tiku and Antebi, 2018), it has become 
imperative to study the intricacies of ribosome biogenesis in higher eukaryotes to better 
understand how defects lead to the development of disease. 
To this end, advances in technologies and high-throughput screening approaches 
have led multiple laboratories to mount screening campaigns to explore ribosome 
biogenesis in higher eukaryotes. A candidate screening approach using small interfering 
RNAs (siRNA) targeting nucleolar proteins in HeLa cells, for instance, classified 
regulators of pre-rRNA processing, identifying a large proportion either with different 
functions from the corresponding yeast ortholog or no known yeast ortholog (Tafforeau 
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et al., 2013). The former observation was independently supported by an siRNA screen 
for ribosomal subunit maturation factors that identified a novel role for exportin 5 
(XPO5) in the nuclear export of pre-60S subunits in vertebrates (Wild et al., 2010). 
Genome-wide screens quantifying changes in nucleolar size in S. cerevisiae and 
Drosophila melanogaster identified the loss of the RNA polymerase I regulatory function 
of the histone information regulator (HIR) complex in higher eukaryotes (Neumuller et 
al., 2013). Furthermore, in a genome-wide screen in HeLa cells for 40S ribosomal 
subunit maturation factors, 302 proteins were identified, several of which were novel 
factors that are not present in yeast (Badertscher et al., 2015). Results from these 
pioneering studies thus not only support divergent roles for proteins in ribosome 
biogenesis that are conserved from yeast to humans, but also support the hypothesis that a 
subset of proteins unique to higher eukaryotes play important functional roles in the 
regulation of ribosome biogenesis.    
Among the early screening campaigns to identify unique regulators of ribosome 
biogenesis in higher eukaryotes, we performed a screen identifying proteins that regulate 
nucleolar number. This screening approach was based on the prior observation that 
depletion of ribosome biogenesis factors, UTP4 and NOL11, decreased nucleolar number 
from 2-3 per nucleus to one (Freed et al., 2012). Kat McCann and the Yale Center for 
Molecular Discovery executed the genome-wide siRNA screen in the near-diploid 
MCF10A human breast epithelial cell line for proteins involved in the regulation of 
nucleolar number, and Katherine Farley-Barnes defined a high confidence set of 139 hits 
that, when depleted, decreased nucleolar number in cells to one per nucleus (Farley-
Barnes et al., 2018). Remarkably, a large proportion of the hits had no previously defined 
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role in ribosome biogenesis and yet investigation on a subset of these proteins revealed 
varied ribosome biogenesis deficits upon depletion, ranging from RNAPI transcriptional 
silencing to aberrant pre-rRNA processing and decreased protein synthesis. Furthermore, 
the majority of hits do not have a known ortholog in yeast, strengthening support for the 
hypothesis that there exist unique regulators of ribosome biogenesis in higher eukaryotes. 
Our screening for regulators of nucleolar number was therefore a viable approach for 
uncovering novel human ribosome biogenesis factors.  
In addition to identifying proteins that decreased nucleolar number when 
depleted, our screen also uncovered proteins that increased nucleolar number. I report on 
my analyses of the results from this side of the screen, where I defined 113 high 
confidence hits that, when depleted, caused an increase in the percentage of cells with ≥5 
nucleoli. I also performed a range of bioinformatic analyses on the screen hits, and with 
the Yale Center for Molecular Discovery, performed screen validation and cell cycle 
profiling. The results from these analyses reveal the identity of a unique subset of 
proteins in the human proteome, the majority of which have no known ortholog in S. 
cerevisiae, that are required for the maintenance of typical nucleolar numbers in the 
MCF10A human breast epithelial cell line. 
 
RESULTS 
siRNA screen for increased nucleolar number revealed 113 hits 
 A genome-wide, high-content siRNA screen was performed by Kathleen L. 
McCann, in collaboration with the Yale Center for Molecular Discovery, to identify 
novel protein regulators of ribosome biogenesis in higher eukaryotes (Figure 2-1). To 
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achieve this objective, the expression of 18,107 genes was targeted in the human breast 
epithelial cell line, MCF10A, by pools of 4 individual siRNAs in order to identify 
proteins whose depletion caused an increase in the percentage of cells with ≥5 nucleoli 
(Figure 2-1, A). Nucleoli were identified based on immunofluorescent staining with a 
monoclonal antibody to the abundant nucleolar protein fibrillarin [72B9 (Reimer et al., 
1987)], and cells were identified using the DNA stain, Hoechst. A pipeline in CellProfiler 
(Carpenter et al., 2006; McQuin et al., 2018) was developed by the Yale Center for 
Molecular Discovery to perform the unbiased enumeration of nucleoli. The average 
number of nucleoli per nucleus was quantified from 3 fields of view for each gene target 
and normalized to the average of the 16 negative and 16 positive control wells (3 fields of 
view each) included on the same plate. The negative control was siRISC-free and set to a 
0 percent effect (PE) and the positive control was siKIF11 and set to a 100 PE. The result 
of this screen was therefore a calculated normalized percent effect (NPE) for each gene 
target that was used to identify screen hits. 
 This screen for increased nucleolar number revealed 113 high-confidence hits. 
Initially, hits were identified as genes with an NPE ≥ mean + 3 standard deviations (SD), 
which revealed 186 hits, including the positive control KIF11 (Figure 2-1, B). I filtered 
this list to identify a high confidence set of hits by first discarding 38 hits that were not 
expressed in MCF10A cells. This was determined based on a transcriptome analysis I 
performed in Partek Flow with RNA collected by Katherine Farley-Barnes from 
MCF10A cells treated with a non-targeting (NT) control pool of siRNAs (n=3; FPKM>0; 
GEO accession no. GSE154764). I then filtered the list by viability, discarding hits with a 
viability of <5% relative to the calculated average viability of the 16 siRISC-free control 
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wells on the same plate. This filter was included to ensure that an adequate number of 
cells were used to determine the NPE. This step resulted in the elimination of 35 hits, 
leaving 113 hits that I identified as high-confidence hits that, when depleted, cause an 
increase in the percentage of cells with ≥5 nucleoli per nucleus (Appendix II). 
 Screen performance based on statistical measures was strong. The Z-prime factor 
was calculated for each screening plate to monitor screen performance (n=58; Figure 2-1, 
C). The Z-prime factor is a statistical measure of the separation between the negative and 
positive controls. A Z-prime =1 indicates an ideal screening assay, whereas a Z-prime <0 
indicates significant overlap between the controls and an unusable assay. While an 
excellent screening assay is often defined as one with a Z-prime >0.5, Z-prime factors 
between 0 and 0.5 are still acceptable for the positive identification of hits. The average 
Z-prime for the screen was strong at 0.41, with a Z-prime for all plates >0. Additionally, 
the mean signal to background ratio (S/B) was also monitored throughout the screen 
(Figure 2-1, D). The average S/B for the screen was 10.29. Viability across all gene 
targets was variable, ranging from 0.41-160.16, and also highly variable among the hits, 
ranging from 0.80-73.70 prior to filtering, but all with a viability of <100% (Figure 2-1, 
E). A representative subset of images and NPE from the scree are shown (Figure 2-2, A), 
including the frequency distribution of nucleoli per nucleus, which shows a flattening and 









Figure 2-1. High-content, genome-wide siRNA screen in human MCF10A cells revealed 
113 hits that increase the percentage of nuclei with ≥5 nucleoli. Previously published in 
(Ogawa et al., 2021). 
(A) Screen workflow. MCF10A cells were reverse transfected into 384-well plates 
containing the siGENOME SMARTpool siRNA genome library (Horizon Discovery). 
After 72 hours, cells were fixed, permeabilized, and stained with an antibody to the 
nucleolar protein fibrillarin and Hoechst dye to stain the nucleus. Cell images were 
collected on an IN Cell Analyzer 2200 widefield, multicolor, fluorescent microscope and 
nucleolar number quantified using a pipeline in CellProfiler (Carpenter et al., 2006; 
McQuin et al., 2018).  
(B) Screen analysis workflow. 18,107 genes were screened, and hits were identified 
based on a cut-off of ≥3 SD from the mean percent effect (PE) normalized to the positive 
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(siKIF11, 100 PE) and negative (siRISC-free, 0 PE) controls. Viability relative to 
siRISC-free negative control was quantified based on Hoechst-stained nuclei, and hits 
were then discarded if not expressed in MCF10A cells and if viability was <5%. 113 high 
confidence hits remained and of those we validated a subset (n=19/20; 95%) by 
oligonucleotide deconvolution, where the siRNAs in the pools are re-tested individually 
to ensure that the observed increase in nucleolar number is driven by more than one 
siRNA. 
(C) Z-prime statistic by plate (left) and as a minimum to maximum box and whiskers plot 
(right) indicated a strong, screenable phenotype with an average Z-prime of 0.41 and a Z-
prime on all plates of >0.  
(D) Signal-to-background (S/B) ratio by plate (left) and as a minimum to maximum box 
and whiskers plot (right) indicated a strong S/B with an average S/B of 10.29.  
(E) Violin plot of the percent viability of all target genes and the 113 hits relative to 







Figure 2-2. Representative hits showing an increase in nuclei with ≥5 nucleoli. 
Previously published in (Ogawa et al., 2021). 
(A) Representative images of hits from the screen and the normalized percent effects 
(NPE). Shown are a selection of nuclei (100x100 μM) stained with Hoechst 33342 (blue) 
and an antibody to the nucleolar protein fibrillarin [72B9 (Reimer et al., 1987); pink] 
from the negative control (siRISC-free, 0 PE), positive control (siKIF11, PE), and 
representative screen hits (siH1-10, siINCENP, siMDN1, siENY2, siATAD5, and 
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siRACGAP1) enlarged 3-fold using bicubic interpolation from a single field of view 
(left), and a bar graph of the NPE (right). 
(B) Histograms of the relative frequency of nucleoli per nucleus and the number of nuclei 
quantified are shown for the controls and representative hits in A. Relative to siRISC-free 
(gray bars), among the hits (and KIF11; black bars) there is a clear decrease in nuclei 
with 2-3 nucleoli and an increase in nuclei with ≥5 nucleoli (gray bars=overlap between 
siRISC-free and hit). Histograms for siRISC-free and siKIF11 are representative and 
were generated from the images collected from a single screening plate (Plate 1; 16 wells; 
48 fields of view). Histograms for each hit were made from the images collected from 
their respective well and plate in the screen (3 fields of view). The x-axis was limited to 
10 nucleoli per nucleus to aid in visualization; protein depletion conditions with nuclei 
with >10 nucleoli include siRISC-free (n=3), siKIF11 (n=36), siH1-10 (n=1), siINCENP 




Bioinformatic analysis reveals a unique subset of proteins 
 To gain insight into the subset of proteins uncovered by this screen, I performed a 
range of bioinformatic analyses aimed at determining the degree of conservation, 
biological functions, and cellular localization of the 113 high confidence hits. Because 
the primary goal of this screen was to identify novel regulators of ribosome biogenesis in 
higher eukaryotes, I first identified the proportion of hits that are conserved to the yeast, 
Saccharomyces cerevisiae. To achieve this objective, I manually curated information 
from the published literature and two data mining tools. Using e!Ensembl’s BioMart tool 
(Kinsella et al., 2011), I identified 22/113 hits with yeast orthologs. Using the 
Saccharomyces Genome Database’s YeastMine tool (Balakrishnan et al., 2012), I 
identified 26/113 hits with yeast orthologs. Manual curation of these data resulted in the 
identification of 39/113 hits with yeast orthologs (Table 2-1; Appendix II). This analysis 
suggests that while one-third of the hits identified are conserved to yeast, two-thirds are 




Table 2-1. One-third (39/113) of the hits identified by increased nucleolar number in 
MCF10A cells are conserved to the yeast, Saccharomyces cerevisiae. For a subset of hits, 
more than one gene name is listed for the yeast ortholog due to a lack of consensus in the 
literature. The ≥5 nucleoli/nucleus normalized percent effect (NPE) and percent viability 
from the screen are also included.  
Screen hit (HGNC) Yeast ortholog ≥5 nucleoli/nucleus 
NPE 
Percent viability 
KIF11 Cin8/Kip1 68.75 19.00 
CDCA8 Nbl1 66.59 12.91 
CMPK2 Cdc8 64.91 17.38 
ATAD5 Elg1 59.75 27.67 
SKP1 Skp1 57.64 13.00 
MAN1A1 Mnl2 46.40 35.63 
INCENP Sli15 45.64 18.92 
ENY2 Sus1 41.93 6.02 
CUL1 Cdc53 41.61 36.50 
MDN1 Rea1 39.82 29.07 
ZDHHC17 Akr1/2 39.45 53.42 
PMM2 Sec53 37.35 23.22 
XRCC5 Yku80 35.61 42.14 
RRM1 Rnr1/3 35.33 9.46 
SMG5 Ebs1/Est1 31.03 27.66 
RFC1 Rfc1 30.18 46.61 
MCM6 Mcm6 29.60 54.59 
OSBP2 Hes1/Kes1 29.58 14.65 
TARS2 Mst1 28.66 36.20 
ABCE1 Rli1 28.57 25.65 
RIMS3 Tcb3 27.82 10.82 
H1-10 Hho1 27.78 31.61 
RACGAP1 Bem2/Rga1/2/Rgd1 27.62 15.60 
STK24 Kic1/Pbs2 27.53 13.92 
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SLC2A12 Stl1 27.49 71.34 
NGRN Rrg9 27.47 25.68 
LUC7L Luc7 27.15 25.86 
YIPF7 Yip1 27.11 5.29 
WRAP53 Swt21 27.10 9.48 
DYNC1H1 Dyn1 26.87 19.67 
FGD4 Cdc24/Rom1/2 26.65 28.85 
TOPBP1 Dpb11 26.37 10.58 
SMAP2 Glo3/Gts1 26.24 33.90 
OXNAD1 Aim33/Pga3 26.16 60.29 
MARCH9 Ssm4 26.06 68.46 
MPV17L2 Mpv17 25.65 13.92 
NFYB Hap3 25.50 41.60 
MASTL Pkh3/Rim15 25.41 32.46 






 To determine the biological functions associated with the 113 high confidence 
hits from the screen, I performed analyses using two distinct software packages with 
unique algorithms to determine statistical enrichment. First, I performed a Gene Ontology 
(GO) over-representation analysis using PANTHER (Mi et al., 2017). This analysis 
revealed enrichment of 80 overlapping GO-Slim categories associated with biological 
process (p<0.05). The top 19 enriched categories, defined as a log2 fold enrichment 
>3.33, were largely associated with DNA replication and mitosis, including Regulation of 
exit from mitosis (GO:0007096), DNA double-strand break processing (GO:0000729), 
Mitotic sister chromatid cohesion (GO:0007064), and Non-recombinational repair 
(GO:0000726), among others (Figure 2-3, A).  
Second, I performed the Molecular and Cellular Function core analysis in the 
Ingenuity Pathway Analysis software (IPA, Qiagen). Results from this analysis revealed 
23 molecular and cellular functions significantly associated with the 113 hits (-log10 
p>1.3; Table 2-2). The top functions revealed by this analysis, defined by the highest -
log10 p-value, were Cell Cycle, Cellular Assembly and Organization, and DNA 
Replication, Recombination, and Repair (Figure 2-3, B). However, an analysis of these 
three top categories in the STRING Consortium database of protein-protein interactions, 
revealed a large degree of overlap among the categories and interconnectedness among 
the hits (Figure 2-3, C). Taken together, both these analyses of biological function 
revealed that the screen uncovered a unique subset of proteins largely associated with cell 
cycle-related processes, particularly in S and M phase, that are also required for the 
regulation of nucleolar number. 
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Finally, I determined the cellular localization of the 113 high confidence hits 
uncovered by this screen. Specifically, I was interested in determining what proportion of 
the hits localize to the nucleolus, because I hypothesize that depletion of a nucleolar 
protein would cause changes to nucleolar form. To determine whether a hit localizes to 
the nucleolus, I utilized 3 nucleolar proteomes, including 2 generated by mass 
spectrometry (Ahmad et al., 2009; Jarboui et al., 2011; Leung et al., 2006), and 1 inferred 
by immunofluorescence confocal microscopy (Thul et al., 2017). If the hit was present in 
at least 1 of the 3 proteomes, I identified it as a nucleolar protein. Based on this analysis, 
23/113 (20.4%) hits were identified as nucleolar (Figure 2-3, D; Appendix II). When 
compared to estimates of the total number of nucleolar proteins in the human proteome 
(4-14%; Figure 2-3, D), this analysis suggests that our hits are enriched in nucleolar 
proteins. Thus, despite the lack of association with ribosome biogenesis categories in the 
analysis of biological function, the hits are enriched for nucleolar proteins suggesting the 
discovery of a unique subset of proteins required for the regulation of nucleolar number 
and the putative discovery of novel proteins required for the regulation of nucleolar 
function. 
The enrichment in nucleolar proteins further led to me ask whether the 113 high 
confidence hits are proteins required for the liquid-liquid phase separation (LLPS) 
behavior reported to drive nucleolar formation. Proteins with intrinsically disordered 
regions (IDRs) are thought to be key drivers of LLPS (Lafontaine et al., 2020); thus, I 
looked for the hits from this screen in the DisProt database of proteins with IDRs (Hatos 
et al., 2020). Intriguingly, only 4/113 hits contain IDRs (HYPK, MICA, SMG5, and 
XRCC5). This analysis suggests that while the hits are enriched in nucleolar proteins, the 
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majority are not proteins likely to contribute to the LLPS behavior associated with 
nucleolar formation; and furthermore, LLPS may not be the key driver in the 




Figure 2-3. Bioinformatic analysis of the 113 hits reveals a unique set of proteins 
required for maintaining normal nucleolar number. Previously published in (Ogawa et al., 
2021). 
(A) Gene Ontology (GO) over-representation analysis using PANTHER is shown as a bar 
graph of the top enriched GO-Slim categories associated with biological process (Log2 
fold enrichment >3.33; Binomial test, Bonferroni correction, p<0.05). Processes 
associated with mitosis [e.g. Regulation of exit from mitosis (GO:0007096) and Mitotic 
sister chromatid cohesion (GO:0007064)], and DNA replication and repair [e.g. DNA 
double-strand break processing (GO:0000729) and Non-recombinational repair 
(GO:0000726)] are common among the top enriched categories, but processes associated 




(B) Molecular and Cellular Function analysis in Ingenuity Pathway Analysis (IPA; 
Qiagen) is shown as a bar graph of the top 10 molecular and cellular functions associated 
with the 113 hits using the Fisher’s Exact Test scoring method in IPA (p<0.05). Top 
associated functions include Cell Cycle (n=31), Cellular Assembly and Organization 
(n=24), and DNA Replication, Recombination, and Repair (n=27). Colored bars are 
associated with the colored circles in C. All significantly associated categories and genes 
are listed in Table 2-2.  
(C) Interaction networks of the hits in the top 3 categories in B are shown as STRING 
high confidence (≥0.700 interaction score) interaction networks and reveal a large degree 
of overlap among the categories and interconnectedness among the hits. The heavier 
weighted lines represent the highest degree of confidence (≥0.900 interaction score).  
(D) Nucleolar proteins are enriched among the 113 hits. The percent of proteins in the 
human proteome (left) and of the hits (right) that localize to the nucleolus are shown as a 
bar graph. 20.4% of hits localize to the nucleolus, whereas the total number of nucleolar 
proteins in the human proteome ranges from 4.4-13.8%. These estimates were based on 3 
published datasets (Ahmad et al., 2009; Jarboui et al., 2011; Leung et al., 2006; Thul et 
al., 2017), and a total number of proteins equal to 19,670 based on (Thul et al., 2017). In 
our calculation based on NOPdb, we used 2,717 proteins as the number of nucleolar 




Table 2-2. Molecular and Cellular Function core analysis in the Ingenuity Pathway 
Analysis software (IPA; Qiagen) revealed a significant association of the 113 hits with 23 
categories. The screen hits included in each category are listed.  




Screen hits (HGNC) 
Cell cycle 5.66 31 CAMK2N1, CASP8AP2, CDCA5, 
CDCA8, CIAO2B, CUL1, DYNC1H1, 
ENY2, GEN1, HYPK, INCENP, KIF11, 
LIG3, MASTL, MCM6, MIA, NR0B2, 
RACGAP1, RBBP8, RFC1, RFFL, 
RRM1, SGO1, SHROOM2, SKP1, 




4.95 24 CDCA5, CDCA8, CIAO2B, CUL1, 
DYNC1H1, FGD4, GEN1, IFT88, 
INCENP, JHY, KIF11, LIG3, MIA, 
OSBP2, PRUNE1, RACGAP1, RAPH1, 
RBBP8, RIMS3, SGO1, SUV39H1, 




4.95 27 ATAD5, CDCA5, CIAO2B, CMPK2, 
CUL1, DYNC1H1, ENY2, GEN1, 
INCENP, KIF11, LIG3, MCM6, MICA, 
PAXX, RACGAP1, RBBP8, RFC1, 
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RRM1, SGO1, STK24, SUV39H1, 
TOPBP1, TPX2, TYMP, WRAP53, 
XRCC5, ZNF219 
Cell Morphology 3.32 16 CTF1, FGD4, IFT88, KIF11, LDB1, 
OSBP2, RACGAP1, RAPH1, RBBP8, 
RIMS3, SMAD5, SUV39H1, TOPBP1, 
TPX2, TYMP, XRCC5 
Nucleic Acid 
Metabolism 
2.91 4 CMPK2, PMM2, RRM1, TYMP 
Small Molecule 
Biochemistry 
2.91 13 CMPK2, DYNC1H1, GLYATL2, 
HSD11B2, KMT2C, NAT2, NR0B2, 
OSBP2, PMM2, RAPH1, RRM1, 
SUV39H1, TYMP 
Molecular Transport 2.69 6 KMT2C, NR0B2, RACGAP1, RAPH1, 
SLC26A7, TYMP 
 
Cellular Function and 
Maintenance 
2.42 17 CD A5, DYNC1H1, FGD4, IFT88, 
JHY, KIF11, MIA, PRUNE1, RAPH1, 
RBBP8, RIMS3, SGO1, SMAD5, 
SUV39H1, TOPBP1, TPX2, XRCC5 
 
Cell Death and 
Survival 
2.42 36 A CE1, AGR2, ASIC1, AT 5, 
CASP8AP2, CCN4, CDCA5, CTF1, 
CUL1, DYNC1H1, FGD4, HSD11B2, 
HYPK, IFT88, INCENP, KIF11, LIG3, 
MDN1, MIA, MICA, NR0B2, OSBP2, 
PAXX, RACGAP1, RFC1, RRM1, 
SHC3, SHROOM2, SMAD5, STK24, 
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2.32 5 ASIC1, GTF2IRD1, HSD11B2, IFT88, 
MICA Cellular Compromise 2.32 9 ASIC1, CTF1, CUL1, DYNC1H1, 
KIF11, MICA, RACGAP1, SKP1, 
XRCC5 
Cellular Development 2.32 15 CCN4, CD 5, CTF1, CUL1, EBF3, 
IFT88, MIA, OSBP2, PRUNE1, RAPH1, 
RFC1, RIMS3, SMAD5, STK24, 
SUV39H1 
Cellular Growth and 
Proliferation 
2.32 16 CCN4, CDCA5, CTF1, CUL1, EBF3, 
HSD11B2, IFT88, LDB1, MIA, OSBP2, 
PRUNE1, RAPH1, RFC1, RIMS3, 
SMAD5, SUV39H1 
Cellular Movement 2.32 5 CCN4, FGD4, IFT88, INCENP, MIA 
Cellular Response to 
Therapeutics 
2.32 2 PAXX, XRCC5 
Drug Metabolism 2.32 3 CMPK2, HSD11B2, NAT2 
Lipid Metabolism 2.32 7 DYNC1H1, GLYATL2, HSD11B2, 
KMT2C, NR0B2, OSBP2, RAPH1 Amino Acid 
Metabolism 
2.02 2 GLYATL2, SUV39H1 
Carbohydrate 
Metabolism 
2.02 2 PMM2, RAPH1 
Gene Expression 2.02 3 LIG3, NR0B2, SUV39H1 
Post-Translational 
Modification 
2.02 4 FGD4, GLYATL2, MAP4K5, SUV39H1 
Vitamin and Mineral 
Metabolism 
1.84 1 NR0B2 




Screen validation supports approach and the identification of unique subset of proteins 
 Following initial evaluation of screen performance and hit analysis, I sought to 
validate the screen due to the known potential for siRNAs to bind unintended targets. 
While nucleolar enrichment served as primary evidence for the validity of the screening 
approach, in addition I performed oligonucleotide deconvolution on a subset of hits in 
collaboration with the Yale Center for Molecular Discovery. Oligonucleotide 
deconvolution is a common approach to siRNA screen validation, where the siRNAs in 
the pools against each target are tested individually in the primary screening assay 
(Sigoillot and King, 2011). I subjectively selected a representative subset of the high 
confidence hits to include in the validation assay (20/113, or ~20% of the hits; Table 2-
3), including mitosis and DNA replication factors, nucleolar and non-nucleolar proteins, 
and proteins with putative RNA binding domains. Results revealed that 19/20 hits 
validated based on at least 2 of the 4 individual siRNAs in the original pools yielding an 
increase in percentage of cells with ≥5 nucleoli per nucleus (Z-prime=0.61; NPE≥15; 
Table 2-4). These data suggested a 95% validation rate, which supported the screen 
results and the unique subset of proteins identified by this approach. 
I also compared the proteins uncovered by the screen to other published screens 
of nucleolar form and function. I compared the 113 high confidence hits to screens in S. 
cerevisiae (Neumuller et al., 2013), D. melanogaster (Neumuller et al., 2013), and in 
human cell lines (Badertscher et al., 2015; Tafforeau et al., 2013; Wild et al., 2010), to 
identify the degree of overlap among the hits and different screening approaches. 
Intriguingly, this analysis revealed minimal overlap between this screen for increased 
nucleolar number and other approaches (<2%; Table 2-5). Notably, however, in the 
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genome-wide screens for changes to nucleolar size or fragmentation in S. cerevisiae and 
D. melanogaster (Neumuller et al., 2013), our positive control and hit 
KIF11/Cin8/Klp61f was identified in both datasets. Furthermore, in S. cerevisiae, an 
enrichment for mitotic spindle assembly proteins was uncovered (Neumuller et al., 2013), 
consistent with the discovery of mitosis-associated factors in this screen. Thus, while 
there was a low degree of overlap among the hits, this analysis revealed a putative 
conserved link between the nucleolar regulation and mitosis.  
The 113 high confidence hits were also compared to screens in human cell lines. I 
compared the hits to 3 screens performed in HeLa cells that aimed to identify novel 
factors required for ribosome biogenesis in humans. Two screens utilized fluorescently-
tagged ribosomal proteins to identify proteins required for ribosomal subunit export 
(Badertscher et al., 2015; Wild et al., 2010), and the third used northern blots to identify 
proteins required for pre-rRNA processing (Tafforeau et al., 2013). Here, only 6 hits 
overlapped with the high confidence hits, including ABCE1, MDN1, DYNC1H1, 
CDCA8, SUV39H1, and TOPBP1 (Table 2-5). DYNC1H1 and CDCA8 both have 
reported roles in mitosis (Gassmann et al., 2004; Raaijmakers and Medema, 2014; 
Sampath et al., 2004); whereas ABCE1, MDN1, SUV39H1, and TOPBP1 have all been 
previously reported to be required for ribosome biogenesis and/or ribosome function 
(Bassler et al., 2010; Galani et al., 2004; Mooser et al., 2020; Murayama et al., 2008; 
Pisarev et al., 2010; Sokka et al., 2015; Young et al., 2015). Possible explanations for the 
lack of significant overlap include species (S cerevisiae vs. human) and cell line 
differences (MCF10A vs. HeLa), as well as differences in scale (genome-wide vs. 
candidate approach) and the screening assay itself (nucleolar number vs. fluorescent r-
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protein retention). Finally, the hits were also completely non-overlapping with the hits 
from the parallel screen for decreased nucleolar number (Farley-Barnes et al., 2018). 
Taken together, this unique screening approach for increased nucleolar number led to the 
discovery of a distinct subset of proteins required to maintain the typical nucleolar form.    
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Table 2-3. High-confidence screen hits validated by oligonucleotide deconvolution. 20 
hits were selected for validation by oligonucleotide deconvolution. The 14 hits selected 
for further analysis have the HGNC symbol in bold. Nucleolar localization (Y/N) and a 
brief description of each hit are included.  
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Table 2-4. Oligonucleotide deconvolution of 20 screen hits supports validity of the 
screen approach and the identification of a unique subset of proteins. Listed are the 4 
individual siRNAs for each hit, the mean percent effect (PE) of 3 wells, standard 
deviation (SD) of 3 wells, the mean normalized percent effect (NPE) relative to the 
negative (siRISC-free) and positive controls (siKIF11 pool), and whether the mean NPE 
was ≥15. If at least 2/4 individual siRNAs yielded a mean NPE≥15, the hit was 
considered validated. 
Hit (siRNA) Mean PE SD (PE) Mean NPE ≥15 Mean 
NPE (Y/N) 
siRISC-free 4.45 0.98 0.00  
siKIF11 (pool) 44.23 4.13 100.00  
siKIF11     
     siKIF11-05 40.25 1.27 116.70 Y 
     siKIF11-06 51.64 3.09 118.62 Y 
     siKIF11-07 34.19 3.93 74.75 Y 
     siKIF11-08 50.88 1.27 116.70 Y 
siATAD5     
     siATAD5-01 26.57 1.51 55.60 Y 
     siATAD5-02 11.01 0.39 16.49 Y 
     siATAD5-03 14.40 1.39 25.01 Y 
     siATAD5-04 13.44 5.39 22.60 Y 
siCCN4     
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     siCCN4-01 11.55 0.45 17.85 Y 
     siCCN4-02 11.81 1.38 18.51 Y 
     siCCN4-03 13.95 0.31 23.89 Y 
     siCCN4-17 21.20 2.96 42.10 Y 
siCDCA8     
     siCDCA8-01 37.14 1.82 82.17 Y 
     siCDCA8-02 28.40 1.02 60.19 Y 
     siCDCA8-03 13.76 1.04 23.40 Y 
     siCDCA8-04 22.11 0.55 44.40 Y 
siENY2     
     siENY2-01 10.67 1.70 15.62 Y 
     siENY2-02 16.01 0.21 29.06 Y 
     siENY2-03 14.25 1.59 24.64 Y 
     siENY2-04 11.03 1.41 16.54 Y 
siINCENP     
     siINCENP-01 29.64 1.48 63.31 Y 
     siINCENP-02 47.36 4.27 107.86 Y 
     siINCENP-03 38.02 4.75 84.39 Y 
     siINCENP-04 30.33 0.53 65.05 Y 
siRACGAP1     
     siRACGAP1-01 24.96 2.42 51.56 Y 
     siRACGAP1-02 18.03 3.41 34.13 Y 
     siRACGAP1-03 30.90 1.33 66.49 Y 
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     siRACGAP1-04 27.69 2.63 58.42 Y 
siTPX2     
     siTPX2-01 19.90 4.89 38.82 Y 
     siTPX2-02 45.26 2.08 102.59 Y 
     siTPX2-03 19.99 1.01 39.05 Y 
     siTPX2-04 17.00 0.77 31.55 Y 
siABCE1     
     siABCE1-01 24.62 2.43 50.71 Y 
     siABCE1-02 13.45 0.98 22.63 Y 
     siABCE1-04 14.92 2.27 26.31 Y 
     siABCE1-17 8.37 1.08 9.86 N 
siDYNC1H1     
     siDYNC1H1-01 13.36 0.73 22.40 Y 
     siDYNC1H1-02 14.36 1.14 24.91 Y 
     siDYNC1H1-03 35.99 3.39 79.29 Y 
     siDYNC1H1-04 8.05 1.42 9.05 N 
siCIAO2B     
     siCIAO2B-01 14.16 0.51 24.41 Y 
     siCIAO2B-03 7.48 0.72 7.62 N 
     siCIAO2B-04 10.61 0.13 15.48 Y 
     siCIAO2B-18 14.87 1.84 26.18 Y 
siFAM98A     
     siFAM98A-01 13.77 2.40 23.43 Y 
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     siFAM98A-02 16.63 2.65 30.61 Y 
     siFAM98A-03 4.01 0.28 -1.10 N 
     siFAM98A-04 19.51 2.30 37.85 Y 
siH1-10     
     siH1-10-01 12.40 1.06 19.98 Y 
     siH1-10-02 19.69 1.57 38.30 Y 
     siH1-10-03 11.17 1.69 16.89 Y 
     siH1-10-04 8.55 1.76 10.30 N 
siINKA1     
     siINKA1-01 36.83 2.22 81.39 Y 
     siINKA1-02 9.41 0.93 12.47 N 
     siINKA1-03 11.47 0.79 17.64 Y 
     siINKA1-04 32.87 1.73 71.44 Y 
siKTN1     
     siKTN1-17 21.11 1.03 41.87 Y 
     siKTN1-18 21.96 1.71 44.02 Y 
     siKTN1-19 6.29 0.58 4.61 N 
     siKTN1-20 11.18 0.80 16.93 Y 
siWRAP53     
     siWRAP53-19 5.60 0.11 2.90 N 
     siWRAP53-20 15.64 1.69 28.11 Y 
     siWRAP53-21 11.79 1.90 18.45 Y 
     siWRAP53-22 19.78 1.31 38.53 Y 
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siLUC7L     
     siLUC7L-01 18.85 3.88 36.19 Y 
     siLUC7L-02 7.11 1.19 6.67 N 
     siLUC7L-03 7.57 0.44 7.84 N 
     siLUC7L-04 13.21 0.27 22.01 Y 
siMDN1     
     siMDN1-03 10.91 0.66 16.23 Y 
     siMDN1-17 8.77 1.43 10.86 N 
     siMDN1-18 8.00 0.41 8.92 N 
     siMDN1-19 15.60 0.96 28.03 Y 
siRFC1     
     siRFC1-01 9.35 0.98 12.31 N 
     siRFC1-02 10.73 0.82 15.79 Y 
     siRFC1-03 12.80 1.63 20.99 Y 
     siRFC1-04 4.69 0.43 0.60 N 
siSTK24     
     siSTK24-05 7.25 0.96 7.04 N 
     siSTK24-21 5.17 0.56 1.81 N 
     siSTK24-22 11.48 0.98 17.66 Y 
     siSTK24-23 16.34 1.21 29.89 Y 
siXRCC5     
     siXRCC5-01 7.67 1.02 8.08 N 
     siXRCC5-02 7.19 0.71 6.89 N 
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     siXRCC5-03 3.85 0.32 -1.50 N 




Table 2-5. Overlap of high confidence screen hits with proteins identified in other 
screens for regulators of ribosome biogenesis reveals a unique subset of proteins. The 113 
high confidence hits were compared to the hit lists from screens in human cell lines 
(Badertscher et al., 2015; Tafforeau et al., 2013; Wild et al., 2010), S. cerevisiae 
(Neumuller et al., 2013), and D. melanogaster (Neumuller et al., 2013) as indicated. 
Indicated in parentheses are the number of overlapping hits compared to the total number 
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Nuclear area is significantly larger in nuclei with ≥5 nucleoli 
Observations of images from the screen, like those shown in Figure 2-2, A, 
suggest that the nuclei of screen hits with ≥5 nucleoli may be larger than the nuclei in the 
siRISC-free control. To test whether nuclei are larger, using the images collected for the 
subset of hits analyzed in the screen validation, I used CellProfiler to classify nuclei by 
nucleolar number (0-4 vs. ≥5) and quantify the nuclear area of the Hoechst stain. My 
analysis revealed that the nuclear area of nuclei ≥5 nucleoli are significantly larger than 
nuclei with 0-4 nucleoli (n=3 or 6; q<0.01; Figure 2-4, A and B; Table 2-6). Interestingly, 
however, this result is observed not only when screen hits are depleted, but also in the 
negative control cells. There is some variability in the nuclear size increase among some 
hits; notably, depletion of CDCA8 and INCENP resulted in a ≥2-fold increase in the 
nuclear area of nuclei with ≥5 nucleoli compared to siRISC-free and a majority of the 
screen hits (Figure 2-4, B). These proteins are known mitotic inhibitors and thus suggests 
that this increase may be driven by a failure in cell division. As a result, and in addition to 
the bioinformatic analyses revealing significant association of screen hits with the cell 
cycle, these data suggest that cell cycle profiling is warranted to address whether failed 
cell cycle progression, specifically in mitosis, is a unifying feature of cells treated with 





Figure 2-4. Nuclear area is significantly greater in nuclei with ≥5 nucleoli. Previously 
published in (Ogawa et al., 2021). 
(A) Nuclear area is greater in nuclei with ≥5 nucleoli, including in the siRISC-free 
treatment. Nuclear area was quantified in pixels using analysis of the Hoechst-stained 
images collected for screen validation by oligonucleotide deconvolution. Three (3) 
replicates were analyzed for each screen hit depletion and 6 replicates were analyzed in 
this analysis for the controls, siRISC-free and siKIF11 (pool). Blue dots=nuclei with 0-4 
nucleoli. Red dots=nuclei with ≥5 nucleoli. Each dot represents the mean ± SD of an 
individual siRNA (SD=black vertical line). For each blue dot there is a corresponding red 
dot (Table 2-6).  
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(B) Volcano plot of the statistical analysis of the data in A reveals that in all depletion 
conditions, including siRISC-free, nuclei with ≥5 nucleoli are significantly larger that 
nuclei with 0-4 nucleoli. Unpaired t-tests were performed, and significance was 
determined based on a False Discovery Rate approach using the two-stage step-up 
method of Benjamini, Krieger and Yekutieli (n=3 or 6; q<0.01/-log q-value>2; Table 2-
6). The x-axis represents the difference in nuclear area between nuclei with 0-4 nucleoli 
and ≥5 nucleoli. The purple dots=individual siRNAs with the greatest difference between 
the two categories. Light orange dots=siINCENP individual siRNAs. Dark orange 




Table 2-6. Nuclear area analysis of screen hit depletions comparing nuclei with 0-4 
nucleoli to nuclei with ≥5 nucleoli. For each screen hit depletion, nuclei were classified 
as either nuclei with 0-4 nucleoli or ≥5 nucleoli and the average nuclear area was 
calculated (n=3 for hits; n=6 for controls). Significance was determined by unpaired t-
tests and based on a False Discovery Rate approach using the two-stage step-up method 
of Benjamini, Krieger and Yekutieli (n=3 or 6; q<0.01/-log q-value>2). siRISC-
free=negative control. siKIF11 (pool)=screen positive control. 
Screen Hit 
(siRNA HGNC, -




(mean ± SD) 
Nuclear area 
≥5 nucleoli 
(mean ± SD) 
Significance 
(q-value) 
siRISC-free 206.4 ± 2.9 365.7 ± 6.5 q<0.0001 
siKIF11 (pool) 435.8 ± 10.1 666.9 ± 18.1 q<0.0001 
siKIF11 -05 382.2 ± 10.4 572.5 ± 14.5 q<0.0001 
siKIF11 -06 374.9 ± 11.9 640.1 ± 29.5 q<0.001 
siKIF11 -07 409.2 ± 16.8 676.5 ± 26.3 q<0.001 
siKIF11 -08 430.4 ± 22.1 678.7 ± 28.5 q<0.001 
siABCE1 -01 345.6 ± 15.5 567.6 ± 22.4 q<0.001 
siABCE1 -02 244.4 ± 3.5 403.3 ± 6.5 q<0.0001 
siABCE1 -04 270.8 ± 4.6 404.7 ± 11.5 q<0.0001 
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siABCE1 -17 243.8 ± 6.0 374.3 ± 3.7 q<0.0001 
siATAD5 -01 342.5 ± 11.0 503.6 ± 23.5 q<0.001 
siATAD5 -02 245.6 ± 3.2 356.4 ± 8.2 q<0.0001 
siATAD5 -03 264.5 ± 7.1 411.7 ± 8.2 q<0.0001 
siATAD5 -04 262.2 ± 5.9 417.5 ± 21.0 q<0.001 
siCCN4 -01 254.2 ± 6.1 437.5 ± 5.7 q<0.0001 
siCCN4 -02 359.6 ± 30.2 551.9 ± 57.1 q<0.01 
siCCN4 -03 294.4 ± 6.8 417.0 ± 7.5 q<0.0001 
siCCN4 -17 347.8 ± 7.6 519.7 ± 11.3 q<0.0001 
siCDCA8 -01 318.2 ± 21.5 892.2 ± 1.5 q<0.0001 
siCDCA8 -02 342.4 ± 5.0 887.7 ± 36.1 q<0.0001 
siCDCA8 -03 301.8 ± 3.9 634.8 ± 12.7 q<0.0001 
siCDCA8 -04 322.3 ± 8.6 728.9 ± 4.6 q<0.0001 
siCIAO2B -01 286.0 ± 5.4 412.7 ± 3.2 q<0.0001 
siCIAO2B -03 277.8 ± 9.4 446.7 ± 21.1 q<0.001 
siCIAO2B -04 270.5 ± 1.9 445.7 ± 4.1 q<0.0001 
siCIAO2B -18 305.7 ± 4.4 433.4 ± 16.5 q<0.001 
 
79 
siDYNC1H1 -01 311.5 ± 2.3 464.9 ± 13.1 q<0.0001 
siDYNC1H1 -02 296.8 ± 2.4 511.1 ± 6.1 q<0.0001 
siDYNC1H1 -03 427.8 ± 2.6 644.3 ± 4.9 q<0.0001 
siDYNC1H1 -04 271.8 ± 5.5 483.0 ± 3.6 q<0.0001 
siENY2 -01 284.6 ± 3.5 507.5 ± 12.6 q<0.0001 
siENY2 -02 254.6 ± 5.3 446.6 ± 15.3 q<0.0001 
siENY2 -03 272.8 ± 1.8 464.5 ± 11.5 q<0.0001 
siENY2 -04 307.5 ± 6.2 479.5 ± 1.7 q<0.0001 
siFAM98A -01 395.4 ± 5.7 663.7 ± 15.4 q<0.0001 
siFAM98A -02 357.8 ± 24.9 554.2 ± 27.6 q<0.001 
siFAM98A -03 206.6 ± 3.9 386.6 ± 9.8 q<0.0001 
siFAM98A -04 329.4 ± 4.2 505.3 ± 14.8 q<0.0001 
siH1-10 -01 274.9 ± 10.2 444.9 ± 16.8 q<0.001 
siH1-10 -02 313.8 ± 4.2 493.6 ± 9.2 q<0.0001 
siH1-10 -03 244.2 ± 4.9 392.5 ± 8.5 q<0.0001 
siH1-10 -04 323.7 ± 6.4 514.4 ± 37.9 q<0.01 
siINCENP -01 340.5 ± 9.4 832.2 ± 13.0 q<0.0001 
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siINCENP -02 426.7 ± 14.7 788.9 ± 10.0 q<0.0001 
siINCENP -03 449.7 ± 8.8 886.4 ± 6.5 q<0.0001 
siINCENP -04 355.5 ± 6.2 672.4 ± 13.8 q<0.0001 
siINKA1 -01 417.5 ± 7.3 630.3 ± 9.4 q<0.0001 
siINKA1 -02 262.5 ± 3.4 488.3 ± 13.9 q<0.0001 
siINKA1 -03 258.9 ± 8.2 382.9 ± 1.4 q<0.0001 
siINKA1 -04 377.2 ± 5.9 579.2 ± 12.5 q<0.0001 
siKTN1 -17 301.1 ± 16.8 467.2 ± 7.8 q<0.001 
siKTN1 -18 364.0 ± 3.1 532.1 ± 11.4 q<0.0001 
siKTN1 -19 216.3 ± 3.0 375.5 ± 5.0 q<0.0001 
siKTN1 -20 262.9 ± 3.8 420.5 ± 11.7 q<0.0001 
siLUC7L -01 299.1 ± 8.4 451.4 ± 14.6 q<0.001 
siLUC7L -02 278.5 ± 12.5 474.4 ± 27.6 q<0.001 
siLUC7L -03 245.2 ± 3.2 379.3 ± 7.9 q<0.0001 
siLUC7L -04 281.2 ± 12.3 424.0 ± 21.0 q<0.001 
siMDN1 -03 251.2 ± 3.0 388.2 ± 12.3 q<0.0001 
siMDN1 -17 343.7 ± 4.7 542.5 ± 14.4 q<0.0001 
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siMDN1 -18 280.5 ± 6.2 460.7 ± 8.9 q<0.0001 
siMDN1 -19 279.3 ± 2.5 431.6 ± 10.9 q<0.0001 
siRACGAP1 -01 318.7 ± 3.5 585.2 ± 6.8 q<0.0001 
siRACGAP1 -02 285.1 ± 9.7 540.0 ± 5.5 q<0.0001 
siRACGAP1 -03 328.5 ± 10.5 624.4 ± 13.5 q<0.0001 
siRACGAP1 -04 300.5 ± 9.1 612.2 ± 28.2 q<0.0001 
siRFC1 -01 268.2 ± 5.5 431.4 ± 6.8 q<0.0001 
siRFC1 -02 288.4 ± 5.9 450.9 ± 3.2 q<0.0001 
siRFC1 -03 288.9 ± 11.5 418.6 ± 12.7 q<0.001 
siRFC1 -04 203.3 ± 1.5 412.1 ± 10.0 q<0.0001 
siSTK24 -05 302.4 ± 4.7 479.9 ± 14.3 q<0.0001 
siSTK24 -21 214.0 ± 0.8 385.5 ± 10.9 q<0.0001 
siSTK24 -22 269.5 ± 3.2 427.1 ± 11.2 q<0.0001 
siSTK24 -23 311.2 ± 3.1 439.1 ± 9.7 q<0.0001 
siTPX2 -01 413.9 ± 25.9 641.0 ± 31.6 q<0.001 
siTPX2 -02 367.8 ± 11.9 613.8 ± 24.1 q<0.001 
siTPX2 -03 352.0 ± 4.8 559.8 ± 0.6 q<0.0001 
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siTPX2 -04 299.9 ± 2.2 570.1 ± 5.9 q<0.0001 
siWRAP53 -19 211.7 ± 1.4 389.8 ± 4.1 q<0.0001 
siWRAP53 -20 276.9 ± 2.9 407.9 ± 7.7 q<0.0001 
siWRAP53 -21 279.4 ± 5.5 457.2 ± 17.4 q<0.0001 
siWRAP53 -22 288.0 ± 1.8 440.0 ± 5.4 q<0.0001 
siXRCC5 -01 243.6 ± 5.8 378.0 ± 3.6 q<0.0001 
siXRCC5 -02 238.6 ± 1.1 389.1 ± 10.2 q<0.0001 
siXRCC5 -03 218.0 ± 2.9 370.8 ± 6.5 q<0.0001 




Cell cycle analysis reveals proteins required for progression through S and G2/M phase 
 
To evaluate whether failed cell cycle progression upon depletion of screen hits is 
a unifying theme, I used high-content image analysis of the Hoechst-stained nuclei as 
previously reported (Chan et al., 2013; Gomes et al., 2018; Roukos et al., 2015; Roukos 
et al., 2013). Using the images collected for screen validation by oligonucleotide 
deconvolution (Table 2-3), the integrated intensity of the Hoechst stain for each nucleus 
was quantified and log2 values were plotted as histograms for each of the 4 individual 
siRNAs from the 20 hits. Cell cycle phases were normalized to the siRISC-free 2N and 
4N peaks as described in (Chan et al., 2013). I concluded cell cycle accumulation 
conservatively when depletion of at least 2 of 4 individual siRNAs resulted in a 
significant ≥2-fold decrease or increase in the percent of nuclei in a phase relative to 
siRISC-free (q<0.01). As expected, depletion of KIF11, a mitotic kinesin, resulted in an 
accumulation of cells in G2/M phase (Figure 2-5; Appendix III). However, depletion of 
only 2/20 hits caused an accumulation of cells in G2/M (INCENP and TPX2), with an 
additional 6/20 hits yielding a significant increase in >4N DNA content (ABCE1, 
CDCA8, DYNC1H1, ENY2, INKA1, and RACGAP1; Figure 2-5; Appendix III). 
Mitosis-associated factors, CDCA8, INCENP, and RACGAP1, yielded the greatest 
accumulation of nuclei with >4N DNA content (>10% nuclei), while the increase among 
the other hits was more modest (<10% nuclei).  
Cell cycle data were confirmed by at least a 50% increase in at least 1 of 2 
replicates in a separate cell cycle profiling experiment where the hits in bold in Table 2-3 
were depleted using the siRNA pools (Table 2-7). Furthermore, cell cycle results are 
consistent with a post hoc analysis of the screen images that I performed to evaluate how 
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our CellProfiler pipeline segmented atypical nuclei and nucleoli. I observed annular and 
semi-annular nuclei among some hits (e.g. siINCENP), which are indicative of late 
mitotic defects, that were counted both as one and more than one nucleus potentially 
skewing estimates of nucleolar number [Figure 2-6; (Verstraeten et al., 2011)]. I also 
observed “stretched” nucleoli, reminiscent of anaphase bridges and mitotic defects [e.g. 
siMDN1; (Daniloski et al., 2019)], that in some cases could lead to an over-estimate of 
nucleolar number (Figure 2-7). Regardless, while defects in G2/M phase progression and 
cytokinesis failures were present among the hits tested, they were not observed in all 
cases. 
Other aspects of the cell cycle were also affected to varying degrees. In addition 
to hits that, when depleted, caused an accumulation of cells in G2/M phase, our analysis 
also revealed that depletion of 8/20 hits caused a significant accumulation of cells in S 
phase (q<0.01; CIAO2B, DYNC1H1, ENY2, FAM98A, LUC7L, RFC1, STK24, and 
WRAP53; Figure 2-5; Appendix III). Interestingly, 2 of these (DYNC1H1 and ENY2) 
were hits that also led to a significant increase in nuclei with >4N DNA content, 
suggesting that defects in S phase progression may also contribute to failures in cell 
division. Furthermore, 4 hits (CDCA8, INCENP, RACGAP1, and TPX2) resulted in a 
significant decrease in nuclei in G0/G1 phase and correlate with the hits that resulted in 
an accumulation of cells in either G2/M or with a >4N DNA content (q<0.01). Finally, 
depletion of 6/20 hits (ATAD5, CCN4, H1-10, KTN1, MDN1, and XRCC5) showed no 
change in cell cycle distribution based on our designated threshold, although significant 
minor differences were observed that may be meaningful (Figure 2-5; Appendix III). 
Finally, when considering whether an individual siRNA treatment that caused a 
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significant cell cycle accumulation also resulted in an increase in the ≥5 nucleoli per 
nucleus NPE, there are instances where a change in cell cycle distribution is observed, 
but no concomitant increase in nucleolar number is observed (CIAO2B, DYNC1H1, 
INKA1, LUC7L, MDN1, RFC1, STK24 and XRCC5; Figure 2-5; Appendix III). Taken 
together, our cell cycle analysis using DNA content suggests that despite an increase in 
the nuclear area of nuclei with ≥5 nucleoli, failures in G2/M phase progression and 
cytokinesis may only in some cases explain the increased numbers of nucleoli that I 
observe, and the contribution of other mechanisms may be in part responsible. 
To further investigate the link between the cell cycle and ≥5 nucleoli per nucleus 
NPE, I asked whether the occurrence of the ≥5 nucleoli per nucleus phenotype correlated 
with an individual phase of the cell cycle. Interestingly, when I restricted our analysis of 
nucleolar number by cell cycle phase and calculated the ≥5 nucleoli per nucleus NPE for 
each of the 20 hits, I found that the median NPE of the 4 individual siRNAs is greater 
when considering cells in the G2/M phase of the cell cycle (19/20; Figure 2-8; Table 2-8). 
The one exception was XRCC5, which was also the only hit that did not pass our initial 
validation. In addition, only when considering cells in the G2/M phase is there an 
observable difference in PE between siRISC-free and siKIF11 (Z-prime=0.47). The Z-
prime statistics were negative for both cells in G0/G1 phase (Z-prime=-0.08) and S phase 
(Z-prime=-0.12), suggesting no significant distinction between the negative and positive 
controls. Furthermore, it has been reported that nuclear volume scales with cellular 
volume, which gradually increases through the cell cycle (Cantwell and Nurse, 2019; 
Jorgensen et al., 2007; Maeshima et al., 2011; Neumann and Nurse, 2007); therefore, 
these data are consistent with our observation that nuclei with ≥5 nucleoli are 
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significantly larger (Figure 2-4, A and B). Taken together, while these data suggest that 
some hits are required for S and G2/M phase progression, in most cases it is likely the 
cells specifically in G2/M phase that are driving the increase in the percentage of nuclei 





Figure 2-5. Cell cycle analysis reveals that hits are required for progression through 
either S or G2/M phase. Representative histograms of DNA content by quantification of 
Hoechst 33342 log2 integrated intensity. The log2 integrated intensities of nuclei in the 
negative, siRISC-free, control (sum of 48 replicates; n=498,155 nuclei) were plotted and 
the G0/G1 peak set to 1.0 (red lines and text) and G2/M peak set to 2.0 (blue lines and 
text), and all other depletion conditions were then normalized to siRISC-free. Phases 
were assigned based on (Chan et al., 2013), with G2/M phase including late G2 nuclei; 
G0/G1=0.75-1.25; S=1.25-1.75; G2/M=1.75-2.25 and 2.25-2.50; >4N=>2.50. Depletion 
of the positive control, siKIF11 (pool) resulted in the expected accumulation of cells in 
G2/M phase and a subset of cells with a >4N DNA content (sum of 48 replicates; 
n=93,027 nuclei). Cell cycle profiling reveals that several hits are required for 
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progression through either S or G2/M phase. Representative histograms for screen hits 
are shown as a sum of the 3 replicates, yet each replicate for every depletion condition 
was characterized individually to perform statistical testing (Appendix III). Significance 
was determined by unpaired t-tests relative to siRISC-free and a False Discovery Rate 
approach using the two-stage step-up method of Benjamini, Krieger and Yekutieli (n=3 
or 48; q<0.01=*; q<0.001=**; q<0.0001=***; Appendix III). Cell cycle defects were 
concluded based on a conservative threshold of whether treatment with ≥2 of 4 individual 
siRNAs resulted in a ≥2-fold significant increase or decrease in the percent of nuclei in a 
phase relative to siRISC-free. Each hit is listed below one of four representative 
histograms for the statistically significant cell cycle defects identified. Previously 




Table 2-7. Cell cycle profiling of screen hits in bold in Table 2-3 by pooled depletion 
validate hits with G2/M phase defects. Mock and siNT were included as negative 
controls. siKIF11 was included as a positive control. Shown are the number of nuclei 
assayed and the percent nuclei in each cell cycle phase for each of two replicates (1/23/20 
and 1/27/20).  
Hits Number of 
cells analyzed 
% G0/G1 % S % G2/M % >4N 
 Rep   
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6025 46.7 47.6 12.5 11.3 9.6 14.1 1.2 2.6 
siKIF11 3685 1943 21.1 22.3 32.4 16.0 29.2 42.8 1.7 6.7 
siINCENP 1927 765 29.9 38.2 24.7 14.9 25.7 18.2 3.5 3.5 
siCDCA8 1287 648 20.6 19.4 27.0 18.8 29.2 29.8 10.6 17.4 
siRACGAP
1 
3839 1531 30.7 26.1 17.8 12.9 24.8 28.2 11.4 17.6 
siINKA1 2340 1099 38.1 32.8 24.0 19.1 22.3 26.0 1.0 3.2 
siTPX2 1168 590 24.1 29.8 31.8 19.0 23.2 26.3 1.5 3.1 
siFAM98A 3331 1469 50.3 52.5 15.8 12.7 8.6 9.6 0.7 1.0 
siWRAP53 5781 1943 45.3 40.1 14.8 12.8 9.2 12.1 1.0 2.0 
siATAD5 6352 1749 47.1 41.0 16.9 13.0 9.7 13.7 0.9 1.9 
siCCN4 3763 1215 48.8 47.2 10.9 10.9 5.7 11.3 0.3 1.5 
siENY2 5378 2208 49.7 42.8 15.0 12.3 7.2 11.4 0.6 2.3 
siH1-10 3490 1268 49.7 48.1 8.2 12.2 3.9 9.6 0.4 3.1 
siRFC1 3728 1337 44.8 37.5 20.8 22.6 11.3 17.0 0.4 2.1 
siMDN1 5064 2038 53.3 56.8 9.0 7.1 4.8 6.9 0.2 0.5 






Figure 2-6. Atypical annular and semi-annular nuclei were counted both as one and more 
than one nucleus, potentially skewing estimates of nucleolar number per nucleus. In a 
subset of screen images where atypical nuclei were observed, CellProfiler pipeline 
segmentation of annular and semi-annular nuclei revealed inconsistent nuclear 
identification. Annular nuclei were sometimes segmented as a single nucleus, whereas 
semi-annular nuclei were sometimes segmented as more than one nucleus. Each colored 
spot represents a single segmented nucleus. In the merge, blue=Hoechst (nuclei) and 
pink=fibrillarin (nucleoli). Normal nuclei shown were from siRISC-free and atypical 





Figure 2-7. Atypical “stretched” nucleoli in some cases led to an overestimate of 
nucleolar number per nucleus. In a subset of screen images where atypical nucleoli were 
observed, CellProfiler pipeline segmentation of “stretched” nucleoli were sometimes 
incorrectly identified as multiple nucleoli. Each colored spot represents a single 
segmented nucleolus. In the merge, blue=Hoechst (nuclei) and pink=fibrillarin (nucleoli). 
Normal nucleoli shown were from siRISC-free and atypical nucleoli shown were from 






Figure 2-8. The observed increase in nucleolar number (NPE) is greater when restricting 
analysis to cells in G2/M phase. ≥5 nucleoli per nucleus NPE is greater when restricting 
the analysis of nucleolar number to cells in G2/M phase. We restricted our analysis of the 
≥5 nucleoli per nucleus NPE for each of the 20 hits based on cell cycle phase. Only when 
considering nuclei in G2/M phase was there a statistical separation between siRISC-free 
and siKIF11 (Z-prime=0.47). The NPE for each individual siRNA are depicted as dots. 
The bars show the median NPE + interquartile range for the 4 individual siRNAs for each 
hit, for all nuclei (gray) and nuclei in G2/M phase only (blue). Previously published in 




Table 2-8. ≥5 nucleoli per nucleus normalized percent effect (NPE) is greater when 
considering cells in G2/M phase only. NPE for each siRNA in the pool of 4 comparing 
NPE for all cells to cells in G2/M only. 
Hits All cells G2/M cells 
 1 2 3 4 1 2 3 4 
siKIF11 89.98 118.62 74.75 116.70 104.40 130.50 111.60 133.20 
siINCENP 63.31 107.86 84.39 65.05 103.10 119.60 106.60 85.90 
siCDCA8 82.17 60.19 23.40 44.40 116.70 90.80 41.80 74.10 
siRACGAP1 51.56 34.13 66.49 58.42 73.40 58.90 89.90 71.90 
siINKA1 81.39 12.47 17.64 71.44 91.90 18.70 48.80 91.60 
siTPX2 38.82 102.59 39.05 31.55 44.60 125.30 91.20 64.60 
siKTN1 41.87 44.02 4.61 16.93 81.80 51.40 14.90 31.90 
siFAM98A 23.43 30.61 -1.10 37.85 47.70 51.00 -2.20 64.00 
siABCE1 50.71 22.63 26.31 9.86 68.80 37.60 60.00 16.50 
siDYNC1H1 22.40 24.91 79.29 9.05 25.70 41.80 104.80 20.90 
siWRAP53 2.90 28.11 18.45 38.53 7.50 53.00 35.60 74.90 
siATAD5 55.60 16.49 25.01 22.60 80.00 30.30 40.90 23.70 
siCCN4 17.85 18.51 23.89 42.10 53.00 30.50 32.30 63.10 
siENY2 15.62 29.06 24.64 16.54 32.70 38.70 49.70 44.00 
siCIAO2B 24.41 7.62 15.48 26.18 55.40 24.40 28.10 64.20 
siH1-10 19.98 38.30 16.89 10.30 26.20 48.60 32.10 37.80 
siLUC7L 36.19 6.67 7.84 22.01 43.50 18.50 29.50 46.80 
siRFC1 12.31 15.79 20.99 0.60 13.60 20.00 26.80 3.50 
siMDN1 16.23 10.86 8.92 28.03 50.30 30.80 21.50 53.00 
siSTK24 7.04 1.81 17.66 29.89 23.10 7.50 35.80 54.50 





Inhibition of DNA replication and mitosis increase nucleolar number 
Cell cycle analysis revealed that depletion of a subset of screen hits resulted in 
failures in progression through S and G2/M phase of the cell cycle. I therefore asked 
whether inhibition of DNA replication and mitosis by small molecule inhibitors is 
sufficient to cause increased nucleolar numbers (Weiss et al., 2007). Small molecules 
tested included tubulin inhibitors (nocodazole and paclitaxel), aurora kinase A and B 
inhibitors [MK-5108 and hesperadin, respectively (de Groot et al., 2015)], topoisomerase 
inhibitors (etoposide and ICRF-193), a KIF11 inhibitor (ispinesib), and the DNA 
replication inhibitors, mitomycin C and 5-fluorouracil. MCF10A cells were incubated 
with low doses of the inhibitors for prolonged periods of time (24, 48, and 72 hrs) to best 
mimic the conditions from our siRNA screen. Following treatment, the ≥5 nucleoli per 
nucleus PE was quantified relative to 0.1% dimethyl sulfoxide (DMSO) treatment, which 
was set to a 100 PE. In this experiment, all mitosis and DNA replication inhibitors tested 
caused a significant >2-fold increase in the percentage of cells with ≥5 nucleoli per 
nucleus by the 72 hr time point (and all but 1 by the 48 hr time point; Figure 2-9). 
Furthermore, the PE increased with each time point. Thus, inhibition of DNA replication 
and mitosis cause an increase in the percentage of cells with ≥5 nucleoli and validates the 
connection between progression through the cell cycle and maintenance of normal 
nucleolar numbers.  
Additionally, I also tested whether inhibition of RNAPI was sufficient to drive 
increased nucleolar number. This was asked, in part, due to the known nucleolar 
segregation that occurs upon treatment with AMD and other chemotherapeutic agents 
(Burger et al., 2010; Reynolds et al., 1964); but was also asked to address whether 
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inhibition of nucleolar function itself is enough to drive increased nucleolar numbers. 
RNAPI inhibitors tested included AMD, BMH-21, and CX-5461. Interestingly, both 
AMD and BMH-21 at most time points yielded a significant decrease in the percentage of 
cells with ≥5 nucleoli (Figure 2-9). Only CX-5461 at the 72 hr time point caused a 
significant >2-fold increase in the percentage of cells with ≥5 nucleoli, progressing from 
a significant decrease at 24 hrs, distinguishing it from the other two RNAPI inhibitors. 
This could be explained, in part, by the different mechanisms by which these inhibitors 
are proposed to function, with the former as DNA intercalators, and the latter as a 
topoisomerase inhibitor (Bruno et al., 2020). Thus, I discovered that inhibition of 
ribosome biogenesis through RNAPI inhibition is not sufficient to cause an increase in 
the percentage of cells with ≥5 nucleoli. Taken together, these data further support the 
role of faithful cell cycle progression through S and G2/M phase as an important 








Figure 2-9. Inhibition of mitosis and DNA replication increase the percentage of nuclei 
with ≥5 nucleoli. The ≥5 nucleoli per nucleus PE was quantified relative to DMSO (set to 
a 100 PE) in MCF10A cells treated with a panel of small molecule inhibitors of the cell 
cycle for 24 (light gray), 48 (dark gray), and 72 hrs (blue). A dotted line is drawn at 100 
PE. M=Inhibitors of mitosis (ispinesib, nocodazole, paclitaxel, hesperadin, and MK-
5108). S=Inhibitors of DNA replication (mitomycin C and 5-fluorouracil). 
M/S=Inhibitors of both mitosis and DNA replication (topoisomerase II inhibitors: 
etoposide and ICRF-193). RNAPI=Inhibitors of RNAPI transcription (AMD, BMH-21, 
and CX-5461). Statistical significance was calculated by unpaired t tests with the Holm-
Sidak method of correction for multiple comparisons (*=p<0.05, **=p<0.01, 





Through a high-content genome-wide siRNA screen in the near-diploid MCF10A 
human breast epithelial cell line, I have identified a high confidence set of 113 proteins 
that, when depleted, cause an increase in the percentage of cells with ≥5 nucleoli. Of the 
113 proteins, two-thirds are proteins without a known ortholog in S. cerevisiae, 
suggesting the identification of a subset of proteins with putative nucleolar regulatory 
functions that are unique to higher eukaryotes. My subsequent analyses revealed that the 
hits are enriched for nucleolar proteins (20%), yet not for proteins typically associated 
with the nucleolar function of ribosome biogenesis. While multiple factors associated 
with ribosome biogenesis were identified [e.g. ABCE1 (Pisarev et al., 2010; Young et al., 
2015), MDN1 (Bassler et al., 2010; Galani et al., 2004), SUV39H1 (Murayama et al., 
2008), and TAF1D (Gorski et al., 2007)], enrichment analyses revealed that the hits are 
instead significantly associated with cell cycle processes including mitosis and 
replication. Cell cycle profiling on a subset of hits confirmed that several, but not all, are 
required for progression through S and G2/M phase of the cell cycle. Thus, this screen for 
increased nucleolar number uncovered a subset of proteins required for the regulation of 
nucleolar number and suggests an interdependence between faithful cell cycle 
progression and the nucleolus.    
The 113 hits uncovered by this screen are a unique subset of proteins when 
compared to other screens for regulators of nucleolar form and function. When compared 
to other screens for regulators of ribosome biogenesis in higher eukaryotes, the overlap 
among the hits was <2%. Of the hits that are shared (ABCE1, MDN1, DYNC1H1, 
SUV39H1, TOPBP1, and CDCA8), there is no clear underlying theme that connects 
 
98 
them. Differences among the model systems employed or experimental readouts 
evaluated however may largely explain the lack of overlap. For instance, the screens for 
human ribosome biogenesis factors were all performed in the aneuploid HeLa cervical 
cancer cell line (Badertscher et al., 2015; Tafforeau et al., 2013; Wild et al., 2010), 
whereas my study was performed in a near-diploid non-cancer-derived cell line, 
MCF10A. Each screen also utilized different experimental methodologies and readouts to 
establish ribosome biogenesis factors, where it is conceivable that the proteins required 
for the regulation of nucleolar number may be different from the proteins that regulate 
ribosomal subunit export. Despite minimal overlap, however, comparison of the 113 hits 
to the screens for changes in nucleolar size in S. cerevisiae and D. melanogaster lends 
support to potentially conserved links between the nucleolus and both mitosis and 
mannose metabolism (Neumuller et al., 2013). For instance, spindle pole body proteins 
required for mitotic spindle assembly were enriched in the S. cerevisiae dataset, and 
spindle assembly factor, KIF11/Cin8/Klp61f, specifically was present in both datasets as 
well as in my screen (a hit and the positive control). Also shared among the datasets and 
my screen are the mannose-associated proteins PMM2/Sec53 identified in S. cerevisiae 
and MAN1A1/alpha-Man-I identified in D. melanogaster, which suggests a novel 
putative role for glycoprotein biosynthesis in the regulation of nucleolar form and 
function. Finally, and perhaps most intriguing, is that I also observed no overlap among 
the hits and over-represented GO categories (Fold enrichment ≥5, p<0.05) when 
compared to our hits for decreased nucleolar number (Farley-Barnes et al., 2018). These 
results suggest that the mechanisms underlying the regulation of nucleolar number are 
likely distinct depending on whether the number has increased or decreased. The 113 hits 
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identified by my screen for increased nucleolar number are therefore unique compared to 
proteins uncovered by other screens for ribosome biogenesis factors and may serve to 
broaden our understanding of the regulation of nucleolar form and function in higher 
eukaryotes. 
Among the discoveries uncovered by my screen are the diverse subset of proteins 
that support a connection between the nucleolus and mitosis. Bioinformatic analyses 
revealed that the hits are enriched for cell cycle-associated proteins, including proteins 
required for mitosis. Cell cycle profiling supported the role for a subset of the hits in 
progression through G2/M phase. Included among the mitosis-associated hits are proteins 
required for mitotic spindle assembly, including KIF11, RACGAP1, and TPX2, as well 
as the aurora B kinase (AURKB)-associated proteins, CDCA8 and INCENP (Uehara et 
al., 2013). In addition, sister chromatid cohesion proteins (CDCA5 and SGOL1) and 
mitosis-associated cell cycle regulators [CUL1, SKP1, and MASTL; (Nakayama and 
Nakayama, 2006)] were also identified. There has long been an appreciation for the role 
of the nucleolus in cell cycle regulation, including in the nucleolar sequestration of 
proteins required for cell cycle progression (Boisvert et al., 2007; Visintin and Amon, 
2000). It is also well known that the nucleolus undergoes dynamic remodeling as a 
consequence of the cell cycle, exemplified by cyclin-dependent kinase 1 (CDK1)-
mediated silencing of RNAPI and the disassembly and reformation of nucleoli in mitosis 
(Hernandez-Verdun, 2011). Furthermore, a novel complex of ribosome biogenesis factors 
required for RNAPI transcription was recently implicated in the regulation of mitotic 
entry, chromatid cohesion, and spindle assembly through AURKB (Fujimura et al., 
2020). Taken together, these data strengthen the support for significant crosstalk between 
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the nucleolus and the cell cycle. Thus, my screen revealed a unique subset of proteins that 
both regulate nucleolar number and mitosis and raises the question of whether they also 
regulate nucleolar function through RNAPI transcription. 
The results from my screen also support a connection between the nucleolus and 
DNA replication. Bioinformatic analyses revealed that the hits are also enriched for 
proteins required for DNA replication, recombination, and repair. Cell cycle profiling 
again supported the role for a subset of hits in the progression through S phase. Included 
among these hits are two proteins, ATAD5 and RFC1, that form heteromeric replication 
factor complexes that are required for the loading and unloading of the DNA clamp and 
processivity factor, PCNA. In eukaryotic genomes, the rDNA loci are the most highly 
transcribed loci and conflict between the transcription and replication machinery can lead 
to genome instability at replication forks (Lindstrom et al., 2018). Furthermore, 
replication stress, particularly at fragile site loci like the rDNA, has been associated with 
defects in mitosis including increased DNA bridges in anaphase, chromosome breakage, 
and cancer (Chan et al., 2009; Franchitto, 2013; Stults et al., 2009; Warmerdam and 
Wolthuis, 2019). As a result, mechanisms have evolved to ensure replication fidelity, 
including evidence for transient silencing of RNAPI in response to DNA damage (Ciccia 
et al., 2014; Kruhlak et al., 2007; Larsen et al., 2014; Larsen and Stucki, 2016). Thus, the 
hits from this screen may represent additional mechanisms by which the fidelity of the 
rDNA loci are maintained through S phase, which may be through regulation of RNAPI 
transcription. Taken together, these data also support an interdependency between the 




Testing small molecule compounds for their impact on nucleolar number further 
supports the association between S and G2/M phase progression and increased nucleolar 
number. I found that prolonged inhibition of mitosis and DNA replication with several 
different inhibitors led to significant increases in the percentage of cells with ≥5 nucleoli 
per nucleus. Furthermore, duration of treatment was an important factor in driving the 
PE, as we observed little to no effect at 24 hrs and the greatest effect at 72 hrs. The drugs 
tested included the KIF11 inhibitor, ispinesib, which independently validated the role for 
KIF11 in the regulation of nucleolar number. Also tested was the AURKB-selective 
inhibitor, hesperadin, and inhibitors of topoisomerases known to aid in the resolution of 
DNA in both anaphase (Daniloski et al., 2019; Gemble et al., 2020) and during 
replication (Vesela et al., 2017). Interestingly, however, prolonged inhibition of nucleolar 
function with the RNAPI inhibitors, BMH-21 and AMD, did not cause an increase in the 
percentage of nuclei with ≥5 nucleoli. These results suggest that disruption of nucleolar 
function alone is not sufficient to cause increased nucleolar numbers; although, 
actinomycin D and BMH-21 both cause nucleolar segregation by 3 hr (Peltonen et al., 
2014; Reynolds et al., 1964), which might appear as an increase in number, and thus we 
may be missing the effect by looking at longer time points. Taken together, these data 
validate the role of faithful cell cycle progression in maintaining typical numbers of 
nucleoli per cell. 
Screening for increased nucleolar number in MCF10A cells was thus a novel 
screening approach that led to the identification of 113 high confidence proteins. 
Included among the hits were a large proportion that do not have a known ortholog in S. 
cerevisiae, supporting the hypothesis that higher eukaryotes may harbor additional 
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regulatory mechanisms over nucleolar form and function. Additionally, subsequent 
analyses of the 113 hits strengthens prior established links between the nucleolus and cell 
cycle regulation and suggests an underappreciated role for mitosis and replication factors, 
in particular, in nucleolar biology. While the mechanisms underlying increased nucleolar 
number remain unknown, we do know that increases in nucleolar number are correlated 
with increased RNAPI transcription and poor prognosis in cancer (Derenzini et al., 2009; 
Montanaro et al., 2008). Furthermore, our screen for decreased nucleolar number was 
successful in identifying proteins with previously undefined roles in the regulation of 
ribosome biogenesis; thus, I hypothesize that my hits too may be proteins that regulate 
nucleolar function. This unique screening approach was therefore successful in 
identifying a novel subset of proteins in the human proteome that are required for the 
maintenance of typical nucleolar numbers in human cells, and may represent proteins 
with fundamental roles in the regulation of nucleolar function. 
 
MATERIALS AND METHODS 
 
Cell lines 
The human breast epithelial cell line, MCF10A (ATCC, CRL-10317), was 2D 
subcultured in DMEM/F-12 medium (Gibco, 1130-032) supplemented with 5% horse 
serum (Gibco, 16050), 10 μg/mL insulin (Sigma, I1882), 0.5 μg/mL hydrocortisone 
(Sigma, H0135), 100 ng/mL cholera toxin (Sigma, C8052), and 20 ng/mL epidermal 





For screen validation and cell cycle analysis, the individual siGENOME Set of 4 
siRNAs (Horizon Discovery) for each hit were used. Unless otherwise noted, 
subconfluent cells (log phase) were transfected with siRNAs (20-30 nM, final 
concentration) using Lipofectamine RNAiMAX Transfection Reagent (ThermoFisher 
Scientific, 13778150) and incubated for 72 hrs prior to the experimental assays.  
 
siRNA screen 
The high-content genome-wide siRNA screen was performed as reported in 
(Farley-Barnes et al., 2018) by Kat McCann and the Yale Center for Molecular 
Discovery using the human siGENOME SMARTpool siRNA library that contained 
18,107 pools of 4 siRNAs against each target. Cells were imaged on an IN Cell Analyzer 
2200 (Cytiva), which is a widefield, multicolor, fluorescence microscope. 3 fields of view 
(20X; 665.63 μm x 665.63 μm) were acquired per well and high throughput image 
analysis was performed using CellProfiler (Carpenter et al., 2006; McQuin et al., 2018) to 
segment nucleoli based on fibrillarin staining (72B9; (Reimer et al., 1987)) and nuclei 
based on Hoechst 33342 staining. In this analysis, raw nucleolar number data was 
normalized to the 16 negative (siRISC-free; 0 PE) and 16 positive (siKIF11; 100 PE) 
control wells run on the same plate and averaged across the fields of view to yield a mean 
NPE. Screen performance was monitored by Z-prime factors and signal-to-background 
(S/B). Hits with ≥5 nucleoli per nucleus were identified based on a stringent cut-off of 3 
standard deviations (SD) from the mean NPE yielding 186 hits, and then I filtered the hits 




RNA sequencing analysis 
 Hits were filtered by expression in MCF10A cells based on a poly(A) 
transcriptome analysis by RNA sequencing performed at the Yale Center for Genome 
Analysis (West Haven, CT; GEO accession no. GSE154764) on siNT-treated RNA 
collected by Katherine Farley-Barnes and analyzed using a pipeline I developed in Partek 
Flow (Partek Inc., St. Louis, MO). Sequencing reads were aligned to the human genome 
(hg19 assembly) using Bowtie 2 (v2.2.5) and quantified to the transcriptome (RefSeq 16 
08 01 v2) using Cufflinks (v2.2.1) (n=3; FPKM>0). Thirty-eight (38) hits are not 
expressed in MCF10A cells based on this analysis and were therefore discarded. 
Since my initial analysis of gene expression in MCF10A cells, however, 3 
additional MCF10A RNA sequencing datasets have been deposited in Gene Expression 
Omnibus (GEO; NCBI). Carson J. Bryant analyzed these datasets in Partek Flow, and re-
analyzed the dataset generated by our laboratory, to identify the genes expressed in 
MCF10A cells based on the zFPKM normalization metric developed by the Salomon 
laboratory (Hart et al., 2013). If the hits were expressed in any one of the 4 RNA 
sequencing datasets, they were considered expressed (log2 zTPM > -3). When aligned to 
the Ensembl annotation database (v99) Carson found that 8 of the 113 high-confidence 
hits that I identified are not likely expressed in MCF10A cells. These hits include 
FAM58A, GOLGA8EP, MARCH9, MICA, NR0B2, PRAM1, SCN2B, and YIPF7, and 






Screen validation by oligonucleotide deconvolution 
 Oligonucleotide deconvolution was performed on the 20 hits listed in Table 2-3, 
as well as on the positive control siKIF11, where the 4 siRNAs in each pool are re-tested 
individually to ensure that the observed increase in nucleolar number is driven by more 
than one siRNA. Three wells per individual siRNA were included in the assay to 
determine the mean percent effect. These data were normalized to the mean of 48 wells 
of the negative control, siRISC-free, and positive control, siKIF11 (pool), yielding a 
mean NPE for each individual siRNA. Hits were validated if the NPE was ≥15.0 in at 
least 2/4 individual siRNAs in the pool. This cutoff was less than the screen cutoff of 
NPE=25.0 based on an analysis of known LSU maturation factor, MDN1. Deconvolution 
of MDN1 yielded 3/4 individual siRNAs with an NPE<25.0, with one siRNA yielding an 
NPE=8.92; yet, all 4 siRNAs yielded pre-rRNA processing defects when analyzed by 
northern blot for defects in the processing of LSU pre-rRNA precursors (Figure 2-10). 





Figure 2-10. Northern blot analysis of pre-rRNA intermediates of MDN1 depletion by 
the pool and each individual siRNA revealed the expected large subunit (LSU) 
processing defect in all depletion conditions.  
(A) Schematic depicting the 47S pre-rRNA and position of the probe, P4, used to detect 
the LSU pre-rRNA intermediates. Black arrows=cleavage sites. 
(B) Northern blot (n=1) of total RNA, which revealed that depletion by the pool and 
each individual siRNA targeting MDN1 all yielded the accumulation of the 32/36S and 
12S pre-rRNA intermediates, despite 3/4 individual siRNAs yielding an NPE less than 
the screen cutoff of 25.0. Mock and siNT=negative controls. 7SL RNA=loading control. 






Total RNA was extracted from siRNA-depleted cells using TRIzol Reagent. To 
assay for changes in levels of pre-rRNA intermediates, 4 μg of total RNA was run on a 
1% agarose/1.25% formaldehyde gel in a 1.5M tricine/1.5M triethanolamine buffer. RNA 
was transferred overnight to a Hybond XL nylon membrane (GE Healthcare, RPN 303S) 
by capillary transfer in 10X saline-sodium citrate (SSC) transfer buffer after a brief 15 
min soak in a 0.5M sodium hydroxide solution. Membranes were then exposed to UV 
(254 nm) to immobilize the RNA, and incubated with denatured yeast tRNA for 1 hr at 
42° C and hybridized overnight at 37° C with 5’ end radiolabeled oligonucleotide probes 
in a solution of 7.5X Denhardt’s solution, 5X sodium chloride-sodium phosphate-EDTA 
(SSPE) buffer, and 0.1% SDS as in (Farley-Barnes et al., 2018). 
 
Cell cycle analysis 
We analyzed the images of the 20 hits collected for oligonucleotide deconvolution 
to evaluate cell cycle based on the integrated intensity of the Hoechst DNA stain. A 
histogram of the log2 integrated intensities for the negative control (siRISC-free; 48 
wells) was plotted and the G1 peak set to 1.0 and G2 peak set to 2.0. Each hit depletion 
condition (3 wells per siRNA) was then normalized to siRISC-free, including siKIF11 as 
individual siRNAs (3 wells per siRNA) as well as a pool (48 wells). Cell cycle phases 
were defined as in (Chan et al., 2013). G0/G1 phase nuclei were defined as normalized 
log2 integrated intensities of 0.75-1.25, S phase nuclei were defined as 1.25-1.75, and 





Small molecule inhibition 
MCF10A cells were treated with inhibitors of the cell cycle for 24, 48, and 72 hrs 
in triplicate. Drugs were all dissolved in dimethyl sulfoxide (DMSO) and doses were 
selected based on reported EC50 values in cell culture conditions for each drug, with final 
DMSO concentration=0.1%. The ≥5 nucleoli per nucleus PE was quantified by the same 
CellProfiler pipeline use in the initial screen and analyzed relative to the 0.1% DMSO 
treatment, which was set to a 100 PE. Tested inhibitors of mitosis included ispinesib 
(0.082 μM; Cayman Chemical, 18014), nocodazole (0.741 μM; Cayman Chemical, 
13857), paclitaxel (0.0274 μM; Sigma, T7402), hesperadin (0.082 μM; Cayman 
Chemical, 24199), and MK-5108 (0.247 μM; Cayman Chemical, 19167). Inhibitors of 
DNA replication included mitomycin C (0.741 μM; Cayman Chemical, 11435) and 5-
fluorouracil (0.741 μM; Sigma, F6627). Topoisomerase inhibitors included etoposide 
(0.741 μM; Sigma, E1383) and ICRF-193 (6.67 μM; Sigma, I4659), and inhibitors of 
RNAPI transcription included AMD (0.00914 μM; Sigma, A1410), BMH-21 (0.741 μM; 
Sigma, SML1183), and CX-5461 (0.741 μM; Cayman Chemical, 18392). Doses were 
selected based on doses used at prolonged time points as reported in the literature. 
 
Statistical analyses 
All statistical analyses were performed in GraphPad Prism 8.2.1 (GraphPad 





















In eukaryotic organisms, nucleoli are large, membraneless, nuclear condensates 
associated with the biogenesis of ribosomes. In mammalian cells, nucleoli form upon 
initiation of transcription by RNAPI around the tandemly arrayed rDNA loci known as 
NORs (Bersaglieri and Santoro, 2019; Grob et al., 2014; Hernandez-Verdun, 2011; 
Potapova and Gerton, 2019). The total number of nucleoli present in mammalian cells is 
highly variable. In the human genome there are 10 NORs located on the short arms of the 
5 acrocentric chromosomes [13-15, 21, and 22; (Floutsakou et al., 2013; Henderson et al., 
1972)]. Yet, high throughput resolution of nucleolar number by fluorescence microscopy 
in diverse cell lines reveals few cells with 10 nucleoli per nucleus, with many averaging 
as few as 3 nucleoli per nucleus (Farley et al., 2015). Furthermore, increased nucleolar 
number and size in the tumors of cancer patients are often associated with increased 
nucleolar activity and a poor prognosis (Derenzini et al., 2009; Montanaro et al., 2008). 
Dynamic remodeling of nucleolar structure, however, is not restricted to changes in 
nucleolar number. During mitosis the nucleolus undergoes dynamic remodeling that is 
exemplified by the disassembly and reformation of nucleoli in an open mitosis 
(Hernandez-Verdun, 2011). Furthermore, diverse cellular stress signals can cause 
nucleolar disruption and large changes to the nucleolar proteome (Boisvert et al., 2010; 
Moore et al., 2011; Rubbi and Milner, 2003). This observation has been studied most 
extensively in the nucleolar response to DNA damage (Kruhlak et al., 2007; Larsen et al., 
2014; Larsen and Stucki, 2016), and most notably upon treatment with AMD, where 
RNAPI transcription is silenced and nucleolar caps are formed at the nucleolar periphery 
(Floutsakou et al., 2013; Reynolds et al., 1964). Thus, the nucleolus is a highly 
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responsive organelle that integrates signals from a vast network of cellular processes and 
that nucleolar form, including both number and morphology, is not fixed. 
Intriguingly, the genome-wide siRNA screen for proteins that regulate nucleolar 
number described in Chapter 2 revealed a unique subset of proteins that are not enriched 
for ribosome biogenesis factors. From this screen I identified 113 hits that cause an 
increase in the percentage of nuclei with ≥5 nucleoli. These hits are enriched for proteins 
that localize to the nucleolus, as well as proteins associated with the cell cycle, including 
specifically mitosis and DNA replication. Furthermore, cell cycle profiling confirmed the 
association of a subset of proteins with S and G2/M phase progression, and several 
proteins were identified as yielding an accumulation of nuclei with a >4N DNA content 
when depleted. These data support failed cell division among a subset of the hits 
evaluated and lend a possible explanation for the increased number of nucleoli observed. 
However, there were several hits that did not reveal accumulation of nuclei with a >4N 
DNA content when depleted and thus a unifying rationale for the observed increase in 
nucleolar number remains unknown. Given that we previously identified novel ribosome 
biogenesis factors when screening for a decrease in nucleolar number, I asked whether 
proteins that, when depleted, increase nucleolar numbers also reveal novel regulators of 
nucleolar function?  
Screening for changes in nucleolar number previously uncovered proteins with 
undefined roles in the regulation of ribosome biogenesis. In our prior screen for 
decreased nucleolar number we reported more than 100 proteins that caused a decrease in 
nucleolar number from 2-3 to just 1 (Farley-Barnes et al., 2018). Of these hits, further 
investigation on a subset revealed varied deficits in ribosome biogenesis upon depletion, 
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including RNAPI transcriptional repression and aberrant pre-rRNA processing. Here, 
based on these discoveries, I likewise tested the role of 14 validated screen hits revealed 
by increased nucleolar number for roles in the regulation of RNAPI transcription and pre-
rRNA processing. Amber Buhagiar confirmed depletion of the selected hits by qPCR, 
and I performed the remaining experiments to ascertain roles in nucleolar function. The 
results from these experiments revealed that the majority of hits evaluated are required 
strictly for the regulation of RNAPI transcription and supports the hypothesis that 
screening for increased nucleolar number could also uncover novel regulators of 
nucleolar function.  
 
RESULTS 
Rationale for the selection of hits 
Hits were subjectively selected to be representative of the dataset based on 
bioinformatic analyses described in Chapter 2 (Table 2-3, in bold). The selected hits 
include cell cycle-associated proteins, including those associated with mitosis and DNA 
replication. Proteins with and without yeast orthologs were also selected. Finally, I 
selected proteins that localize to the nucleolus, as well as those not reported to localized 
to the nucleolus.  
 
72 hr depletion by siGENOME pools yields effective knockdown of screen hits 
To test whether the screen hits are involved in the nucleolar function of ribosome 
biogenesis, I first sought to validate knockdown of the mRNA levels of the 14 screen hits 
selected for further analysis. This was performed by quantitative reverse transcription 
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polymerase chain reaction (qRT-PCR) by Amber Buhagiar, using RNA collected and 
reverse transcribed by me. Hits were depleted in MCF10A cells for 72 hrs, as they were 
in the screen, by siGENOME pools of 4 siRNAs. In all conditions, depletion for 72 hrs 
with the siRNA pools led to a significant decrease in the mRNA of the target relative to 
the non-targeting (NT) negative control (Figure 3-1). Depletion of UTP4 and KIF11 were 
also confirmed (Figure 3-1). UTP4 is a nucleolar protein required for ribosome 
biogenesis and the positive control in the screen that identified proteins that when 
depleted caused a decrease in nucleolar number (Farley-Barnes et al., 2018). KIF11 is a 
mitotic kinesin and the positive control in this screen for increased nucleolar number 
described in Chapter 2. These data suggest that this method of depletion is sufficient to 




Figure 3-1. 72 hr depletion using siGENOME pools yields effective mRNA knockdown 
of hits. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis 
confirms depletion of a subset of validated nucleolar (n=7; gray) and non-nucleolar (n=7; 
white) screen hits in MCF10A cells. After depletion using pools of siRNAs targeting the 
indicated genes, respectively, or non-targeting siRNA control (siNT), the mRNA levels 
were quantified relative to beta-actin mRNA expression. Relative expression values were 
calculated using the comparative CT method. Statistical significance for three biological 
replicates, each with three technical replicates, was performed using a two-tailed, 
unpaired t-test. All comparisons are relative to siNT (p<0.05=*, p<0.01=**, 
p<0.001=***; n=3). Data are shown as a bar graph (mean ± SD), and with each replicate 
shown as a dot. These data were collected, analyzed, and graphed by Amber Buhagiar, 
using RNA collected and reverse transcribed by me. Previously published in (Ogawa et 
al., 2021).  
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11/14 screen hits are required for RNA polymerase I transcription 
To test the hypothesis that increased nucleolar number reflects changes in RNAPI 
transcription, I used an established dual-luciferase reporter assay system (Ghoshal et al., 
2004). In this system, two plasmids are co-transfected into cells 24 hrs prior to lysis and 
luminescence detection. One plasmid encodes the firefly luciferase gene, in which 
expression is driven by the human rDNA promoter. The second plasmid is included as a 
transfection control and encodes the Renilla luciferase gene, in which expression is 
driven by a constitutively active cytomegalovirus promoter. MCF10A cells were depleted 
for 72 hrs of the 14 selected hits, as well as the NT negative control, the screen positive 
control, KIF11, and known ribosome biogenesis factors, UTP4 and NOL11. Cells were 
then lysed, and firefly luminescence was normalized to Renilla luminescence and plotted 
relative to siNT.  
Strikingly, depletion of 11/14 hits significantly affect RNAPI transcription. An 
increase in the ratio of firefly to Renilla luminescence suggests increased transcription by 
RNAPI, whereas a decrease in the ratio of firefly to Renilla luminescence suggests 
decreased transcription by RNAPI. As expected, depletion of known RNAPI transcription 
co-factors, UTP4 and NOL11, decreased RNAPI transcription relative to siNT [(Freed et 
al., 2012); n=10; p<0.05; Figure 3-2], whereas mock treated cells revealed no effect. Of 
the 14 selected hits, depletion of only 2 caused a significant increase in RNAPI 
transcription (RFC1 and ATAD5; n=5 or 6; p<0.05); whereas depletion of 9 caused 
significant decreases in RNAPI transcription (H1-10, INCENP, MDN1, TPX2, ENY2, 
FAM98A, RACGAP1, CCN4, and WRAP53; n=5 or 6; p<0.05; Figure 3-2). Of these 
hits, INCENP, H1-10, MDN1, TPX2, and RFC1 are reported in the nucleolus suggesting 
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that this regulation may be direct at the rDNA loci (Appendix II). ENY2, FAM98A, 
RACGAP1, CCN4, WRAP53, and ATAD5, on the other hand, have not been reported in 
the nucleolus and thus their regulation of RNAPI may be indirect. In contrast, depletion 
of CDCA8, STK24, and INKA1 showed no significant impact on RNAPI transcription; 
however, depletion of the screen positive control KIF11 revealed an unexpected decrease 
in RNAPI transcription. These data suggest that increased nucleolar number is indeed 
reflective of impacts on nucleolar function. Furthermore, these data reveal that screening 
for an increase in the percentage of cells with ≥5 nucleoli per nucleus was successful in 






Figure 3-2. Depletion of the selected hits reveal 11/14 significantly decrease or increase 
RNAPI transcription. RNAPI transcription was assayed using a dual-luciferase reporter 
system utilizing a plasmid encoding the firefly luciferase gene, in which expression is 
driven by the human rDNA promoter [-410 to +314; (Ghoshal et al., 2004)]. Data were 
normalized to Renilla luciferase gene expression driven by a constitutively active 
cytomegalovirus promoter. Statistical significance for 5 or 6 replicates relative to siNT 
was calculated by two-tailed, unpaired t tests (*=p<0.05, **=p<0.01, ***=p<0.001; n=5 
or 6). Mock=negative control; siNOL11 and siUTP4=positive controls. Data are shown 
as minimum to maximum box and whiskers plots, and with each replicate represented as 
a dot. Gray=nucleolar proteins; white=non-nucleolar proteins (Table 2-3; Appendix II). 




1/14 screen hits are required for pre-rRNA processing 
Several ribosome biogenesis factors that are required for transcription of the 
rDNA also have defined roles in processing the pre-rRNA (Calo et al., 2015; Farley-
Barnes et al., 2018; Freed et al., 2012; Gallagher et al., 2004; Prieto and McStay, 2007). 
These factors include nucleolar proteins like those in the SSU subcomplex t-UTP/UTPA 
(Freed et al., 2012; Gallagher et al., 2004; Prieto and McStay, 2007), as well as non-
nucleolar proteins including several previously identified in the screen for decreased 
nucleolar number (Farley-Barnes et al., 2018). To test whether the 14 selected screen hits 
are required for pre-rRNA processing I used northern blots to quantify steady-state levels 
of pre-rRNA intermediates and analyzed precursor-product relationships. Northern blots 
were performed using RNA from MCF10A cells depleted of each of the 14 hits, as well 
as UTP4 as a positive control, and hybridized to 4 previously reported oligonucleotide 
probes that detect different intermediates in the pre-rRNA processing pathways [(Farley-
Barnes et al., 2018); Figure 3-3; Figure 3-4]. Intermediates were then quantified by 
phosphorimager and Ratio Analysis of Multiple Precursors profiles were plotted relative 
to siNT [RAMP; (Wang et al., 2014); Figure 3-5; Figure 3-6].  
Interestingly, depletion of only 1/14 hits resulted in aberrant pre-rRNA 
processing. Overall, while depletion of the 14 selected hits led to some ratios from 
individual probes to be statistically significant, only depletion of the nucleolar protein 
MDN1 caused a more than 2-fold change in ratios of intermediates relative to siNT (n=3; 
p<0.05; Figure-3-4; Figure 3-5; Figure 3-6). Specifically, MDN1 depletion resulted in a 
significant increase in the ratios of the 12S pre-rRNA to its precursors and is an 
intermediate of the large ribosomal subunit (LSU) 5.8S rRNA (Figure 3-4, D; Figure 3-
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5), which is consistent with the protein’s reported role in LSU maturation (Bassler et al., 
2010; Galani et al., 2004). As expected, RNA from mock-treated cells showed no 
significant difference relative to siNT (Figure 3-4; Figure 3-5), whereas UTP4 depletion 
caused a significant increase in the 30S+1 pre-rRNA precursor and a decrease in the 21S 
product (n=3; p<0.05; Figure 3-4, A-C; Figure 3-5). These results suggest that increased 
nucleolar number is largely not reflective of impacts on pre-rRNA processing for either 
nucleolar or non-nucleolar hits.  
Further analysis of the northern blots also revealed a decreasing trend in the 
overall steady-state levels of pre-rRNA intermediates after depletion of the 14 selected 
hits. Individual pre-rRNA intermediates were quantified relative to the 7SL RNA 
component of the signal recognition particle, which was probed on all northern blots as a 
loading control (Figure 3-7). As expected, UTP4-depleted cells showed a significant 
increase in the primary transcript plus (43S-47S; PTP) and 30S+1, and decrease in the 
30S and 21S pre-rRNAs, whereas mock-treated cells showed little impact on the levels of 
steady-state intermediates. Overall, among the 14 hits, steady-state levels trended towards 
a modest decrease (<2-fold) among all pre-rRNA intermediates measured, with all but 2 
showing a significant decrease of at least 1 intermediate by a single probe. While these 
differences are small, they are consistent with the majority of selected hits causing 
significant decreases in RNAPI transcription (Figure 3-2). Intriguingly, the 2 that did not 
show a significant decrease of an intermediate (ATAD5 and RFC1) were also the only 2 
hits to show a significant increase in RNAPI transcription. Taken together, analysis of 
pre-rRNA intermediates by northern blots revealed that screening for an increase in the 
percentage of cells with ≥5 nucleoli per nucleus uncovered proteins that are less likely to 
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be required for pre-rRNA processing and more likely to be required for the regulation of 








Figure 3-3. Pre-rRNA processing diagram labeled with the oligonucleotide probes used 
to detect pre-rRNA intermediates. Depletion of a subset of nucleolar (n=7) and non-
nucleolar (n=7) hits in MCF10A cells were analyzed by northern blot to ask whether 
depletion affects steady-state levels of pre-rRNA intermediates, and whether pre-rRNA 
processing defects can be inferred from observed changes in precursor-product 
relationships. The two predominant pathways for releasing the mature ribosomal RNAs 
(18S, 5.8S, and 28S) from the primary 47S transcript are depicted. Cleavage sites are 
indicated with black triangles and are listed next to the black arrows. The 4 
oligonucleotide probes used to quantify levels of the different pre-rRNA intermediates 
are indicated below the 47S both by colored lines and probe number (P5’ETS, P5’ITS1, 




Figure 3-4. Qualitative analysis of pre-rRNA intermediates reveals no obvious pre-rRNA 
processing defects among the 14 selected hits. Representative northern blots are shown 
for each of the 4 probes, (A) P5’ETS, (B) P5’ITS1, (C) P3, and (D) P4. The 7SL RNA 
component of the signal recognition particle was used as a loading control. In each blot, 
mock and siNT=negative controls, and siUTP4=positive control. PTP=primary transcript 





Figure 3-5. Quantitative analysis of the northern blots of total RNA from nucleolar hits 
reveals that MDN1-depletion significantly affects processing of the 12S pre-rRNA. 
Quantitative analysis of the northern blots of nucleolar hits was performed by Ratio 
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Analysis of Multiple Precursors (RAMP) relative to siNT (mean ± SD). Mock-treated 
cells and UTP4-depleted cells were included as negative and positive controls, 
respectively. Depletion of the screen positive control, KIF11, was also analyzed. 
Statistical significance was calculated for 3 replicates by unpaired t tests for each ratio 
with the Holm-Sidak method of correction for multiple comparisons (*=p<0.05, 
**=p<0.01, ***=p<0.001; n=3). PTP=primary transcript plus, 43S-47S. Previously 





Figure 3-6. Quantitative analysis of the northern blots of total RNA from non-nucleolar 
hits reveals pre-rRNA processing is not impacted. Quantitative analysis of the northern 
blots of non-nucleolar hits was performed by Ratio Analysis of Multiple Precursors 
(RAMP) relative to siNT (mean ± SD). Statistical significance was calculated for 3 
replicates by unpaired t tests for each ratio with the Holm-Sidak method of correction for 
multiple comparisons (*=p<0.05, **=p<0.01, ***=p<0.001; n=3). PTP=primary 




Figure 3-7. Quantitative analysis of pre-rRNA intermediates relative to the 7SL RNA 





Quantitative analysis of the northern blots was performed relative to the 7SL RNA 
component of the signal recognition particle relative to siNT (mean ± SD). Statistical 
significance for 3 replicates was calculated by unpaired t tests for each ratio with the 
Holm-Sidak method of correction for multiple comparisons (*=p<0.05, **=p<0.01, 
***=p<0.001; n=3). PTP=primary transcript plus, 43S-47S. Previously published in 




13/14 screen hits are required for global protein synthesis 
Finally, if depletion of a protein impacts ribosome biogenesis through either 
RNAPI transcription or pre-rRNA processing, I hypothesize that ribosome levels and 
translational function will also be impacted. To test whether depletion of the 14 selected 
screen hits impacts global protein synthesis, I used an established puromycin labeling 
assay of nascent peptides followed by western blot with a puromycin antibody (Kelleher 
et al., 2013). MCF10A cells were depleted of the 14 screen hits prior to puromycin 
treatment (1 μM) and protein harvest. MCF10A cells were also mock-treated and treated 
with siNT as negative controls, and half the concentration of puromycin (0.5 μM) and the 
ribosome biogenesis factor siUTP4 as positive controls.  
Puromycin labeling followed by western blot revealed that depletion of 13/14 hits 
caused a significant decrease in global protein synthesis (p<0.05; Figure 3-8). As 
expected, mock-treated cells showed no significant difference relative to siNT, and cells 
treated with half the concentration of puromycin (0.5 μM) showed a decrease in global 
protein synthesis by half. Furthermore, as predicted, depletion of the ribosome biogenesis 
factor UTP4 also led to a decrease in protein synthesis. Results from this assay therefore 
suggest that depletion of nearly all hits tested, 13/14, cause a significant reduction in 
global levels of protein synthesis. Furthermore, consistent with previous reporting 
(Bartoli et al., 2011), depletion of the screen positive control, KIF11, also yielded a 
significant decrease in protein synthesis. Intriguingly, while depletion of ATAD5 and 
RFC1 caused an increase in the transcription of the pre-rRNA (p<0.001; Figure 3-2), 
protein synthesis was reduced (p<0.05; Figure 3-8). These data suggest that in the case of 
ATAD5 or RFC1 depletion, increased transcription does not necessarily lead to an 
 
129 
increase in ribosome levels and consequently ribosomal function. Additionally, INKA1, 
STK24, and CDCA8 were not identified as either pre-rRNA transcription or processing 
factors (Figure 3-2; Figure 3-5; Figure 3-6), yet depletion also resulted in a significant 
decrease in protein synthesis (p<0.001; Figure 3-8). These data suggest that these 
INKA1, STK24, and CDCA8 may have an as yet unidentified role in some other aspect 
of ribosome biogenesis, such as ribosome assembly or subunit export. Conversely, 
depletion of FAM98A revealed a significant decrease in RNAPI transcription by nearly 
50% (p<0.001; Figure 3-2), but did not yield a significant impact on global protein 
synthesis (Figure 3-8), suggesting possible limitations in using this assay to infer 
functional consequences of defects in RNAPI transcription, or a downstream 
compensatory response that limited the impacts of FAM98A on ribosome biogenesis and 
ribosomal function. Thus, from these results, I conclude that screening for an increase in 
the percentage of nuclei with ≥5 nucleoli uncovered proteins, in most cases, required for 





Figure 3-8. Global protein synthesis was significantly decreased upon depletion of 13/14 
of the selected screen hits. Previously published in (Ogawa et al., 2021). 
(A) Shown are representative western blots from the total protein harvested from hit-
depleted MCF10A cells treated with 1 μM puromycin for 1h. Protein was quantified by 
Bradford assay and run on a 10% SDS-PAGE gel followed by western blots using an 
antibody to puromycin to test for puromycin incorporation into the nascent peptides. 
Beta-actin (ACTB)=loading control. Mock (1 μM) and siNT=negative controls. Mock 
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(0.5 μM)=cells treated with half the concentration of puromycin. Depletion of ribosome 
biogenesis factor UTP4=positive control. 
(B) Quantification of results in A from 3 replicates. ImageJ was used to quantify the 
differences in puromycin signal intensity, normalized to the beta-actin signal intensity. 
Statistical significance for the 3 replicates relative to siNT was calculated by two-tailed, 
unpaired t tests (*=p<0.05, **=p<0.01, ***=p<0.001; n=3). Data are shown as a bar 
graph (mean ± SD), and with each replicate represented as a dot. Gray=nucleolar 




Depletion of 2/14 screen hits results in p53 stabilization 
Considering that I identified defects in cell cycle progression for several of the 
screen hits analyzed as reported in Chapter 2, it may be possible that these defects could 
lead to RNAPI transcription and translation defects through TP53 (p53) repression of 
RNAPI (Beckerman and Prives, 2010). On the contrary, it is also possible that defects in 
RNAPI transcription and translation could lead to cell cycle arrest through both p53-
mediated and p53-independent mechanisms through what is commonly referred to as the 
nucleolar stress response (James et al., 2014; Rubbi and Milner, 2003). As a result, I also 
evaluated levels of p53 by western blot. As expected, depletion of the known ribosome 
biogenesis factor, NOL11, resulted in a significant 2-fold increase in p53 levels [n=3; 
p<0.05; (Griffin et al., 2015)]. Depletion of a subset of screen hits, on the other hand, 
revealed that only 2/14 caused a significant increase in p53 (RFC1 and RACGAP1; n=3; 
p<0.05; Figure 3-9). These data suggest that while it is possible that p53 could be 
mediating the effects on RNAPI transcription that I observe when RFC1 and RACGAP1 
are depleted, it is not likely mediating the effects I observe in all cases. In conclusion, 
screening for increased nucleolar number was successful in identifying novel regulators 





Figure 3-9.  Depletion of only 2 hits results in the stabilization of the tumor suppressor 
protein, p53. Previously published in (Ogawa et al., 2021). 
(A) Representative western blots from the total protein harvested from MCF10A cells 
depleted of the screen hits in Table 2-3 (in bold). Protein was quantified by Bradford 
assay and run on a 10% SDS-PAGE gel followed by western blots using an HRP-
conjugated antibody to the tumor suppressor protein, p53 (TP53). Beta-actin (ACTB) was 
used as a loading control. Mock and siNT-treated cells=negative controls. 
siNOL11=positive control. siUTP4 was included as a known ribosome biogenesis factor, 
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and siKIF11 was included because it was the screen positive control and elicited a 
RNAPI and protein synthesis defect upon treatment.  
(B) Quantification of results in A from 3 replicates. ImageJ was used to quantify the 
differences in p53 signal intensity, normalized to the beta-actin signal intensity. 
Statistical significance for the 3 replicates relative to siNT was calculated by two-tailed, 
unpaired t tests (*=p<0.05; n=3). Data are shown as a bar graph (mean ± SD), and with 





Table 3-1. Summary of discoveries associated with nucleolar function upon depletion of 
a subset of screen hits, and the screen positive control, KIF11. Inc=Increased, 
Dec=Decreased, Y=Yes, N=No, and Dash (“-“)=No significant change are concluded 
based on statistical analysis that identified a significant difference from siNT (p<0.05). 











ATAD5 Inc - Dec - 
CDCA8 - - Dec - 
ENY2 Dec - Dec - 
FAM98A Dec - - - 
H1-10 Dec - Dec - 
INCENP Dec - Dec - 
INKA1 - - Dec - 
KIF11 Dec - Dec - 
MDN1 Dec Y Dec - 
RACGAP1 Dec - Dec Y 
RFC1 Inc - Dec Y 
STK24 - - Dec - 
TPX2 Dec - Dec - 
CCN4 Dec - Dec - 





A genome-wide siRNA screen for increased nucleolar number has uncovered 
proteins required for nucleolar function. Biochemical analyses of a subset of the 113 
identified proteins revealed several required for ribosome biogenesis, including 11/14 
required for RNAPI transcription and 1/14 required for pre-rRNA processing. The 
identified pre-rRNA processing factor (MDN1), however, also resulted in decreased 
RNAPI transcription, suggesting the overwhelming association of screen hits with the 
transcriptional regulation of the pre-ribosomal RNA. Additionally, as expected for 
defects in the biogenesis of ribosomes, depletion of 13/14 screen hits further resulted in 
decreased protein synthesis. These data are in contrast to the dataset generated when 
screening for a decrease in nucleolar number (Farley-Barnes et al., 2018). In the screen 
for proteins that cause a decrease in nucleolar number when depleted, of the hits 
evaluated for roles in ribosome biogenesis, the majority were associated with defects in 
pre-rRNA processing (16/20). Proteins required for RNAPI transcription were also 
uncovered (7/20); however, all but one demonstrated a concomitant pre-rRNA processing 
defect (Farley-Barnes et al., 2018). Taken together, these data suggest that changes in 
nucleolar number in MCF10A cells are indicative of a negative impact on nucleolar 
function. Screening for increased nucleolar number revealed a unique subset of proteins 
required primarily for the nucleolar function of RNAPI transcription.   
Of the identified regulators of RNAPI transcription few were repressors of 
nucleolar activity. Cancer pathologists know that increased nucleolar number and area are 
associated with increased nucleolar activity and poor prognosis in cancer patients 
(Derenzini et al., 2009). As such, one possibility is that hits that cause an increase in 
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nucleolar number when depleted will also reveal increased RNAPI transcription. In this 
analysis, however, only 2/14 screen hits evaluated resulted in an increase in RNAPI 
transcription upon depletion (RFC1 and ATAD5), suggesting roles as repressors. In 
support of this finding, RFC1 has previously been reported to repress rDNA transcription 
in S. cerevisiae (Smith et al., 1999), and in plants (Liu et al., 2010). Furthermore, both 
proteins are large subunits of heteropentameric protein complexes that share subunits, 
RFC2-5, and associate with proliferating cell nuclear antigen (PCNA) during DNA 
replication. The majority of hits tested were thus promoters of rDNA transcription. Of the 
14 hits tested, 9 caused a decrease in RNAPI transcription upon depletion, as well as the 
screen positive control, KIF11. In all, each screen hit that caused defects in RNAPI 
transcription upon depletion, with the exception of FAM98A, which also resulted in 
decreased protein synthesis. Thus, while increased nucleolar number and size are 
commonly associated with cancer and increased growth and proliferation, our screen for 
increased nucleolar number identified primarily promoters of RNAPI transcription.  
The p53-mediated nucleolar stress response is not likely to be the only root cause 
of the observed reduction in RNAPI transcription. The tumor suppressor protein, p53 
(TP53), is a well-documented cellular stress sensor that suppresses oncogenic activity 
through its regulation of transcription, which leads to cell cycle arrest and apoptosis 
(Mantovani et al., 2019). Mutations in p53 are some of the most commonly observed in 
human cancer (Kandoth et al., 2013). While the most widely reported gene targets of p53 
include genes transcribed by RNA polymerase II (Allen et al., 2014; Kim et al., 2011), 
p53 has also been reported to directly inhibit RNAPI (Zhai and Comai, 2000). 
Furthermore, the stabilization of p53 is mediated by the nucleolus and scales with the 
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degree of cellular stress, with greater stress eliciting higher levels of p53 and vice versa 
(Rubbi and Milner, 2003). Thus, the inhibition of RNAPI transcription I observe upon 
depletion of a subset of screen hits can be a cause or consequence of p53 stabilization. 
Intriguingly, however, while MCF10A cells maintain wild-type p53 (Merlo et al., 1995) 
inhibition of RNAPI is concomitant only with increased levels of p53 after depletion of 
2/14 proteins (siRFC1 and siRACGAP1). These data suggest that not only is the RNAPI 
transcriptional inhibition I observe not likely caused by p53-mediated inhibition of 
RNAPI, but also that the level of RNAPI transcription is not sufficient to trigger p53 
stabilization. Furthermore, RFC1 depletion led to increased RNAPI transcription rather 
than decreased transcription counter to what would be expected with p53 stabilization, 
and thus further analysis is required to better understand the specific relationship between 
RFC1 and p53. Together, these data suggest that for 12/14 hits, the reduction in RNAPI 
transcription is independent of increased levels of p53, and further supports that this 
screen for increased nucleolar number identified novel regulators of ribosome biogenesis.  
Finally, depletion of several of the novel regulators of RNAPI transcription 
yielded defects in cell cycle progression and cell division. Of the screen hits evaluated, 
depletion of KIF11 and 8/20 hits resulted in the accumulation of cells with a >4N DNA 
content (Chapter 2). Failures in cell division could provide an explanation for the 
observed increase in the percentage of nuclei with ≥5 nucleoli. However, given that 
several of these proteins also resulted in defects in RNAPI transcription (KIF11, ENY2, 
INCENP, RACGAP1, and TPX2), the cause for increased nucleolar number may not be 
so easily explained. Additionally, depletion of KIF11, INCENP, and TPX2 resulted in the 
accumulation of cells in G2/M phase and depletion of ENY2, FAM98A, RFC1, and 
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WRAP53 resulted in an accumulation of cells in S phase (Chapter 2). Thus, alternatively, 
failures in the regulation of RNAPI transcription during S or G2/M phase could lead to 
the increase in nucleolar number observed. While it is possible that each of the screen hits 
may function in ribosome biogenesis outside of S or G2/M phase, as reported previously 
for KIF11 in translation (Bartoli et al., 2011), the enrichment of replication and mitosis 
factors among the hits supports the possibility that the regulation of RNAPI specifically 
during S and G2/M phase is essential to maintaining nucleolar integrity. In conclusion, 
the functional analysis of a subset of screen hits has supported the hypothesis that 
screening for increased nucleolar number could also identify novel regulators of 
nucleolar function and has further broadened our understanding of the regulation of 
ribosome biogenesis in higher eukaryotes.  
 
MATERIALS AND METHODS 
 
Cell lines 
As described in Chapter 2, the human breast epithelial cell line, MCF10A (ATCC, 
CRL-10317), was 2D subcultured in DMEM/F-12 medium (Gibco, 1130-032) 
supplemented with 5% horse serum (Gibco, 16050), 10 μg/mL insulin (Sigma, I1882), 
0.5 μg/mL hydrocortisone (Sigma, H0135), 100 ng/mL cholera toxin (Sigma, C8052), 
and 20 ng/mL epidermal growth factor (Peprotech, AF-100-15).  
 
RNAi  
For biochemical assays on the subset of validated hits, the siGENOME 
SMARTpool siRNAs (Horizon Discovery) were used, except for with siNT, which was 
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the ON-TARGETplus Non-targeting pool (D-001810-10-20). Unless otherwise noted, 
subconfluent cells (log phase) were transfected with siRNAs (20-30 nM, final 
concentration) using Lipofectamine RNAiMAX Transfection Reagent (ThermoFisher 
Scientific, 13778150) and incubated for 72 hrs prior to the experimental assays. 
 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
Total RNA was extracted from siRNA-depleted cells using TRIzol reagent 
(ThermoFisher Scientific, 15596018) as per the manufacturer’s instructions. After 
validating that A260/280 values were >1.80 and A260/230 values were >1.7, 
complementary DNA synthesis was performed using the iScript gDNA Clear cDNA 
Synthesis Kit (Bio-Rad, 172–5035) using 1 μg of total RNA and a mix of random 
hexamer and oligo dT primers. Previously published primers were used to test mRNA 
levels of ATAD5 (Bell et. al, 2011) and RFC1 (Stielow et. al, 2014). BioRad PrimePCR 
Assay gene-specific primers were used to test mRNA levels of the remaining hits (Bio-
Rad, 10025636; UTP4, qHsaCID0021354; KIF11, qHsaCID0015908; CDCA8, 
qHsaCED0044566; H1-10, qHsaCED0019411; INCENP, qHsaCID0010103; MDN1, 
qHsaCID0006754; STK24, qHsaCID0012429; TPX2, qHsaCID0016024; ENY2, 
qHsaCED0003040; FAM98A, qHsaCID0010948; INKA, qHsaCED0020031; 
RACGAP1, qHsaCID0011308; CCN4, qHsaCED0036389; WRAP53, 
qHsaCID0006849). Beta-actin primers were designed in our laboratory (intron-spanning; 
Forward - 5’ ATT GGC AAT GAG CGG TTC 3’ and Reverse - 5’ CGT GGA TGC CAC 
AGG ACT 3’). All qPCR reactions were completed using the iTaq Universal SYBR 
Green Supermix (Bio-Rad, 172-5121). To verify the amplification of a single PCR 
product, melt curves were generated for each sample. Three biological replicates, each 
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with three technical replicates, were measured for each of the 14 tested hits as well as 
siUTP4, siKIF11, and the negative non-targeting control (siNT). Amplification of the 
beta-actin mRNA was used as an internal control, and analysis was completed using the 
comparative CT method (ΔΔCT).  
 
Dual-luciferase reporter assay 
 Following siRNA-depletion of hits for 48 hrs, cells were transfected with 1000 ng 
of pHrD-IRES-Luc (Ghoshal et al., 2004) and 0.1 ng of a plasmid that constitutively 
expresses Renilla luciferase (Freed et al., 2012) using Lipofectamine 3000 Reagent 
(ThermoFisher Scientific, L3000015). After 72 hrs of siRNA-depletion and 24 hrs of 
incubation with the reporter plasmids, luminescence was detected using the Dual-
Luciferase Reporter Assay System (Promega, E1910) and a GloMax 20/20 luminometer 
(Promega). In addition to incubation with the 1X passive lysis buffer for 15 min, 
MCF10A cells were scraped prior to collection for luminescence readings.   
 
Northern blots 
Total RNA was extracted from siRNA-depleted cells using TRIzol Reagent. To 
assay for changes in levels of pre-rRNA intermediates, 4 μg of total RNA was run on a 
1% agarose/1.25% formaldehyde gel in a 1.5M tricine/1.5M triethanolamine buffer. RNA 
was transferred overnight to a Hybond XL nylon membrane (GE Healthcare, RPN 303S) 
by capillary transfer in 10X saline-sodium citrate (SSC) transfer buffer after a brief 15 
min soak in a 0.5M sodium hydroxide solution. Membranes were then exposed to UV 
(254 nm) to immobilize the RNA, and incubated with denatured yeast tRNA for 1 hr at 
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42° C and hybridized overnight at 37° C with 5’ end radiolabeled oligonucleotide probes 
in a solution of 7.5X Denhardt’s solution, 5X sodium chloride-sodium phosphate-EDTA 
(SSPE) buffer, and 0.1% SDS as in (Farley-Barnes et al., 2018). The oligonucleotide 
probes used were the same as in (Farley-Barnes et al., 2018) and include:  
5’ETS 5’ – CCTCTCCAGCGACAGGTCGCCAGAGGACAGCGTGTCAGC - 3’ 
5’ITS1 5’ – CCTCGCCCTCCGGGCTCCGTTAATGATC - 3’ (Sloan et al., 2013) 
P3 5’ – AAGGGGTCTTTAAACCTCCGCGCCGGAACGCGCTAGGTAC - 3’ 
P4 5’ – CGGGAACTCGGCCCGAGCCGGCTCTCTCTTTCCCTCTCCG - 3’ 
7SL 5’ – TGCTCCGTTTCCGACCTGGGCCGGTTCACCCCTCCTT - 3’ 
  
Puromycin labeling assay 
Following siRNA-depletion of hits for 72 hrs, cells were treated as described in 
(Farley-Barnes et al., 2018), with the exception that puromycin antibody (Kerafast, 
EQ0001) was used at a 1:500 dilution.  
 
Western blots  
 Following siRNA-depletion of hits for 72 hrs, total protein was harvested by the 
same method used in the puromycin labeling assay described in (Farley-Barnes et al., 
2018). Protein concentration was quantified by Bradford assay and 30 μg of total protein 
was run by SDS-PAGE on a 10% gel with a 5% stacking gel. Protein was transferred to a 
PVDF membrane using a Trans-Blot Turbo Transfer System (Bio-Rad) and blocked for 1 
hr with 5% milk in PBST before incubating overnight with HRP-conjugated p53 antibody 
(Santa Cruz Biotechnology, sc-126) diluted in PBST (1:5000). Following imaging on a 
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ChemiDoc Imaging System (Bio-Rad), blots were stripped and re-probed for beta-actin 
as performed in the puromycin labeling assay and quantified using ImageJ. 
 
Statistical analyses 
All statistical analyses were performed in GraphPad Prism 8.2.1 (GraphPad 

























High-throughput screen for nucleolar-targeted cancer therapies reveals small 




 Ribosome biogenesis is essential for cell growth and proliferation and is linked to 
cancer pathogenesis. Cancer pathologists observe larger and more numerous nucleoli in 
aggressive tumors (Derenzini et al., 2009), and retrospective studies found that several 
chemotherapeutic agents target ribosome biogenesis either directly or indirectly (Burger 
et al., 2010; Quin et al., 2014). While the enthusiasm was initially put towards identifying 
inhibitors of translation for cancer therapy (Hagner et al., 2010; Malina et al., 2012; 
Novac et al., 2004; Ruggero, 2013; Silvera et al., 2010), interest surrounding the 
development of drugs targeting ribosome biogenesis specifically has gained recent 
momentum (Brighenti et al., 2015; Drygin et al., 2010; Pelletier et al., 2018; Quin et al., 
2014). Thus, targeting the nucleolus and ribosome biogenesis holds promising therapeutic 
potential.  
Preclinical and clinical data support that drugs developed specifically to target 
RNAPI transcription hold promise in the treatment of cancer. While drugs targeting a 
ubiquitous cellular function may hold limited therapeutic efficacy and yield poor toxicity 
profiles, studies on pioneering RNAPI-selective inhibitors suggest instead that growth 
adaptations in cancer may actually make tumors more sensitive to the inhibition of 
ribosome biogenesis (Brighenti et al., 2015; Ruggero, 2012). The RNAPI inhibitor, CX-
3543 (quarfloxin), may in part target rDNA-enriched G-quadruplexes (Drygin et al., 
2009; Drygin et al., 2008). Phase I and II clinical trials of CX-3543 in solid tumors and 
blood cancer revealed no serious adverse events and resulted in stable disease through the 
course of the study for several participants (Papadopoulos et al., 2007). CX-5461, 
likewise, has shown promising preclinical and clinical data for the treatment of 
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hematological malignancies and DNA repair-deficient cancers (Hilton et al., 2020; Khot 
et al., 2019; Sanij et al., 2020; Xu et al., 2017b). CX-5461 inhibits RNAPI by disrupting 
the interaction between RNAPI and the transcription initiation factor, SL1 (Drygin et al., 
2011). More recent studies on the mechanism, however, suggest that CX-5461 may also 
inhibit topoisomerase II (Bruno et al., 2020), and therefore the therapeutic benefit from 
its effect on RNAPI versus topoisomerase remains to be elucidated. Finally, the RNAPI 
inhibitor, BMH-21, a planar heterocyclic DNA intercalator, leads to the selective 
degradation of the large catalytic subunit of RNAPI, RPA194 (Peltonen et al., 2014). In 
preclinical studies, BMH-21 treatment has shown promising antiproliferative activity 
across a range of cancer cell lines with limited impact on normal fibroblast cells (Fu et 
al., 2017; Peltonen et al., 2014). Furthermore, BMH-21 also has promising antineoplastic 
activity in mouse xenograft models of melanoma and drug-resistant prostate cancer (Low 
et al., 2019; Peltonen et al., 2014). Taken together, promising preclinical and clinical 
research on these pioneering compounds have energized some laboratories to further 
explore inhibition of ribosome biogenesis for cancer drug discovery. 
High-throughput screens to identify novel inhibitors of ribosome biogenesis have 
yielded some success in identifying promising new drug candidates. In one screen, 
~150,000 compounds were screened for reduced nascent ribosome levels in the human 
melanoma A375 cell line (Scull et al., 2019). This primary screen was then followed by a 
secondary screen for compounds that specifically decrease pre-rRNA levels, which 
revealed 2 structurally similar compounds, RB1 and RB2, that both decreased cell 
viability. Furthermore, RB2 had limited impact on viability of normal, HUVEC, cells and 
RB2 treatment resulted in decreased colony growth in a metastatic, anchorage-
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independent growth model (Scull et al., 2019). Another screen of ~700 compounds used a 
virtual structure-based screening approach using the yeast crystal structure of the human 
RNAPI ortholog (Tan and Awuah, 2019). Six compounds were identified in this virtual 
screen, including CX-5461 and, intriguingly, the HMG-CoA reductase inhibitor, 
cerivastatin sodium. Follow up using a yeast cell line engineered with the human rDNA 
and promoter sequence revealed that cerivastatin sodium inhibited yeast growth and also 
decreased proliferation when tested in human cancer cell lines (Tan and Awuah, 2019). 
Finally, in yet another recent high-throughput screen for inhibitors of ribosome 
biogenesis, ~1,000 compounds were surveyed in a yeast system detecting defects in 
ribosomal subunit export. Of the compounds tested, several were identified to impact 
either 40S or 60S export and subsequent analysis of hits revealed that many inhibit pre-
rRNA processing; however, they have yet to be validated in a mammalian system (Awad 
et al., 2019). Thus, there has been success in screening for small molecule inhibitors of 
ribosome biogenesis in eukaryotes and the data suggest that the approach may be a 
promising opportunity for the identification of novel drugs for therapeutic development. 
 Previously, the Baserga lab, including myself, was successful in identifying 
proteins required for ribosome biogenesis by performing a high-throughput RNAi screen 
in the non-cancer-derived human, MCF10A, breast epithelial cell line for changes in 
nucleolar number [(Farley-Barnes et al., 2018); Chapter 2]. I applied this robust assay to 
discover putative new cancer therapeutics by screening for small molecule compounds 
that effect nucleolar number. I therefore performed two high-throughput screens for small 
molecules that regulate nucleolar number. Here, I report on the results from these two 
screens, which included a pilot screen of nearly 4,000 FDA-approved drugs, followed by 
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a screen of a curated collection of approximately 25,000 synthetic compounds selected 
based on exhibiting promising pharmaceutical properties. Through these screens I 
discovered several small molecule regulators of nucleolar number, including both 
compounds that decrease nucleolar number and those that increase nucleolar number. 
Validation screening of the hits as well as bioinformatic analyses to classify hits reveal 
not only several promising drug candidates, but also common molecular targets that lend 
insight into the regulation of nucleolar number and activity. I performed these two 
screens, screen validation, and the structure clustering in collaboration with the Yale 
Center for Molecular Discovery. 
 
RESULTS 
Identification of small molecule positive controls for high-throughput screening 
 To identify novel cancer therapeutics by screening for small molecule regulators 
of nucleolar number I needed to identify small molecule compounds that yield a strong 
and reproducible decrease in nucleolar number [one nucleolus per nucleus percent effect 
(PE)] and increase in nucleolar number (≥5 nucleoli per nucleus PE) to use as positive 
controls. To identify these positive controls, I tested 25 compounds with different 
mechanisms of action at eight different concentrations (20 μM-9.14 nM, 3-fold dilutions), 
three different time points (24, 48, and 72 hrs), and two cell seeding densities (1,000 and 
2,000 cells/well; Table 4-1). I curated the list of compounds with Katherine Farley-
Barnes and Cecelia Harold, and I performed the high-throughput screen and data analysis 
in collaboration with the Yale Center for Molecular Discovery. Nucleoli were identified 
based on immunofluorescent staining with a monoclonal antibody to the abundant 
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nucleolar protein fibrillarin [72B9 (Reimer et al., 1987)], and cells were identified using 
the DNA stain, Hoechst. Nucleolar number was quantified using CellProfiler as described 
in (Farley-Barnes et al., 2018), and the one nucleolus PE and ≥5 nucleoli PE were both 
quantified relative to the negative control (0.1% DMSO; DMSO=100 PE). The seeding 
density of 2,000 cells per well and a 48 hr incubation led to several promising candidates 
with adequate viability (Appendix IV). As a result, we selected several with which to 
perform follow-up testing in order to identify the best candidates with which to move 
forward with as positive controls for the screen.  
 To identify positive controls from among the candidates in this small screen, we 
selected compounds that yielded a high PE for each phenotype (one nucleolus and ≥5 
nucleoli) to re-screen for reproducibility. The Z-prime statistic is the best measure of a 
strong and reproducible control as it reports the separation between the distributions of 
the positive and negative controls. As described in Chapter 2, a Z-prime =1 indicates an 
ideal screening assay, whereas a Z-prime <0 indicates overlap between the controls and a 
noisy assay. While in high-throughput screening a Z-prime ≥0.5 is desired, Z-prime 
values <0.5 may still identify positive hits. I selected two compounds for each phenotype 
to re-screen at several different concentrations at a seeding density of 2,000 cells per well 
and an incubation time of 48 hr and calculated the Z-prime statistic for each condition. 
These compounds included RNAPI inhibitors, BMH-21 and CX-5461, for the one 
nucleolus per nucleus phenotype, and mitomycin C and topotecan for the ≥5 nucleoli per 
nucleus phenotype. Interestingly, based on the results from this experiment, BMH-21 (1 
and 1.5 μM) and mitomycin C (14 μM) both yielded promising Z-prime values (Z-prime 
≥0.5) for decreased nucleolar number (Table 4-2). This was intriguing given that 
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mitomycin C had originally been selected as a putative positive control for increased 
nucleolar number and suggests a possible relationship between the two unique 
phenotypes. With regards to the ≥5 nucleoli per nucleus phenotype neither of the selected 
compounds yielded Z-prime values ≥0.5; however, mitomycin C at 250 nM did yield a 
positive Z-prime value (Z’=0.11; Table 4-3). Based on these data, BMH-21 (1 μM) and 




Table 4-1. Candidate compounds screened in positive control search for a high-
throughput screen to identify small molecule regulators of nucleolar number. The twenty-
five (25) compounds selected harbored a wide range of mechanisms of action and 
reported effects on the nucleolus or nucleolar proteins.  
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CDK9 inhibitor Preclinical blood cancer drug and 
putative rRNA processing 
inhibitor (Burger et al., 2013; 
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KIF11 inhibitor KIF11 inhibition by siRNA 
yields an increase in nucleolar 
number (Chapter 2)  
IWP-2 I0536 (Sigma-
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WNT inhibitor Wnt proteins regulate ribosome 
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mTOR inhibitor mTOR regulates ribosome 
biogenesis (Mayer and Grummt, 
2006) 
Mitomycin C 50-07-7 
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substrate (Pelletier et al., 2000) 
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Aldrich) 
WNT inhibitor Wnt proteins regulated ribosome 






Table 4-2. Screen statistics for re-screened one nucleolus per nucleus candidates. 
Compound, concentration tested (μM), coefficient of variation (CV), signal-to-
background (S/B), and Z-prime value are reported. A Z-prime >0.5 is desired for high-
throughput screening, although Z-prime values between 0 and 0.5 are still acceptable for 
the positive identification of hits. Compounds at concentrations that led to a viability of 
<10% are not reported. Compound and concentration selected as the positive control is in 









BMH-21 2.2 14.3 3.3 0.24 
BMH-21 1.5 5.7 3.7 0.64 
BMH-21 1.0 7.0 3.5 0.57 
BMH-21 0.75 6.3 3.5 0.59 
BMH-21 0.375 7.1 2.3 0.37 
CX-5461 20 8.5 2.5 0.36 
Mitomycin C 14 5.4 4.1 0.67 
Mitomycin C 7 8.0 3.2 0.49 





Table 4-3. Screen statistics for re-screened ≥5 nucleoli per nucleus candidates. 
Compound, concentration tested (μM), coefficient of variation, signal-to-background 
(S/B), and Z-prime values are reported. A Z-prime >0.5 is desired for high-throughput 
screening, although Z-prime values <0.5 may still identify positive hits. Compounds at 
concentrations that led to a viability of <10% are not reported. Compound and 









Mitomycin C 0.5 16.7 2.4 -0.3 
Mitomycin C 0.25 10.7 2.6 0.11 
Mitomycin C 0.125 11.3 2.3 -0.05 




Pilot screen of FDA-approved drugs revealed 140 compounds 
 To identify new cancer therapeutics by screening for small molecule regulators of 
nucleolar number, I first performed a pilot screen of FDA-approved compounds to test 
whether any proven small molecule drugs impact nucleolar number. I screened 3,923 
compounds maintained in 3 different drug libraries curated by the Yale Center for 
Molecular Discovery. MCF10A cells were seeded at a density of 2,000 cells per well and 
24 hrs later cells were treated for 48 hrs with compounds at a final concentration of 10 
μM. Nucleolar number was quantified by CellProfiler as reported in (Farley-Barnes et al., 
2018), and the one nucleolus PE and ≥5 nucleoli PE were both quantified and normalized 
to the average of the 12 negative (0.1% DMSO; PE=0) and 12 positive (1 μM BMH-21 
or 0.25 μM mitomycin C; PE=100) control replicates included on each screening plate. 
The calculated normalized percent effect (NPE) values were then used to identify hits in 
the screen.  
 The screen for compounds that cause a decrease in nucleolar number was robust 
and revealed 110 active compounds. Statistical monitoring of the 13 screening plates 
revealed a mean S/B of 3.09 (range, 2.91 to 3.26) and mean Z-prime value of 0.56 (range, 
0.40 to 0.68), suggesting good signal and separation of the two controls (Figure 4-1, A). 
Based on a conservative threshold of ≥3 standard deviations (SD) from the median NPE, 
compounds that yielded a one nucleolus NPE ≥53.2 were considered a hit. This yielded a 
hit rate of 2.8%, or 110 compounds, with a mean percent viability of 10.9% relative to 
DMSO (range, 0.5 to 33.6; Figure 4-1, B-D; Appendix V). Of the 110 hits, several were 
identified multiple times due to overlap in the compound libraries (Table 4-4). As a 
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result, 83 unique compounds were identified to cause a decrease in nucleolar number and 
suggests the identification of several putative new regulators of nucleolar function. 
 In contrast, the screen for compounds that cause an increase in nucleolar number 
was not as robust. Statistical monitoring of the 13 screening plates revealed a mean S/B 
of 1.88 (range, 1.56 to 2.28) and mean Z-prime value of -0.56 (range, -1.05 to -0.20). 
Negative Z-prime values suggest overlap among the percent effect distributions of the 
controls; however, the means of the controls were separated with only slight overlap of 
the distributions (Figure 4-2, A), and therefore I proceeded with caution. I identified hits 
based on the same conservative threshold of ≥3 SD from the median NPE (NPE ≥108.3), 
which yielded a NPE greater than the positive control. Based on this threshold, 30 hits 
were identified to cause an increase in the percentage of nuclei with ≥5 nucleoli (hit 
rate=0.8%) with a mean percent viability relative to DMSO among the hits of 35.7% 
(range, 0.8 to 99.2; Figure 4-2, B-D; Appendix VI). While some of these hits may be 
false positives, they are good candidates for re-screening to identify a better positive 
control.  
The pilot screen to identify small molecule regulators of nucleolar number was 
therefore effective in identifying 140 compounds that either decrease or increase 
nucleolar number. While the screen for decreased nucleolar number was more robust 
with favorable and reproducible Z-prime values among the screening plates, the screen 
for increased nucleolar number may still hold promise and revealed 30 hits with an 
NPE>100. Interestingly, mebendazole was a hit in both screens (Appendix V; Appendix 
VI). Comparisons to prior screens for inhibitors of ribosome biogenesis revealed several 
overlapping hits (Table 4-5). These data support to my results, but also suggest that the 
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Baserga lab’s unique screening approach may reveal a broader range of regulators of 
nucleolar function than the previously reported screens. While promising, these data 
necessitate further analysis and validation, including repeat testing, dose-response curves 
to identify EC50 concentrations, and testing in cancer versus normal cell lines to identify 
the extent to which hits share any common targets and whether they harbor any anti-





Figure 4-1. High-throughput screen of FDA-approved drugs revealed 110 compounds 
(2.8%) that caused a decreased in nucleolar number.  
(A) Frequency distribution of the one nucleolus phenotype mean percent effect (PE) of 
the negative and positive control treatments included on each screening plate (n=13). 
DMSO=negative control (red line) and mean PE set to 0. BMH-21=positive control (dark 
blue line) and mean PE set to 100. All FDA-approved drugs tested=compounds (light 
blue line). Mean Z-prime value for the screen was 0.56 (range, 0.40 to 0.68). 
(B) Distribution of the one nucleolus per nucleus normalized percent effect (NPE) for 
each of the 3,923 compounds tested in the pilot screen of FDA-approved compounds. 
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Threshold used to define hits was ≥3 standard deviations from the median NPE (red 
dashed line) or NPE ≥53.2.  
(C) Percent viability relative to the one nucleolus per nucleus NPE for the 110 hits. Each 
dot represents a hit. Mean percent viability of the 110 hits was 10.9% relative to DMSO, 
set to 100% (range, 0.5 to 33.6). 
(D) Representative images of the controls and top hits that caused a decrease in nucleolar 
number to one nucleolus per nucleus. DMSO=negative control and BMH-21=positive 
control. Hits represented include sanguinarine sulfate, pixantrone dimaleate, vindesine, 




Table 4-4. Compounds identified more than once in the screen for decreased nucleolar 
number. Drug name, the number (No.) of times the drug appeared in the hit list, and the 
range of the normalized percent effect (NPE) for the drug in the screen are indicated.  
Drug name No. of times  
in hit list 
Mean NPE  
(Lowest NPE, Highest NPE) 
Vinblastine (Velban) 5 106.0 (78.2, 125.7) 
Mycophenolic acid (Mycophenolate 
mofetil; CellCept) 
4 77.8 (63.8, 99.7) 
Vinorelbine (Navelbine) 3 106.0 (91.7, 114.8) 
Plicamycin (Mithracin) 3 86.2 (73.6, 100.9) 
Vincristine (Oncovin) 3 112.7 (105.8, 122.5) 
Podofilox (Condylox) 2 83.6 (81.0, 86.2) 
Piroctone olamine (Octopirox; 
piroctone) 
2 94.1 (94.0, 94.1) 
Ouabain 2 98.1 (96.3, 99.8) 
Colchicine 2 81.7 (75.3, 88.1) 
Mitoxantrone hydrochloride 
(Mitoxantrone) 
2 160.3 (131.9, 188.7) 
Ciclopirox olamine (Ciclopirox) 2 84.6 (83.7, 85.5) 
Albendazole 2 73.4 (70.4, 76.4) 
Mebendazole (Vermox) 2 60.1 (55.0, 65.2) 
Aclarubicin 2 107.7 (96.8, 118.6) 
Proscillaridin (Caradrin) 2 107.7 (99.1, 116.3) 
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Digitoxin (Crystodigin) 2 107.5 (102.3, 112.7) 
Mitomycin (Mitomycin C; 
Mutamycin) 
2 90.4 (77.3, 103.5) 
Vindesine sulfate (Eldesine) 2 117.3 (96.5, 138.1) 
Topotecan hydrochloride (Topotecan) 2 123.5 (120.5, 126.4) 




Figure 4-2. High-throughput screen of FDA-approved drugs revealed 30 compounds 
(0.8%) that caused an increase in nucleolar number. 
(A) Frequency distribution of the one nucleolus phenotype percent effect (PE) of the 
negative and positive control treatments included on each screening plate. 
DMSO=negative control (red line) and mean PE set to 0. Mitomycin C=positive control 
(purple line) and mean PE set to 100. All FDA-approved drugs tested=compounds (light 
blue line). Mean Z-prime value for the screen was -0.56 (range, -1.05 to -0.20). 
(B) Distribution of the normalized percent effect (NPE) for each of the 3,923 compounds 
tested in the pilot screen of FDA-approved compounds. Threshold used to define hits was 
≥3 standard deviations from the median NPE (red dashed line) or NPE ≥108.3. 
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(C) Percent viability relative to the ≥5 nucleoli per nucleus NPE for the 30 hits. Each dot 
represents a hit. Mean percent viability of the 30 hits was 35.7% relative to DMSO, set to 
100% (range, 0.8 to 99.2). 
(D) Representative images of the controls and top hits yielding an increase in the 
percentage of nuclei with ≥5 nucleoli. DMSO=negative control and mitomycin 
C=positive control. Hits represented include melphalan, merimepodib, docetaxel, 




Table 4-5. Comparison to other screens for small molecule inhibitors of ribosome 
biogenesis. Drug names are indicated. In parentheses are the number of overlapping hits 
compared to the total number of hits identified by the screening approach.  
Low-throughput screen of 
chemotherapeutic drugs for 
inhibition of ribosome 
biogenesis  
(Burger et al., 2010) 
(7/20) 
Virtual structure-based 
screen for RNAPI 
inhibitors  
(Tan and Awuah, 2019) 
(1/6) 
Screen for ribosomal 
subunit export and pre-
rRNA processing 
inhibitors  
(Awad et al., 2019) 
(7/128) 
Cycloheximide Cerivastatin sodium Daunorubicin 
Doxorubicin  Doxorubicin 
Etoposide  Flubendazole 
Melphalan  Idarubicin 
Mitoxantrone  Lasalocid A 
Mitomycin C  Mycophenolic acid 




Bioinformatic analysis of screen hits reveals known cancer therapeutics 
 Screening for changes in nucleolar number was successful in identifying 
compounds that regulate nucleolar number; but, was I successful in identifying drugs 
approved for use in cancer treatment? To address this question, I manually curated 
medical use and molecular target information for each of the 140 hits using KEGG 
DRUG Database, DrugBank Online and a review of relevant literature (Appendix V; 
Appendix VI). The analysis of drug hits by medical use revealed that when screening for 
regulators of nucleolar number, antineoplastic drugs were the most common type of 
drugs among the hits (Figure 4-3; Appendix V; Appendix VI). Also represented among 
top hits were several unexpected categories of drugs, including antiparasitic compounds, 
cardiovascular agents, antifungals, antiseptics, and antibiotics. Among the antiparasitc 
drugs, antihelmintics were the most common; among the cardiovascular agents, cardiac 
glycosides were the primary drugs identified. Interestingly, however, differences between 
decreased and increased nucleolar number among the drug medical uses identified were 
minimal, which suggests in part a possible shared mechanism by which these two 
phenotypes are generated. Taken together, screening for changes in nucleolar number 
was successful in identifying several antineoplastic drugs and may therefore be a viable 
approach for the discovery of novel antineoplastic compounds.    
  Classification of the molecular target for each hit also revealed significant 
overlap among the drugs identified by decreased versus increased nucleolar number. 
Common molecular targets among the drug hits include tubulin, DNA, topoisomerases 
and inosine-5’-monophosphate dehydrogenase (IMPDH; Figure 4-4; Appendix V; 
Appendix VI). Interestingly, a common mechanism underlying the targeting of DNA, 
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topoisomerases, and IMPHD is the inhibition of DNA and RNA synthesis and implies, 
not unexpectedly, the importance of these essential cellular functions in maintaining 
normal nucleolar numbers. Other notable drug targets among the hits include the 
ribosome, which supports a putative feedback mechanism between translation and 
ribosome biogenesis (Figure 4-4, A and B), and the Na+/K+ ATPase, which is the 
molecular target for cardiac glycosides, but has also been reported to be up-regulated in 
cancer [Figure 4-4, A-C (Khajah et al., 2018)]. Differences, among the two datasets 
however are also present, including most notably the identification of several drugs 
identified by increased nucleolar number that target ergosterol, a fungal cell wall lipid 
(Figure 4-4, B and D; Appendix V; Appendix VI). Intriguingly, however, ergosterol is 
also a provitamin in humans that is converted into vitamin D2 upon UV exposure and 
suggests a putative link between vitamin D2 and the nucleolus that has yet to be 
elucidated. Thus, analysis of the molecular targets among the drugs identified by 
screening for changes in nucleolar number again support common mechanisms 
underlying the generation of the two phenotypes, and further emphasize promising drug 
targets for the development of new cancer therapeutics.  
 In conclusion, I screened for compounds that regulate nucleolar number and 
identified several known antineoplastic drugs. Furthermore, I identified several common 
unexpected categories of drugs that will be interesting to explore in greater detail with 
regards to harboring antineoplastic potential. Additionally, I identified drugs with several 
common molecular targets that will be intriguing to explore with regards to putative 
functional roles in nucleolar biology. In all, these data suggest that screening FDA-
approved compounds for changes in nucleolar number was a successful endeavor, and 
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one that supports expanding our search for novel cancer therapeutics using our approach 





Figure 4-3. Antineoplastic drugs were the most frequently identified compounds among 
the FDA-approved drugs that regulate nucleolar number. 
(A) Compounds that caused a decrease in nucleolar number classified by medical use. Of 
the 110 hits identified, 13 categories of drugs were defined. Antineoplastic drugs were 
the most common (n=52 hits). Cardiovascular agents include cardiac glycosides (n=10), 
statins (n=1), vasopressin receptor antagonists (n=1), and Ca+ channel blockers (n=1). 
Antiparasitics include anthelmintics (n=12) and antiprotozoals (n=3). 11 drugs were 
classified in more than one category.     
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(B) Compounds that caused an increase in nucleolar number classified by medical use. Of 
the 30 hits identified, 11 categories of drugs were defined. Antineoplastic drugs were the 
most common (n=11). Antiparasitics include broad-spectrum antiparasitic (n=2) and 
antihelmintics (n=1). Four drugs were classified in more than one category.   
(C) Pie chart of top 4 categories of drugs that cause a decrease in nucleolar number by 
medical use. The most common categories of drugs identified were (1) antineoplastic 
drugs, (2) antiparasitics, (3) cardiovascular agents, and (4) antiseptics. Created, in part, 
with Biorender.com. 
(D) Pie chart of top 4 categories of drugs that cause an increase in nucleolar number by 
medical use. The most common categories of drugs identified were (1) antineoplastic 






Figure 4-4. Several common molecular targets were identified among the FDA-approved 
drugs that regulate nucleolar number.  
(A) Compounds that caused a decrease in nucleolar number classified by molecular 
target. Of the 110 hits identified, 24 different categories were defined. The most common 
molecular target among the hits was tubulin (n=32).  
(B) Compounds that caused an increase in nucleolar number classified by molecular 
target. Of the 30 hits identified, 15 different categories were defined. The most common 
molecular target among the hits was ergosterol, a sterol found in fungal cell membranes 
and also precursor to vitamin D2 (n=6).  
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(C) Pie chart of top 4 molecular targets that cause a decrease in nucleolar number. The 
most common molecular targets are (1) tubulin, (2) plasma membrane, (3) topoisomerase, 
and (4) Na+/K+ ATPase. Created, in part, with Biorender.com. 
(D) Pie chart of top 4 molecular targets that cause an increase in nucleolar number. The 
most common categories of drugs identified were (1) ergosterol, (2) DNA, (3) tubulin, 







Screen of synthetic library of drug-like small molecules identified 234 hits 
 With the objective of identifying new cancer therapeutics, I therefore expanded 
our search by screening a library of novel, synthetic, drug-like compounds to identify 
regulators of nucleolar number. First, however, given the poor Z-prime values obtained in 
the pilot screen for increased nucleolar number due to a low PE among some treatments, I 
selected 3 of the top hits to re-screen as new positive controls. The 3 hits included, 
oxiconazole, butoconazole, and melphalan, which all yielded a NPE ≥100 and were 
therefore promising candidates. Re-screening, however at several different concentrations 
for each compound, revealed that only melphalan yielded positive Z-prime values and a 
high signal to background (S/B; Table 4-6). Mitomycin C, however, was included in the 
experiment for comparison and yielded similar results. As a result, I decided to proceed 
with the original positive control, mitomycin C (250 nM), with which to expand our 
search for novel small molecule regulators of nucleolar number.  
The high-throughput screen for novel small molecule regulators of nucleolar 
number revealed 202 compounds that decrease nucleolar number. I screened 25,246 
compounds on 79 plates that contained a synthetic library of compounds enriched in sp3 
tetravalent carbons (3-D) and other physicochemical properties common among known 
bioactive, therapeutic compounds (Life Chemicals, Inc.). The library was also designed 
to be void in known pan-assay interference compounds (PAINS). Screening for 
compounds that cause a decrease in nucleolar number revealed 202 compounds. The 
mean S/B across all 79 screening plates was 3.17 (range, 1.96 to 5.60) and the mean Z-
prime value was 0.53 (range, 0.21 to 0.74), suggesting good separation between the 
negative (DMSO) and positive control (BMH-21; Figure 4-5, A). As with the FDA-
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approved pilot screen, hits were then identified based on a conservative threshold of ≥3 
SD from the median NPE of all 25,246 compounds. As a result, compounds that yielded a 
one nucleolus per nucleus NPE ≥16.8 were considered a hit, yielding 202 hits with a 
mean percent viability of 68.1 (range, 6.2 to 354.7; Figure 4-5, B-D; Appendix VII). As 
with the pilot screen for decreased nucleolar number, this screen was robust and 
identified 234 novel small molecular regulators of nucleolar number with the potential to 
harbor antineoplastic activity.   
 The screen for novel small molecules that cause an increase in nucleolar number 
revealed 32 compounds. Again, however, Z-prime calculation of the screen controls 
revealed a less than robust screen. While the mean S/B across the 79 screening plates was 
strong, 2.38 (range, 1.15 to 3.46), the mean Z-prime value was -0.39 (range, -6.70 to 
0.41) suggesting poor separation of the controls due to variability in PE of mitomycin C, 
at least on some assay plates (Figure 4-6, A). The majority of screening plates, however, 
yielded relatively consistent Z-prime values >0, except for a few of the early plates and a 
later batch of plates. I therefore decided again to proceed with caution in evaluating the 
results for increased nucleolar number. Hits were identified as those that yielded a NPE 
≥3 SD from the median NPE of all 25,246 compounds. As a result, compounds that 
yielded a ≥5 nucleoli per nucleus NPE ≥139.9 were considered a hit, yielding 32 hits with 
a mean percent viability of 81.3 (range, 24.3 to 155.0; Figure 4-6, B-D; Appendix VII). 
While some of these hits may again be false positives due to the poor screening statistics, 




 In conclusion, the screen of a synthetic library of drug-like compounds was 
effective in identifying 234 compounds that regulate nucleolar number. As observed in 
the pilot screen of FDA-approved drugs, the screen for decreased nucleolar number was 
more robust with favorable and reproducible Z-prime values, while the screen for 
increased nucleolar number was more variable. The one nucleolus per nucleus NPE was 
also more successful in the number of compounds it identified, uncovering 202 
compounds. However, while the ≥5 nucleoli per nucleus NPE identified only 32, each 
compound yielded an NPE greater than the positive control (NPE≥100). Given the high 
percentage of antineoplastic compounds identified in the pilot screen by screening for 
regulators of nucleolar number, these results are promising candidates for the discovery 





Table 4-6. Summary statistics of candidate positive controls for increased nucleolar 
number. Top hits from the pilot screen of FDA-approved drugs were re-screened at three 
different concentrations. Signal-to-background (S/B), Z-prime values, and percent 
viability were calculated to evaluate suitability as a new control and compared to 
statistics from the current control, mitomycin C (in bold).  
Candidate  Concentration 
(μM) 




Mitomycin C 0.25 3.9 0.26 35.8 
Melphalan 20 4.3 0.17 16.8 
Melphalan 10 4.7 0.14 20.9 
Melphalan 5 2.7 -0.26 35.4 
Oxiconazole 20 1.6 -1.63 62.1 
Oxiconazole 10 1.7 -0.82 84.6 
Oxiconazole 5 1.4 -1.74 100.6 
Butoconazole 10 1.8 -1.05 65.2 
Butoconazole 5 1.4 -2.08 98.7 






Figure 4-5. High-throughput screen of a synthetic library of drug-like compounds 
identified 202 hits that decrease nucleolar number. 
(A) Z-prime values across all 79 screening plates. The mean Z-prime value was 0.53 
(range, 0.21 to 0.74). A Z-prime >0 suggests separation between the positive and 
negative controls and ≥0.5 is a robust screening assay (black dashed line). 
(B) Distribution of the normalized percent effect (NPE) for each of the 25,246 
compounds. Threshold used to define hits was ≥3 standard deviations from the median 
NPE (red dashed line) or NPE ≥16.8. Screen hits are compounds (black dots) above the 
red dashed line. 
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(C) Percent viability relative to the one nucleolus per nucleus NPE. Each dot represents a 
hit. Mean percent viability of the hits was 68.1% relative to DMSO (range, 6.2 to 354.7). 
(D) Representative images of the controls and top hits yielding an increase in the 
percentage of cells with one nucleolus per nucleus. DMSO=negative control and BMH-





Figure 4-6. High-throughput screen of a synthetic library of drug-like compounds 
identified 32 hits that increase nucleolar number. 
(A) Z-prime values across all 79 screening plates. The mean Z-prime value was -0.39 
(range, -6.70 to 0.41). A Z-prime >0 suggests separation between the positive and 
negative controls and ≥0.5 is a robust screening assay (black dashed line).  
(B) Distribution of the normalized percent effect (NPE) for each of the 25,246 
compounds. Threshold used to define hits was ≥3 standard deviations from the median 
NPE (red dashed line) or NPE ≥139.9. Screen hits are compounds (black dots) above the 
red dashed line. 
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(C) Percent viability relative to the ≥5 nucleoli per nucleus NPE. Each dot represents a 
hit. Mean percent viability of the hits was 81.3% relative to DMSO (range, 24.3 to 
155.0). 
(D) Representative images of the controls and top hits yielding an increase in the 
percentage of cells with ≥5 nucleoli per nucleus. DMSO=negative control and mitomycin 




Re-screening revealed 185 high confidence hits 
 The Baserga lab’s unique screening approach identified several hundred 
compounds required to maintain typical numbers of nucleoli in cells. Furthermore, 
analysis of the FDA-approved drug hits revealed several antineoplastic compounds. 
Together, these data suggest that the hits identified in the screen of the synthetic, drug-
like library are promising novel antineoplastic drug candidates. To identify a promising 
subset of compounds to investigate for antineoplastic potential, I validated each hit and 
its ability to yield the initially observed effect on nucleolar number. To validate the hits, I 
re-screened each hit from both the FDA-approved drug libraries and the synthetic drug-
like compound library. Re-screening was performed in duplicate and hits were identified 
based on an average of the negative, DMSO, control wells on the 3 screening plates. The 
threshold was thus designated as ≥3 SD from the median percent effect (PE) of the 
negative control (Table 4-7). This change was necessary given that the population of 
compounds tested are now enriched for compounds known to regulate nucleolar number 
and therefore setting a threshold based on the median of the screened population of 
compounds would exclude those with milder, yet still potentially significant effect. Hits 
were considered validated if they yielded the same phenotype in at least 1 of the 2 
replicates.  
 Of the FDA-approved drug hits, I re-screened 130 compounds. One-hundred and 
four (104) were compounds that decreased nucleolar number, 26 were compounds that 
increased nucleolar number, and 10 were compounds discarded prior to re-screening 
based on a manual review of the images to confirm the quality of the images and 
presence of the expected phenotype. Of the 120 hits re-screened, 105 were identified as 
 
183 
compounds that yielded the one nucleolus per nucleus phenotype. Interestingly, however, 
12 of these compounds were originally designated as hits that caused an increase in 
nucleolar number. Thus, excluding those, 93 of 104 hits that decreased nucleolar number 
validated (89%), 84 of which were identified in both replicates (Table 4-8; Appendix 
VIII). With regard to the hits that caused an increase in nucleolar number, 27 were 
identified as yielding an increase in nuclei with ≥5 nucleoli. Of these, however, 13 were 
originally designated as hits that decrease nucleolar number, and therefore 14 of the 26 
compounds re-screened validated (54%), of which 11 were identified in both replicates 
(Table 4-8; Appendix VIII).  In all, of the 130 FDA-approved compounds re-screened, 
107 showed reproducible activity with a consistent phenotype suggesting a strong 
approach for identifying novel compounds with antineoplastic potential. 
 Of the synthetic, drug-like hits, I re-screened 233 compounds. 183 were 
compounds that decreased nucleolar number, 50 were compounds that increased 
nucleolar number, and 1 was discarded based on a manual review of the images. Of the 
183 hits re-screened that yielded a decrease in nucleolar number, 157 were identified as 
compounds that yielded the one nucleolus per nucleus phenotype, 11 of which were 
originally designated as hits that yielded an increase nucleolar number. Excluding those 
hits that switched designation, 147 hits validated (80%), 92 of which were identified in 
both replicates (Table 4-8; Appendix VIII). With regards to the hits that increased 
nucleolar number, the reproducibility of these compounds was poor. Strikingly, of the 50 
hits re-screened, only 8 yielded an increase in the percentage of nuclei with ≥5 nucleoli, 
and all 8 were originally designated as hits that caused a decrease in nucleolar number. 
As a result, no hits from the initial screen that were designated to increase nucleolar 
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number validated (Table 4-8). In reviewing data from the original screen, all but 1 of the 
hits that caused an increase in nucleolar number came from the same 2 assay plates. The 
Z-prime values for these two plates were, -1.53 and -6.7, which suggests that the positive 
control (100 PE) was not significantly different from the negative control (0 PE). Because 
compounds are normalized to the controls screened on the same plate, this could cause 
some compounds on plates with poor Z-prime values to have exaggerated NPE values 
relative to compounds on plates with good Z-prime values and lead to false positives. 
This may likely explain the lack of reproducibility among hits that increased nucleolar 
number and suggests that this dataset should be re-analyzed following the removal of 
plates with poor Z-prime values in order to identify true positive hits. In all, re-screening 
the synthetic, drug-like library of compounds resulted in the identification of 147 novel 
compounds that have a reproducible effect nucleolar number.  
Finally, in addition to validation by identifying hits that yield reproducible effects 
on nucleolar number, I also considered viability in order to identify a high confidence 
subset of hits to investigate for putative antineoplastic potential. In this analysis, hits were 
discarded if viability was <10% between the two replicates. The rationale for discarding 
hits with low viability is to ensure an adequate population of cells with which to calculate 
the PE on nucleolar number. Furthermore, our objective is to identify drugs that effect 
cancer cell viability more than normal cell viability and since MCF10A cells are not 
derived from cancer, a viability filter seems appropriate. Using this threshold, among the 
107 validated hits identified in the re-screening of the FDA-approved drugs, 59 were 
discarded due to low viability (Table 4-8; Appendix VIII). This left 48 high confidence 
hits, and of those, 39 decreased nucleolar number and 9 increased nucleolar number. 
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Among the 147 validated hits identified in the re-screening of the synthetic, drug-like 
compounds, 10 were discarded due to low viability (Table 4-8; Appendix VIII). This left 
137 high confidence hits, and of those, all 137 decreased nucleolar number. In all, by re-
screening hits and applying reproducibility and viability filters I identified 185 high 





Table 4-7. Designated thresholds to identify hits in the validation re-screening assays. 
Two replicates were performed, each with their own set of thresholds. Thresholds were 
set at the median of the DMSO percent effect (PE) for each phenotype +3 standard 
deviations (SD). Hits with a percent effect ≥ the designated threshold were considered a 
validated hit. DMSO=negative control. 
Replicate DMSO one nucleolus per nucleus PE 
(median + 3SD) 
DMSO ≥5 nucleoli per nucleus PE  
(median + 3SD) 
1 14.0 26.6 





Table 4-8. Number of high confidence hits identified by re-screening all hits in duplicate 
and applying reproducibility and viability filters. Compounds were considered high 
confidence hits if they yielded the same phenotype in at least 1 of the 2 replicates 











































Cluster analysis reveals diverse structures among the high confidence hits 
 High-throughput screening for regulators of nucleolar number identified 185 high 
confidence compounds, 137 of which are novel, synthetic, drug-like compounds with no 
known medical use or molecular target. Due to the large number of compounds 
identified, to help select compounds for further evaluation, I decided to perform a 
chemical structure cluster analysis to determine whether there were any structural 
similarities shared among the hits. Using the DataWarrior software [OSIRIS (Sander et 
al., 2015)], I performed the Cluster Compounds analysis to identify structural clusters 
among the 137 high confidence hits from the synthetic, drug-like compounds library. 
Compounds were analyzed based on the Simplified Molecular Input Line Entry System 
(SMILES) code structure, and the number of clusters present in the dataset were 
identified.  
To determine whether screening for changes in nucleolar number identified 
compounds with high structural similarity, I performed the cluster analysis based on a 
threshold of ≥80% similarity. This initial analysis of the 137 high confidence hits from 
the synthetic drug-like library returned 98 clusters, suggesting few compounds with 
highly similar structural features (Table 4-9). While initially striking given the shared 
effect on nucleolar number for each compound, it is common in order to enhance 
discovery for curated compound libraries to be designed to limit compounds with a high 
degree of structural similarity [≥85 similarity; (Martin et al., 2002)]. As a result, I 
repeated the cluster analysis with two additional thresholds, ≥65% and ≥50% similarity. 
Clustering based on a ≥65% similarity revealed 47 clusters, 20 of which included just one 
compound; and, at a threshold of ≥50% similarity, 11 clusters were revealed, 3 of which 
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included just a single compound. Furthermore, at the latter threshold, one cluster included 
75 compounds or nearly 55% of the dataset. Taken together, there is little similarity 
among the high confidence compounds identified in the synthetic drug-like compound 
screen, thus further analysis of these clusters is necessary to help identify candidate 
compounds for exploring antineoplastic potential. 
    In an attempt to gain additional information on the 137 high confidence 
compounds identified by screening the synthetic drug-like library, I also evaluated the 
high confidence compounds identified in the screen of FDA-approved drugs. 
Interestingly, structure cluster analysis alone on the 48 high confidence FDA-approved 
drugs revealed similar results. At a similarity threshold of ≥80%, 40 clusters were 
identified, suggesting very little structural similarity among the FDA-approved drugs hits 
that regulate nucleolar number (Table 4-9). Decreasing the threshold to ≥50% similarity, 
only reduced the number of clusters to 23, with 15 including just a single drug. Finally, I 
decided to evaluate the synthetic, drug-like hits together with the FDA-approved drug 
hits. Because more about the mechanisms underlying the FDA-approved drugs are 
known, any clusters containing both an FDA-approved drug and a synthetic, drug-like 
compound could be informative. In this analysis of the 185 total high confidence 
compounds, 138 clusters were identified at a ≥80% similarity threshold, 82 were 
identified at a ≥65% similarity threshold, and 31 were identified at ≥50% similarity 
threshold (Table 4-9; Appendix VIII). Among the 31 clusters including drugs with ≥50% 
similarity, 5 clusters contained both FDA-approved drug hits and the synthetic drug-like 
hits. Interesting clusters from this analysis are cluster 3 and cluster 11. Cluster 3 is the 
largest with 73 synthetic, drug-like compounds and 7 FDA-approved drugs, including 
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antineoplastic mitotic inhibitors and antifungal metal ion chelators. Cluster 11 contained 
4 compounds, 3 synthetic compounds and the FDA-approved translation inhibitor, 
cycloheximide. In all, analyzing the FDA-approved drugs together with the synthetic, 
drug-like compounds revealed limited structural similarities between the two sets of 
compounds, and further reinforced that the synthetic, drug-like library contains diverse 
and novel compounds that may lead to the discovery of novel cancer therapeutics.  
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Table 4-9. Number of compound clusters identified among the high confidence hits using 
different structure similarity thresholds. Cluster analysis was performed in DataWarrior 
software based the Simplified Molecular Input Line Entry System (SMILES) code-
derived structure. 
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To identify putative new cancer therapeutics, I performed two high-throughput 
screens for small molecules that regulate nucleolar number in MCF10A cells. In a pilot 
screen of nearly 4,000 FDA-approved drugs, I identified 140 compounds that impact 
nucleolar number, the majority of which decreased the percentage of nuclei with 2-3 
nucleoli and increased the percentage of nuclei with just a single nucleolus. 
Bioinformatic analysis of these drugs revealed that several are antineoplastic agents used 
in the treatment of cancer, suggesting that regulators of nucleolar number are promising 
targets for cancer therapeutics. I therefore expanded the search for regulators of nucleolar 
number by screening a curated collection of approximately 25,000 synthetic drug-like 
compounds and uncovered 234 novel small molecules that alter nucleolar number. Re-
screening of both drug libraries to test for reproducibility and viability ≥10% led to the 
identification of 185 high confidence compounds, several of which may harbor 
antineoplastic activity. This screening campaign was thus successful as it revealed several 
small molecular compounds that regulate nucleolar number and that have putative drug 
development potential.  
 Antineoplastic compounds were the most frequently identified compounds in the 
screen of FDA-approved drugs, even when filtering from the analysis the compounds that 
were included more than once in screened libraries. Some of the more common molecular 
targets for these drugs included tubulin and DNA. The mechanism underlying targeting 
tubulin in cancer therapeutics lies in the stabilization of microtubules and impairing 
mitosis in actively dividing cells or neoplasms (Mukhtar et al., 2014; Zhou and 
Giannakakou, 2005). These data suggest a strong interdependence between microtubule 
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dynamics and nucleolar biology, that may be related to the dissolution and reformation of 
nucleoli that occurs during mitosis (Hernandez-Verdun, 2011). The targeting of DNA on 
the other hand included compounds that are either intercalators or crosslinking agents, 
both leading to impaired replication and RNA synthesis. The preclinical cancer 
therapeutic, BMH-21, that specifically targets RNAPI transcription is also a DNA 
intercalator and was the positive control for increased nucleolar number in these screens. 
While structure analyses clustered few novel compounds with drugs known to function 
through interactions with tubulin or DNA, this does not rule out the possible 
identification of novel classes of tubulin and DNA-targeting drugs. Thus, screening for 
changes in nucleolar number identified several antineoplastic drugs, including modulators 
of tubulin dynamics and DNA replication, and further validates the approach of screening 
novel compounds for effects on the nucleolus in order to identify novel cancer 
therapeutics. 
 While the structure analysis clustered many of the FDA-approved drug hits 
together, the synthetic, drug-like hits often formed distinct clusters. While it is possible 
that the synthetic drug-like hits may represent novel classes of compounds that target the 
same molecular targets revealed by the FDA-approved drug hits, it is also likely that 
these compounds target different proteins and ones that specifically regulate nucleolar 
function. Prior screening for changes in nucleolar number using a genome-wide siRNA 
approach identified several hundred proteins required for maintaining typical nucleolar 
numbers [(Farley-Barnes et al., 2018); Chapter 2-3]. Follow up biochemical studies 
revealed that depletion of both hits that decrease and increase nucleolar number, caused 
defects not only in protein synthesis, but also in RNAPI transcription or pre-rRNA 
 
194 
processing (and in some cases, both). It is, however, exciting to speculate that the 
targeting of tubulin and/or other molecular targets revealed by the bioinformatic analysis, 
like ergosterol and the Na+/K+ ATPase may also regulate ribosome biogenesis. In fact, 
there is a literature on the potential of repositioning cardiac glycosides as cancer 
therapeutics (Newman et al., 2008; Prassas and Diamandis, 2008). Furthermore, the 
recent discovery that the cardiovascular drug and HMG-CoA inhibitor, cerivastatin 
sodium (which was also a hit in our screen), inhibits RNAPI (Tan and Awuah, 2019), acts 
as independent validation. Additional validation includes the prevalence of the vinca 
alkaloid cancer drugs among the screen hits [vincristine, vinblastine, vinorelbine,  
(Johnson et al., 1963; Martino et al., 2018), and literature proposing antihelmintics, like 
mebendazole, as putative cancer therapies although further research on clinical efficacy 
and safety are required (Laudisi et al., 2020; Mezzatesta et al., 2020).  In all, these data 
suggest that while some of the novel compounds identified in this screen may be 
targeting tubulin, DNA or topoisomerases, it is also possible that these compounds target 
proteins that regulate ribosome biogenesis, which have not yet been fully explored as 
therapeutic targets. 
Finally, the screen for small molecule regulators of nucleolar number has revealed 
confounding results regarding the putative mechanisms underlying increased versus 
decreased nucleolar number. The Baserga lab has often considered the two phenomena as 
produced by distinct processes. This understanding is supported by the non-overlapping 
subset of proteins uncovered in our prior screens using a genome-wide siRNA approach 
for decreased and increased nucleolar number, respectively [(Farley-Barnes et al., 2018); 
Chapter 2]. In this study, however, in re-screening to validate reproducibility of the hits 
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in regulating nucleolar number, 23 compounds were identified as switching from either a 
compound that decreases nucleolar number to one that increases nucleolar number, or 
vice versa. This switching phenomenon was even evident in our initial screening to 
identify positive controls for the screens. For example, BMH-21, at 1 μM caused an 
increase in the one nucleolus per nucleus PE, whereas at lower concentrations resulted in 
an increase in the ≥5 nucleoli per nucleus PE (Appendix IV). Mitomycin C, as well, 
caused an increase in the ≥5 nucleoli per nucleus PE at low concentrations, but at higher 
concentrations caused an increase in the one nucleolus per nucleus PE (Appendix IV; 
Table 4-2; Table 4-3). In fact, although mitomycin C was the positive control for the 
screen for increased nucleolar number, it was also a hit (screened at 10 μM) among the 
FDA-approved drugs that caused a decrease in nucleolar number (Appendix V). Finally, 
the clustering analysis of the high confidence compounds based on structural similarities 
revealed that both subsets of hits can be found in the same clusters (e.g. cluster 2). Taken 
together, these data suggest that while there are some identifiable differences between the 
two phenotypes and >80% yielded the same phenotype in subsequent replicate 
experiments, changes in nucleolar number may be more dynamic and may represent 
different stages of nucleolar disruption by impacts on nucleolar function.   
In conclusion, this high-throughput screening campaign to uncover small 
molecule regulators of nucleolar number was effective in identifying several hundred 
compounds that either increase or decrease nucleolar number. Several of these 
compounds are FDA-approved as cancer therapeutics and suggests that the novel drug-
like compounds also identified may too harbor antineoplastic potential. Furthermore, it is 
known that the assay reports changes in nucleolar number that predict changes in 
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nucleolar function [(Farley-Barnes et al., 2018); Chapter 2-3], and several cancer 
therapeutics are reported to have secondary effects on nucleolar activity (Burger et al., 
2010; Quin et al., 2014); thus, it is probable that we have identified new compounds that 
regulate ribosome biogenesis that will be important to test in future studies. Furthermore, 
this screen has also identified several unexpected drug targets that not only may be 
promising novel targets for drug discovery programs, but further may lend insight into 
mechanisms underlying the regulation of nucleolar number and activity. Thus, this screen 
not only broadens our understanding of what governs changes in nucleolar number, but 
also revealed several compounds that hold potential as next generation cancer 
therapeutics.  
   
MATERIALS AND METHODS 
 
Cell culture 
As described in Chapter 2, the human breast epithelial cell line, MCF10A (ATCC, 
CRL-10317), was 2D subcultured in DMEM/F-12 medium (Gibco, 1130-032) 
supplemented with 5% horse serum (Gibco, 16050), 10 μg/mL insulin (Sigma, I1882), 
0.5 μg/mL hydrocortisone (Sigma, H0135), 100 ng/mL cholera toxin (Sigma, C8052), 
and 20 ng/mL epidermal growth factor (Peprotech, AF-100-15).  
 
High-content screening 
The high-content small molecule screening was performed as reported in (Farley-
Barnes et al., 2018) with the Yale Center for Molecular Discovery. Cells were imaged on 
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an IN Cell Analyzer 2200 (Cytiva), which is a widefield, multicolor, fluorescence 
microscope. 9 fields of view (20X; 665.63 μm x 665.63 μm) were acquired per well and 
high throughput image analysis was performed using CellProfiler (Carpenter et al., 2006; 
McQuin et al., 2018) to segment nucleoli based on fibrillarin staining (72B9; (Reimer et 
al., 1987)) and nuclei based on Hoechst 33342 staining.  
 
Positive control identification 
 To identify positive controls to use in a high-throughput screen for small molecule 
regulators of nucleolar number, we tested 25 unique compounds with different 
mechanisms of action (Table 4-1). All compounds were dissolved in DMSO and tested at 
eight different concentrations, 20.0 μM, 6.67 μM, 2.22 μM, 741 nM, 247 nM, 82.3 nM, 
27.4 nM, 9.14 nM (3-fold dilutions), three times points (24, 48, and 72 hrs), and two cell-
seeding densities (1,000 and 2,000 cells/well) in 384-well plates. MCF10A cells were 
seeded in 30 uL growth medium 24 hrs prior to adding the different compounds or 
DMSO control (0.1%, final concentration). 30 nL of compounds were dispensed at 
1000X by an Echo 550 Acoustic Liquid Handler (Labcyte, Inc.). Following compound 
addition, plates were incubated at 37° C and 5% CO2. At 24, 48, or 72 hrs, the plates 
were then fixed, permeabilized, stained and imaged as described in (Farley-Barnes et al., 
2018). For each compound, concentration, time point and seeding density, 3 replicates 
were performed and 9 fields of view imaged (20X). Select candidates were re-screened at 
several different concentrations, 16 replicates each (9 fields of view), and Z’ statistics 
were calculated relative to 64 replicates of DMSO (9 fields of view; Table 4-2; Table 4-
3). These candidates included BMH-21 (8.8 μM, 4.4 μM, 2.2 μM, 1.5 μM, 1 μM, 750 
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nM, and 375 nM) and CX-5461 (30 μM, 20 μM, and 10 μM) for the one nucleolus 
phenotype, and mitomycin C (14 μM, 7 μM, 3.5 μM, 500 nM, 250 nM, and 125 nM) and 
topotecan (18 nM, 9 nM, 4.5 nM and 2.3 nM) for the ≥5 nucleoli phenotype. 
 
High-throughput FDA drug screen 
 FDA-approved compounds were screened in a high-throughput assay for small 
molecule regulators of nucleolar number. Three libraries comprising a total of 3,923 
drugs were screened. The libraries included the MicroSource Pharmakon 1600, Enzo 640 
FDA-approved drug, and the Yale Center for Molecular Discovery curated “Tested in 
Humans” collection. Compounds were screened in MCF10A cells seeded at a cell density 
of 2,000 cells per well in 13 x 384-well plates. Cells were incubated with 10 μM of each 
compound dissolved in 0.1% DMSO for 48 hrs, and then fixed and stained to detect 
nuclei and nucleoli as described in (Farley-Barnes et al., 2018). Nucleolar number per 
nucleus was quantified using the same CellProfiler pipeline developed in (Farley-Barnes 
et al., 2018), and a normalized percent effect (NPE) from an average of 9 fields of view 
(20X) was calculated relative to the average of the 12 negative (PE=0) and 12 positive 
(PE=100) control replicates included on each screening plate. The negative control was 
0.1% DMSO, and the positive controls were BMH-21 (1 μM) for the one nucleolus per 





High-throughput synthetic, drug-like screen 
Synthetic, drug-like compounds were screened in the same high-throughput assay 
as performed for the FDA-approved drug pilot screen. The compounds screened were 
from an Fsp3-enriched screening library curated by Life Chemicals, Inc. Included in the 
library were 25,246 small molecules enriched in sp3 tetravalent carbons (3-D) and other 
physicochemical properties common among known bioactive, therapeutic compounds, 
including molecular weight <450 Da and ClogP values <4 (Lipinski, 2000, 2004; 
Lovering et al., 2009). The library was also curated to limit common pan-assay 
interference compounds (PAINS). 
Three (3) top hits from the FDA-approved pilot screen for increased nucleolar 
number were re-screened to test for a new positive control following the inconsistent Z-
prime values attained in the pilot screen. The three hits included oxiconazole (SML1474, 
Sigma-Aldrich), butoconazole (SML1663, Sigma-Aldrich), and melphalan (M2011, 
Sigma-Aldrich), and were tested at three different concentrations (Table 4-6). Screening 
statistics were compared to mitomycin C and only melphalan yielded comparable results. 
As a result, mitomycin C was kept as the positive control for increased nucleolar number. 
 
Bioinformatic analysis 
 The bioinformatic analysis of the FDA-approved pilot screen hits was performed 
by manual curation of the medical use and molecular target from the KEGG DRUG 
Database (https://www.genome.jp/kegg/drug/), DrugBank Online 
(https://go.drugbank.com/), and a review of relevant literature. Compounds with more 
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than one medical use or molecular target were classified as both, and led to the total 
number classified exceeding the total number of screen hits. 
  
Cluster Compounds analysis 
 The Cluster Compounds analysis was performed in the open-source software, 
DataWarrior [OSIRIS; http://www.openmolecules.org/datawarrior/; (Sander et al., 
2015)]. The analysis was performed based on the Simplified Molecular Input Line Entry 
System (SMILES) code structure produced by DataWarrior and compared to database of 
512 predefined structure fragments. Compound clusters were evaluated multiple times 
using different Tanimoto similarity thresholds, 0.8, 0.65, and 0.5 (Bajusz et al., 2015) on 



































 High-throughput screening for changes in nucleolar number has revealed several 
novel discoveries in the regulation of nucleolar form and function in higher eukaryotes. 
Here, I asked whether novel factors governing ribosome biogenesis could be identified by 
investigating regulators of nucleolar number in the human breast epithelial cell line, 
MCF10A. What I discovered was that, indeed, identifying factors required to maintain 
typical nucleolar number is a viable approach for identifying factors required for 
maintaining typical nucleolar function. In Chapter 1, I provided background on the 
nucleolus, its primary function in ribosome biogenesis, and its association with a panoply 
of diseases. In Chapter 2, I identified 113 proteins that when depleted cause an increase 
in nucleolar number that were enriched in cell cycle related proteins, including ones 
required specifically for faithful progression through S and G2/M phase. In Chapter 3, I 
discovered that a subset of the proteins identified were also overwhelmingly required for 
the regulation of RNAPI transcription and protein synthesis. In Chapter 4, based on these 
discoveries and prior results from our lab (Farley-Barnes et al., 2018), I applied our 
screening platform to cancer drug discovery and identified several small molecule 
regulators of nucleolar number. Together, the data presented in this thesis broaden our 
understanding of the regulation of nucleolar number and provide a foundation for 
defining novel mechanisms and proteins required to maintain nucleolar form and 
function.    
 Several novel discoveries have thus been made, however several questions still 
remain. While it is clear that nucleolar number artificially increased by siRNA depletion 
overwhelmingly predicts defects in RNAPI transcription and protein synthesis, the 
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mechanisms that underly the increase in nucleolar number remain incompletely 
understood. Other questions stemming from this research include: (1) How do DNA 
replication, recombination and repair factors contribute to maintaining typical nucleolar 
form and function?; (2) How do mitosis factors contribute to maintaining typical 
nucleolar form and function?; and, (3) Are small molecule regulators of nucleolar number 
effective cancer therapies? In this chapter, I will elaborate on these questions, suggest 
testable models, and present possible future directions.   
 
Increased nucleolar number reflects changes in RNAPI transcription 
 siRNA screening for increased nucleolar number has revealed several proteins 
required for cell cycle progression and RNAPI transcription. These results, however, 
were based on a functional analysis of only a subset of the 113 high confidence hits. 
While my initial bioinformatic analysis of the screen hits did not necessarily suggest 
factors required for ribosome biogenesis or RNAPI transcriptional regulation (Chapter 2), 
I questioned whether there were other known transcription factors among the screen hits 
that might suggest novel transcriptional regulators of RNAPI. Thus, using the PANTHER 
classification system (v16.0; (Thomas et al., 2003)), I identified the screen hits by protein 
class and performed an overrepresentation analysis to determine whether any of the 
protein classes were enriched. Although 40 hits could not be defined using this 
classification system (“undefined”), in this analysis only 1 protein class was significantly 
enriched among the hits. DNA metabolism protein (PC00009) was enriched 6-fold 
among the hits (Binomial test with Bonferroni correction for multiple testing; p<0.05), 
and is a sub-class within nucleic acid metabolism protein (PC00171), which was among 
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the top represented protein classes (Figure 5-1, A; Table 5-1). The discovery of proteins 
associated with nucleic acid metabolism is not unexpected given that ribosomes are 
comprised mostly of RNA that are transcribed from DNA. What is striking, however, is 
that proteins associated with DNA metabolism were not only enriched, but also more 
abundant relative to proteins associated with RNA metabolism (Figure 5-1, B; Table 5-1). 
The screen hits associated with DNA metabolism are primarily associated with DNA 
replication, recombination, and repair, which is consistent with prior bioinformatic 
analysis (Chapter 2). Furthermore, among these hits, RFC1 and ATAD5 were also tested 
for functional roles in ribosome biogenesis and identified as repressors of RNAPI 
transcription (Chapter 3). Thus, while these results were unexpected, together these data 
support the intriguing connection between DNA-associated processes and nucleolar 
function.  
Proteins associated with RNA metabolism were also identified among the screen 
hits. Of the hits associated with nucleic acid metabolism, only 4 were associated with 
RNA metabolism, and they were all unique (Table 5-1). TAF1D is a known RNAPI 
transcription cofactor, whereas SMG5 is associated with non-sense mediated decay and 
telomerase function. FAM98A is a regulator of the arginine methyltransferase, PRMT1, 
and I also identified it as a regulator of RNAPI transcription in my functional analysis 
(Chapter 3). Finally, GTF2IRD1 may function as a positive transcriptional regulator with 
the tumor suppressor, retinoblastoma protein, but intriguingly has also been identified in 
the 7q11.23 deletion associated with Williams-Beuren syndrome (Franke et al., 1999). 
Williams-Beuren syndrome is a congenital disorder that manifests with craniofacial 
dysmorphology and cognitive delays that are consistent with features of those with 
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ribosomopathies (Farley-Barnes* and Ogawa* et al., 2019; Franke et al., 1999). 
Williams-Beuren syndrome has also previously been suggested to be a putative 
ribosomopathy based on homology of WBSCR20 and WBSCR22 in the 7q11.23 deletion 
to yeast proteins, Nol1 and Bud23, respectively (Doll and Grzeschik, 2001; Sondalle and 
Baserga, 2014). Nol1 is a nucleolar protein and Bud23 is a methyltransferase required for 
SSU maturation (Black et al., 2020). GTF2IRD1-null mice, however, also show features 
consistent with William-Beuren syndrome (Tassabehji et al., 2005), and it is intriguing to 
speculate that as a hit identified in this screen GTF2IRD1 may also contribute to the 
pathophysiology of the syndrome through a role in ribosome biogenesis. Thus, while 
proteins associated specifically with RNA metabolism were few, they highlight a range 
of functions that may be linked to the function of the nucleolus.   
Remarkably, also among the top represented protein classes were transcriptional 
regulators. In the PANTHER protein class analysis, 12 proteins were classified as gene-
specific transcription regulators [(PC00264); Figure 5-1, A). Of these, the majority were 
DNA-binding transcription factors, rather than transcription cofactors (Figure 5-1, C). 
Manual review of the screen hits also revealed 2 additional “undefined” proteins that are 
known or probable regulators of transcription (Table 5-2). Included among these proteins 
are 2 nucleolar proteins based on my analysis in Chapter 2, GZF1 and ZNF678. ZFN678 
is a ubiquitously expressed zinc finger protein that has not been reported in the literature 
(Thul et al., 2017). GZF1, on the other hand, is a zinc finger protein that is also expressed 
in all tissues and has recently been associated with a form of Larsen syndrome (Patel et 
al., 2017; Thul et al., 2017). Larsen syndrome is a congenital disorder caused by several 
genes including FLNB and is associated with joint dislocations and an abnormal facial 
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appearance, including cleft palate and hearing loss (Patel et al., 2017; Stanley et al., 1988; 
Zeng et al., 2021). Again, craniofacial dysmorphology is a common clinical feature of the 
ribosomopathies, as is hearing loss in some patients (Farley-Barnes* and Ogawa* et al., 
2019). Together, these data are again intriguing in that, as a hit identified in this screen, 
GZF1 may regulate RNAPI transcription and contribute to the pathophysiology of the 
disease. 
Several other intriguing transcription regulators were identified among the screen 
hits. Included among these are putative tumor suppressors, including EBF3 and RBBP1. 
EBF3, or early B-cell factor, is required not only for B-cell differentiation, but has also 
been reported to be important for bone development and neurogenesis (Chao et al., 2017; 
Seike et al., 2018; Sleven et al., 2017). RBBP1, on the other hand, is reported as a 
putative tumor suppressor through its interaction with the retinoblastoma protein (pRB). 
pRB is required for cell cycle progression and has been reported to also regulate RNAPI 
transcription (Giacinti and Giordano, 2006; Voit et al., 1997), suggesting a possible role 
for RBBP1 in the regulation of RNAPI through pRB. NFYB, on the other hand, was 
another identified transcription factor among the screen hits; it functions in a trimeric 
complex that directly regulates c-Myc (Izumi et al., 2001). The myc-family of 
transcription factors are also reported regulators of ribosome biogenesis and thus NFYB 
may be a regulator of ribosome biogenesis through its interaction with myc (van Riggelen 
et al., 2010). Additionally, NFYB depletion has also been reported to inhibit cell cycle 
progression through G2/M phase and stabilize p53 independent of DNA damage (Benatti 
et al., 2008). These data suggest activation of the nucleolar stress response, which is 
concomitant with inhibition of RNAP1, and suggest another possible indirect mechanism 
 
207 
through which NFYB may regulate nucleolar function. Finally, ENY2 was also identified 
among the transcription factors and is a known RNAPII transcription co-activator 
through its association with the SAGA complex and others (García-Oliver et al., 2012; 
Kopytova et al., 2010; Vijayalingam et al., 2016). Interestingly, ENY2 was also a protein 
that I tested for a role in ribosome biogenesis and identified that depletion caused a 
significant decrease in not only RNAPI transcription but also protein synthesis. Taken 
together, these results suggest that although I tested only a subset of screen hits for roles 
in ribosome biogenesis, given the identification of several transcription factors and 
cofactors, it is possible there are several more novel regulators of RNAPI transcription 





Figure 5-1. Screen hit classification by protein class reveals several proteins involved in 
nucleic acid metabolism and transcriptional regulation.  
(A)  Bar graph of the PANTHER protein classifications for the screen hits. 40 hits were 
undefined in the PANTHER classification system. 
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(B)  Eleven hits (~10%) were classified as proteins associated with nucleic acid 
metabolism. PANTHER sub-classification revealed proteins associated with both DNA 
(PC00009) and RNA metabolism (PC00031).   
(C) Twelve hits (~11%) were classified as proteins associated with gene-specific 
transcriptional regulation. PANTHER sub-classification revealed both DNA-binding 
transcription factors (PC00218) and transcription cofactors (PC00217).   
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Table 5-1. Screen hits identified as nucleic acid metabolism proteins (PC00171) using 
the PANTHER classification system by protein class. Sub-classification [DNA 
metabolism (PC00009) or RNA metabolism (PC00031)] and protein descriptions are 
included. Descriptions are summarized from GeneCards (Stelzer et al., 2016), and the 
literature. 
Screen hit  
(HGNC) 





RFC1 Replication factor 
C subunit 1 
DNA 
metabolism 
Large subunit of the DNA 









complex subunit; complex is a key 
component of the pre-replication 
complex 
XRCC5 X-ray repair cross 
complementing 5  
DNA 
metabolism 
Ku protein (80 kDa) that binds DNA 
in non-homologous end joining 
DNA repair 
LIG3 DNA ligase 3 DNA 
metabolism 









Large subunit of an alternate DNA 




binding protein 1 
DNA 
metabolism 
Interacts with topoisomerase and 
supports DNA double strand break 
repair; aids in rescue of stalled 
replication forks 
GEN1 GEN1 Holliday 




Required for Holliday junction 
resolution in DNA repair by 
homologous recombination 





Required for nonsense-mediated 
mRNA decay; also necessary for 
telomerase reverse transcriptase 
activity 





May function as a positive 
transcriptional regulator with 
retinoblastoma protein; plays a role 
in craniofacial and cognitive 







factor containing the TATA-binding 




RNAPI subunit D 






Regulator of arginine 
methyltransferase, PRMT1, and 






Table 5-2. Screen hits identified as gene-specific transcription regulators (PC00264) 
using the PANTHER classification system by protein class. Sub-classification [DNA-
binding transcription factor (PC00218) or transcription co-factor (PC00217)] and protein 
descriptions are included. Two “Undefined” proteins that were not included in the 
PANTHER classification, but were included based on a manual review of the screen hits. 
Descriptions are summarized from GeneCards (Stelzer et al., 2016), and the literature. 
Screen hit  
(HGNC) 








Required for B-cell differentiation, 
bone development and 
neurogenesis, and may function as 
a tumor suppressor 
NFYB Nuclear 
transcription 
factor Y beta 
DNA-binding 
transcription factor 
Recognizes CCAAT motifs in a 
trimeric complex; complex 
regulates MYC and also interacts 
with p53 




Inhibits proliferation of 
hematopoietic progenitor cells 
through TGF-beta signaling; 
activated by BMP1 kinase 




Krüppel-like zinc finger protein; 
Repressor of HMGN1 expression 
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Data deficient; mainly localized to 
cytosol and mitochondria, but also 









May function in spermatogenesis; 
associated with measures of height  
(Carty et al., 2012) 






through association with the 








Transcriptional corepressor in a 
IRF-2 dependent manner; may 
also have E3 ligase activity 
GZF1 GDNF-
inducible zinc 
finger protein 1 
DNA-binding 
transcription factor 
Transcriptional repressor that 
binds the GZF1 responsive 
element; associated with joint 
laxity, short stature and myopia 










Orphan nuclear receptor; inhibits 






Leukemia and tumor suppressor 
that interacts with the 
retinoblastoma protein 




Binds LIM domain in LIM 
domain-containing transcription 
factors; acts with LMO2 in red 




Undefined Data deficient; Krüppel-associated 
box proteins are transcriptional 
repressors  





D (41 kDa) 
Undefined RNAPI transcription-associated 
factor containing the TATA-






An interaction network of the high confidence screen hits also revealed several 
intriguing proteins that were not selected as part of my functional analysis. An interaction 
network was generated in STRINGdb, using a medium confidence threshold and MCL 
clustering (inflation parameter=2; Figure 5-2). This analysis revealed 12 distinct clusters 
of proteins representing 44 of the 113 hits. As expected, the largest clusters were mitosis 
and DNA replication, recombination, and repair factors, as determined from my 
bioinformatic analysis in Chapter 2. However, in addition to these proteins, other small 
protein clusters stood out. MAN1A1 and PMM2 are interacting proteins associated with 
mannose metabolism and were also uncovered in screens identifying regulators of 
nucleolar size (Neumuller et al., 2013). PMM2/Sec53 was identified in S. cerevisiae and 
MAN1A1/alpha-Man-I was identified in D. melanogaster, together supporting a putative 
novel role for glycoprotein biosynthesis in the regulation of nucleolar form and function. 
Additionally, the interacting proteins SKP1 and CUL1 are also intriguing. These two 
proteins are both members of the Skp1-Cul1-Fbox protein (SCF) E3 ubiquitin ligase 
complex required for cell cycle progression from late G1 through anaphase (Nakayama 
and Nakayama, 2006). Although no SCF-associated Fbox proteins were identified among 
the screen hits, the association with progression through S and G2/M phase are consistent 
with the cell cycle defects observed when screen hits were depleted. Finally, a cluster of 
3 interacting proteins, SMG5, WRAP53, and ZNF219, is also interesting in that SMG5 
and WRAP53 are both associated with telomerase activity. In fact, WRAP53 is an 
essential component of the telomerase enzyme. Furthermore, depletion of WRAP53 led 
to a significant decrease in both RNAPI transcription and protein synthesis. A link 
between telomeres and the nucleolus is tantalizing given the relatively close physical 
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proximity between the telomeres and the rDNA arrays on the short arms of the 
acrocentric chromosomes. While ZNF219 has not been reported to be associated with 
telomerase function its interaction with this cluster of proteins suggests perhaps an 
associated role that links telomerase function to nucleolar function. In all, analyzing the 
screen hits as an interaction network highlights clusters of proteins that may otherwise 
have been overlooked and suggests intriguingly cellular functions that may integral to the 
regulation of ribosome biogenesis.   
In conclusion, several intriguing proteins were identified as important for the 
maintenance of typical nucleolar numbers. While the majority of these hits were not 
tested in the screen validation assay, of the 20 hits that were tested, 19 or 95% validated. 
That being said, prior to follow up on any of these hits, the appropriate validation should 
be performed to rule out potential off-target effects that can be common with siRNA-
mediated knockdown. Once validated, however, screen hits beyond the initial subset 
tested in Chapter 3 hold significant promise in revealing proteins and novel mechanisms 





Figure 5-2. Interaction network of high confidence screen hits that, when depleted, cause 
an increase in nucleolar number. Interaction network was generated in STRINGdb, using 
a medium confidence threshold and MCL clustering (inflation parameter=2) revealing 12 
clusters. Screen hits that did not interact with other screen hits are not shown. Mitosis 
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(red circle) and DNA replication, recombination, & repair (yellow circle) clusters are 




What mechanism underlies the increase in nucleolar number? 
Screening for increased nucleolar number has revealed several proteins required 
for cell cycle progression and RNAPI transcription, yet the mechanisms underlying the 
change in number remains unclear. I now know that several screen hits, but not all, are 
required for S and G2/M phase progression (Figure 5-3; Table 5-3). I also know that the 
increased number of nucleoli observed is largely driven by cells in G2/M phase of the 
cell cycle and cells with ≥5 nucleoli exhibit significantly larger nuclei. Furthermore, of a 
subset of hits tested, the majority regulate RNAPI transcription, and consequently global 
protein synthesis (Table 5-3). Yet, how failures in cell cycle progression and RNAPI 
transcription regulate nucleolar number remains unclear. Two leading models emerge 









Figure 5-3. Model illustrating our current understanding of increased nucleolar number 
based on discoveries reported in this thesis. Observed increases in nucleolar number are 
linked to RNAPI transcription and the cell cycle. Depletion of several proteins required 
for S and G2/M phase progression resulted in an increase in the percentage of nuclei with 
≥5 nucleoli (solid-line rectangle). The increase is largely driven by cells in G2/M phase 
of the cell cycle (dashed-line rectangle). Consistent with the latter, nuclear volume is 





Table 5-3. Expanded summary of discoveries on the subset of screen hits that cause an 
increase in nucleolar number. Depleted hits were tested for defects in RNAPI 
transcription, pre-rRNA processing, global protein synthesis, p53 stabilization, and cell 
cycle defects inferred by accumulation of nuclei in a particular phase. Inc=Increased; 




















siATAD5 Inc - Dec - - 
siCDCA8 - - Dec - >4N 
siENY2 Dec - Dec - S; >4N 
siFAM98A Dec - - - S 
siH1-10 Dec - Dec - - 
siINCENP Dec - Dec - G2/M; >4N 
siINKA1 - - Dec - >4N 
siKIF11 Dec - Dec - G2/M 
siMDN1 Dec Y Dec - - 
siRACGAP1 Dec - Dec Y >4N 
siRFC1 Inc - Dec Y S 
siSTK24 - - Dec - S 
siTPX2 Dec - Dec - G2/M; >4N 
siCCN4 Dec - Dec - - 






What mechanism underlies the increased nucleolar number observed when DNA 
replication, recombination, and repair factors are depleted?  
 Proteins required for DNA replication, recombination, and repair, were among 
some of the most common proteins identified in the screen for increased nucleolar 
number. Furthermore, depletion of a subset of hits resulted in failures in S phase 
progression (Chapter 2). The mechanism that underlies the connection between these 
processes and nucleolar number remain unknown; however, based on results obtained 
upon depletion of DNA replication and repair proteins in functional assays (Chapter 3), a 
possible model has emerged. Depletion of RFC1 and ATAD5 both resulted in a 
significant increase in RNAPI transcription; however, depletion of these proteins was 
also identified as causing a concomitant decrease in protein synthesis. This suggested the 
possible model that screen hits associated with DNA replication and repair are important 
for maintaining genome stability at the replication fork (Figure 5-4). DNA replication at 
highly transcribed loci can cause conflict and DNA double strand breaks. Thus, 
maintaining genome stability during DNA replication and repair is important because 
instability, particularly at the rDNA loci, has been associated with increased rates of 
recombination, rDNA copy loss, and cancer (Lindstrom et al., 2018; Stults et al., 2009; 
Xu et al., 2017a). Protective mechanisms, however, have evolved to deal with replication 
stress (Lindstrom et al., 2018). For instance, the RNAPI transcription termination factor 1 
(TTF-1) and a replisome component, TIMELESS (TIM), have been reported to regulate 
replication fork activity during DNA replication (Akamatsu and Kobayashi, 2015). Thus, 
I hypothesize that screen hits may encompass another protective mechanism to maintain 
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genome stability during DNA replication through dynamic regulation of RNAPI at the 
replication fork. 
 The proteins identified as screen hits have been localized to the replication fork 
and nascent chromatin. A recent proteomic analysis using 5-ethynyl-2′-deoxyuridine (5-
EdU) labeling and enrichment followed by quantitative mass spectrometry, identified 
proteins associated with nascent chromatin and the replication fork (Wessel et al., 2019). 
Comparing the proteins identified in this experiment to the screen hits revealed that 9 
screen hits are present at the replication fork (Table 5-4). These data would support a 
putative role for screen hits in the regulation of RNAPI during DNA replication. Among 
these hits were RFC1 and ATAD5, further supporting the hypothesis that these proteins 
may be important for the repression of RNAPI transcription during DNA replication to 
limit conflict. Furthermore, of the proteins enriched at the replication fork, 148 localize to 
the nucleolus based on identification in at least one of the three datasets used in Chapter 2 
[Appendix IX; (Ahmad et al., 2009; Jarboui et al., 2011; Leung et al., 2006; Thul et al., 
2017)]. Interestingly, of these hits, several have previously been reported to regulate 
RNAPI transcription, including BLM, FANCI, ATM and ATR. ATM and ATR are 
kinases that regulate the DNA damage response, which includes the transient inhibition 
of RNAPI during DNA repair (Kruhlak et al., 2007). BLM and FANCI, on the other 
hand, are reported to decrease RNAPI transcription when depleted. Together, these data 
suggest not only the localization of screen hits at the replication fork, but also proteins 
required for the regulation of RNAPI.   
 DNA repair is important for maintaining genome stability during DNA 
replication, especially at highly transcribed loci like the rDNA. The existence of a 
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mechanism to transiently silence RNAPI transcription in response to DNA damage 
validates this importance. An ATM- and ATR- mediated mechanism has been described 
that results in the activation and recruitment of proteins required not only to silence 
RNAPI, but to repair the DNA damage (Ciccia et al., 2014; Korsholm et al., 2019; 
Kruhlak et al., 2007; Larsen and Stucki, 2016; Mooser et al., 2020). As such, several 
substrates of ATM and ATR have been defined, and several others have been predicted. 
In one study aimed at defining all the substrates of ATM and ATR in response to DNA 
damage identified ~700 putative proteins (Matsuoka et al., 2007). I therefore asked 
whether any of the screen hits were also identified among the putative ATM and ATR 
substrates in response to DNA damage. Interestingly, 10 screen hits were identified and 
included among these were RFC1 and ATAD5 (Table 5-4). TOPBP1 was also identified 
and has already been reported as important for mediating the transcriptional silencing of 
RNAPI upon DNA damage (Mooser et al., 2020). Finally, KIF11 was another hit 
identified as a putative ATM or ATR substrate. KIF11 is primarily known for its role in 
spindle assembly during mitosis (Blangy et al., 1995); however, I have also discovered 
that depletion of KIF11 leads to a decrease in RNAPI transcription, which begs the 
question, is KIF11 required for the regulation of RNAPI in response to DNA damage 
rather than in a mitosis-specific role? These data thus suggest that a subset of screen hits 
may regulate RNAPI transcription during DNA replication through the ATM- and ATR- 
mediated response to DNA damage.   
Moving forward, it will be important to establish whether DNA damage and 
replication stress at the rDNA loci might be the cause for the increased numbers of 
nucleoli that we observe. Furthermore, it will be interesting to ascertain whether other 
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screen hits also regulate RNAPI transcription and if it is in response to DNA damage 
during replication. Finally, to link the defects in RNAPI transcription to increased 
nucleolar numbers, it will be critical to further define nucleoli from these cells. 
Outstanding questions pertaining to this objective include: (1) Are these nucleoli 
functional nucleoli with a defined tripartite substructure? And (2), are these nucleoli 
mature nucleoli that contain multiple NORs or is there just a single NOR per nucleolus? 
The latter might suggest the disassembly of nucleoli in response to a particular stressor, 
like DNA damage, or a defect in S phase that manifests in mitosis as a failure in 
reassembly and discussed in more detail in the next section. Taken together, the increased 
number of nucleoli that we observe upon depletion of screen hits remains incomplete, but 
several lines of evidence suggest the phenotype reflects changes in RNAPI transcription 
and perhaps proteins required for maintaining genome stability at the rDNA loci during 





Figure 5-4. Screen hits may be required for maintaining genome stability at the 
replication fork. Due to the high rate of transcription among the rDNA genes, 
transcription by RNAPI presents a potential conflict. One hypothesis for the increase in 
nucleolar number observed upon depletion of screen hits is that the screen hits are 
required for dynamic regulation of RNAPI during replication to prevent conflict. In the 
absence of this regulation, the rDNA loci would exhibit genome instability and nucleoli 




Table 5-4. Screen hits identified at the replication fork and as substrates of ATM and 
ATR kinases.   
Screen hits at replication 
fork and nascent chromatin 
(Wessel et al., 2019) 
Screen hits phosphorylated 
by ATM/ATR in response 
to DNA damage (Matsuoka 















What mechanism underlies the increased nucleolar number observed when mitosis 
factors are depleted? 
Proteins required for mitosis were also among the most common proteins 
identified in the screen for increased nucleolar number. Furthermore, depletion of a 
subset of hits resulted in failures in G2/M phase progression (Chapter 2). The 
mechanism, however, that underlies the connection between mitosis and increased 
nucleolar number remains unknown. Yet, based on results obtained from depletion of 
mitosis proteins in functional assays (Chapter 3), a possible model has emerged. 
Depletion of KIF11, RACGAP1, TPX2, and INCENP all resulted in a significant 
decrease in RNAPI transcription and concomitant decrease in protein synthesis. This 
suggested the possible model that screen hits associated with mitosis are important for the 
re-initiation of RNAPI transcription following metaphase (Figure 5-5). Nucleoli are 
highly dynamic organelles during mitosis that not only require the coordinated 
disassembly and relocalization of pre-rRNA and ribosome biogenesis factors, but also 
require reassembly upon mitotic exit (Gautier et al., 1992; Hernandez-Verdun, 2011; 
Savino et al., 2001). Furthermore, in early G1, nascent nucleoli fuse to form mature 
nucleoli (Hernandez-Verdun, 2011), which might be a consequence of LLPS (Lafontaine 
et al., 2020), although convincing evidence is still lacking. Failure of nucleoli to fuse 
upon mitotic exit due to defects during mitosis could lead to the increased nucleolar 
number observed.  
Beyond the functional assays reported in this thesis, currently there is little 
additional evidence to support a hypothesis for lack of nucleolar fusion upon mitotic exit. 
Not only are the screen hits not enriched for proteins associated with LLPS, but screen 
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hits are also not associated with proteins identified as localizing to the chromosomes 
during mitosis. Proteins with intrinsically disordered regions (IDRs) are thought to be key 
drivers of LLPS (Lafontaine et al., 2020); yet, in an analysis of proteins in the DisProt 
database of proteins with IDRs (Hatos et al., 2020) only 4 hits were identified (HYPK, 
MICA, SMG5, and XRCC5). Additionally, in the recent survey identifying nucleolar 
proteins associated with the mitotic perichromosomal compartment, 65 proteins were 
identified and 36 were not previously known to localize to chromosomes (Stenström et 
al., 2020). A comparison of the screen hits with proteins that localize to mitotic 
chromosomes reveal 0 overlapping proteins. Interestingly, this study also found that 
proteins that localize to the perichromosomal compartment are enriched in proteins with 
intrinsically disordered domains (IDRs). These data are consistent with the fact that few 
proteins with IDRs were identified among the screen hits. Thus, the proteins identified in 
this screen may represent a unique subset of proteins that are required for nucleolar form 
and function.  
Moving forward, it will be important to understand whether failure in the re-
initiation of transcription during mitosis leads the increased numbers of nucleoli that we 
observe. The identification of several mitosis-associated hits that when depleted lead to 
decreased RNAPI transcription supports this putative link. Furthermore, it will be 
important to ascertain whether the increased nucleolar numbers in fact represent nascent 
nucleoli or mature nucleoli. A similar set of experiments as proposed in the prior section 
can answer this question and include determining whether the nucleoli observed contain 
the tripartite substructure consistent with mature functional nucleoli, and whether a single 
or multiple NORs are present. Again, if the nucleoli contain only a single NOR, then 
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these data would support failure in nascent nucleolar fusion. Taken together, the 
mechanism underlying the increased nucleolar numbers that we observe in cells depleted 
of screen hits remains incomplete; however, discoveries described herein suggest that the 










Figure 5-5. Screen hits may be required for the re-initiation of RNAPI transcription 
during mitosis. In every mitosis, the nucleolus disassembles in late prophase and 
reassembles in telophase. In prophase, pre-rRNA and processing factors relocate to the 
chromosomal periphery, also called the perichromosomal compartment. Activation of 
CDK1-cyclin B inhibits RNAPI transcription by metaphase (red). Inhibition of CDK1-
cyclin B by PP1 phosphatases re-initiates RNAPI transcription by telophase (green). In 
telophase, nucleolar proteins in the perichromosomal compartment condense into 
prenucleolar bodies (PNB) from which ribosome biogenesis factors are recruited to the 
competent nucleolar organizer regions (NORs) and, with early processing factors and 
pre-rRNA, promote nascent nucleolar formation. In early G1, nascent nucleoli fuse to 
from mature nucleoli. One hypothesis for the increase in nucleolar number observed upon 
depletion of screen hits is that screen hits are required for re-initiation of transcription 
during mitosis and when disrupted, results in the failure of nascent nucleoli to mature and 
fuse. Failure to fuse upon mitotic exit could appear as an increase in nucleolar number. 
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FC=fibrillar center (green); DFC=dense fibrillar component; GC=granular component. 





Targeting the nucleolus for cancer therapy 
The nucleolus holds promise as a target for the development of novel cancer 
therapeutics. Not only has the nucleolus been associated with cancer for over two 
hundred years, but an analysis of common cancer therapies has revealed that many 
impact nucleolar form and function. The screen I performed of FDA-approved drugs for 
regulators of nucleolar number revealed several drugs used in the treatment of cancer. 
These results suggest that screening for changes in nucleolar number is an effective 
strategy for identifying novel cancer therapies. As a result, I expanded the screen to test 
~25,000 novel, synthetic compounds which uncovered an additional 234 compounds that 
regulate nucleolar number. While we know that changes in nucleolar number reflect 
changes in nucleolar function, this needs to be tested in order to identify a subset of lead 
compounds with antineoplastic potential. 
 RNAPI is a promising target for the development of novel cancer therapeutics. 
Several FDA-approved drugs target RNAPI through non-specific mechanisms, which 
include drugs like AMD, oxaliplatin, doxorubicin and camptothecin (Ferreira et al., 
2020). Furthermore, in the past decade, specific RNAPI inhibitors have been developed 
that not only show promising preclinical efficacy but have also had positive results in 
Phase I trials for breast cancer and hematological malignancies. Indeed, the large subunit 
of RNAPI, RPA194/POLR1A, is highly expressed among a range of cancers and is a 
prognostic marker specifically in liver, ovarian, and thyroid cancer (Uhlen et al., 2017). 
Survival analysis based on expression of RPA194/PORL1A, has revealed that patients 
with tumors that exhibit high RPA194/POLR1A expression had a lower survival 
 
235 
probability (Uhlen et al., 2017). Thus, identifying novel compounds that effectively target 
RNAPI would be a good strategy for the treatment of cancer. Given that changes in 
nucleolar number have been successful in identifying novel regulators of RNAPI, moving 
forward, a secondary screen testing specifically for regulators of RNAPI transcription 
from among the 185 high confidence compounds would be a good strategy moving 
forward.  
 Pre-rRNA processing may also be a promising target for the development of 
novel cancer therapeutics. While fewer FDA-approved drugs have been demonstrated to 
regulate pre-rRNA processing, there are still several that have been used in the treatment 
of cancer, including 5-fluorouracil, flavopiridol, roscovitine, and bortezomib (Burger et 
al., 2010). These data suggest, that while drugs targeting pre-rRNA processing are not as 
common, they still may be viable in the development of a novel cancer therapeutic. We 
know from prior studies that regulators of nucleolar number can also reflect changes in 
pre-rRNA processing; however, this observation was restricted primarily to proteins that 
when depleted cause a decrease in nucleolar number. Furthermore, northern blots are the 
best way to determine impact on pre-rRNA processing and therefore it would be difficult 
to perform a high-throughput secondary assay to determine whether the screen hits are 
regulators of pre-rRNA processing. Thus, a more low-throughput survey of a subset of 
the novel synthetic compounds that cause a decrease in nucleolar number might be the 
best approach to identify regulators of pre-rRNA processing. Cluster analysis was 
performed to identify compounds with structural similarities, and based on a threshold of 
50% similarity, 11 clusters were revealed among the novel synthetic compounds (Chapter 
4). Thus, testing a single compound from each cluster for pre-rRNA processing defects 
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might be the best approach. Taken together, while identifying regulators of RNAPI 
transcription may be a highly effective strategy, targeting pre-rRNA may also hold 
promise for the discovery of novel and effective cancer therapies. 
 
 In conclusion, the nucleolus is a fascinating nuclear domain that is integral to a 
multitude of cellular functions. Screening for changes in nucleolar number has only 
further highlighted the centrality of the nucleolus by uncovering several novel proteins 
and small molecules that are associated with a wide range of cellular processes. 
Furthermore, probing changes in nucleolar number has uncovered novel regulators of 
nucleolar function, and has led to intriguing hypotheses for the role of these diverse 
proteins in maintaining typical nucleolar form. Moving forward, however, it will be 
critical to further validate screen hits through rescue experiments due the off-target 
effects common among siRNA depletion methods like the siGENOME pools used here. 
Furthermore, it will be important to develop the model used to study changes in nucleolar 
number, perhaps through live cell imaging to observe changes in nucleolar number in real 
time. Overall, the discoveries described herein broaden our understanding of nucleolar 
biology in higher eukaryotes and provide a foundation for the development of novel and 
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166 DNA repair proteins localize to the nucleolus. Three nucleolar proteomes were 
analyzed for the presence of DNA repair proteins based on Gene Ontology (GO) 
Consortium categorization (GO: 0006281). The “Combined” column is the 166 total 
unique DNA repair proteins identified. HGNC symbols are shown. Proteins in bold were 
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ACTL6A APEX1 APEX2 ACTL6A 
APEX1 AQR APTX APEX1 
APTX BAZ1B CDC5L APEX2 
AQR BRCA2 CHAF1A APTX 
ASF1A CDC5L CSNK1D AQR 
ATM CHD1L DCLRE1A ASF1A 
ATR DDB1 DTL ATM 
ATRIP DDX1 FANCD2 ATR 
ATRX DEK FANCG ATRIP 
BAZ1B EXO1 FEN1 ATRX 
BCCIP FANCI HMGA1 BAZ1B 
BLM FEN1 HMGA2 BCCIP 
CDK1 HMGA1 HMGB2 BLM 
CDK2 HMGB1 INO80C BRCA2 
CDK7 HMGB2 INO80E CDC5L 
CDK9 HUWE1 KDM2A CDK1 
CHAF1A KDM2A KDM4A CDK2 
COPS2 NONO MAD2L2 CDK7 
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COPS3 PARP1 MEIOB CDK9 
COPS7B PCNA MUS81 CHAF1A 
COPS8 PRKDC NPM1 CHD1L 
CSNK1D RAD21 NUDT16 COPS2 
CSNK1E RAD50 PARP2 COPS3 
CUL4A RBM14 PNKP COPS7B 
CUL4B RFC1 POLR2F COPS8 
DDB1 RFC2 POLR2K CSNK1D 
DDX1 RFC4 PRMT6 CSNK1E 
DEK RFC5 RAD51 CUL4A 
ERCC2 RPA1 RNF111 CUL4B 
ERCC3 SETX RPAIN DCLRE1A 
FANCD2 SFPQ SETMAR DDB1 
FANCI SMC1A SFR1 DDX1 
FEN1 SMC3 SMARCA5 DEK 
GTF2H1 SSRP1 SUMO1 DTL 
GTF2H2 SUMO3 SUPT16H ERCC2 
GTF2H2C TERF2 UBE2N ERCC3 
GTF2H4 TRRAP UBE2T EXO1 
H2AFX UHRF1 USP28 FANCD2 
HIST1H4A  WDR33 FANCG 
HIST3H2A  YY1 FANCI 
HIST3H3   FEN1 
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HLTF   GTF2H1 
HMGA1   GTF2H2 
HMGA2   GTF2H2C 
HMGB1   GTF2H4 
HMGB2   H2AFX 
HSPA1A   HIST1H4A 
HUS1B   HIST3H2A 
HUWE1   HIST3H3 
INTS3   HLTF 
ISG15   HMGA1 
KDM1A   HMGA2 
KDM2A   HMGB1 
KIN   HMGB2 
KPNA2   HSPA1A 
LIG1   HUS1B 
LIG3   HUWE1 
MC1R   INO80C 
MDC1   INO80E 
MLH1   INTS3 
MMS19   ISG15 
MNAT1   KDM1A 
MORF4L1   KDM2A 
MRE11A   KDM4A 
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MSH2   KIN 
MSH6   KPNA2 
MUTYH   LIG1 
NONO   LIG3 
NPM1   MAD2L2 
NSMCE1   MC1R 
NSMCE4A   MDC1 
OTUB1   MEIOB 
PARG   MLH1 
PARP1   MMS19 
PCNA   MNAT1 
PNKP   MORF4L1 
POLR2E   MRE11A 
POLR2H   MSH2 
POLR2K   MSH6 
POLR2L   MUS81 
PPIE   MUTYH 
PPP4C   NONO 
PRKDC   NPM1 
PRPF19   NSMCE1 
PSMD14   NSMCE4A 
PSME4   NUDT16 
RAD21   OTUB1 
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RAD50   PARG 
RAD51AP1   PARP1 
RBM14   PARP2 
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RECQL   PNKP 
RFC1   POLR2E 
RFC2   POLR2F 
RFC3   POLR2H 
RFC4   POLR2K 
RFC5   POLR2L 
RIF1   PPIE 
RPA3   PPP4C 
RPS27A   PRKDC 
RPS27L   PRMT6 
RPS3   PRPF19 
RUVBL1   PSMD14 
RUVBL2   PSME4 
SFPQ   RAD21 
SMARCA5   RAD50 
SMC1A   RAD51 
SMC3   RAD51AP1 
SMC5   RBM14 
SMC6   RBX1 
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SSRP1   RECQL 
SUMO1   RFC1 
SUMO2   RFC2 
SUMO3   RFC3 
SUPT16H   RFC4 
TCEA1   RFC5 
TOPBP1   RIF1 
TRIM28   RNF111 
TRIP12   RPA1 
TRRAP   RPA3 
UBA52   RPAIN 
UBB   RPS27A 
UBC   RPS27L 
UBE2D3   RPS3 
UBE2I   RUVBL1 
UBE2N   RUVBL2 
UBE2V2   SETMAR 
UBR5   SETX 
USP28   SFPQ 
USP7   SFR1 
VCP   SMARCA5 
WHSC1   SMC1A 
WRN   SMC3 
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XRCC1   SMC5 
XRCC5   SMC6 
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The 113 high confidence screen hits that, when depleted, caused an increase in the 
percentage of nuclei with ≥5 nucleoli. Yeast ortholog, ≥5 nucleoli per nucleus 
normalized percent effect (NPE), percent viability, and nucleolar localization are 












KIF11 Cin8/Kip1 68.75 19.00 N 
CDCA8 Nbl1 66.59 12.91 Y 
ASIC1  65.17 5.21 N 
CMPK2 Cdc8 64.91 17.38 N 
WBP11  64.64 12.61 Y 
KRT222  61.43 30.53 N 
MICA  60.63 28.23 N 
ATAD5 Elg1 59.75 27.67 N 
RAP2C  57.83 38.96 N 
SKP1 Skp1 57.64 13.00 Y 
TPX2  53.84 5.99 Y 
CIAO2B  47.53 26.97 N 
PRRT2  47.35 21.61 N 
RFFL 
 
 47.17 8.70 N 
C11orf63  47.03 11.05 N 
ZER1  46.73 43.72 N 
MAN1A1 Mnl2 46.40 35.63 N 
MFSD4  46.29 15.22 N 
INCENP Sli15 45.64 18.92 Y 
SHC3  45.32 21.55 N 
ENY2 Sus1 41.93 6.02 N 
CUL1 Cdc53 41.61 36.50 Y 
SHROOM2  40.79 16.04 N 
CTF1  40.36 8.66 N 
MDN1 Rea1 39.82 29.07 Y 
ZDHHC17 Akr1/2 39.45 53.42 N 
CDCA5  39.33 9.55 N 
CASP8AP2  39.14 13.82 Y 
HYPK  38.87 15.80 N 
INKA1  38.64 14.41 N 
NAT2  38.52 27.49 N 
IRF2BP1  37.62 38.21 N 
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PMM2 Sec53 37.35 23.22 N 
GLYATL2  36.68 28.51 N 
TTC22  36.12 21.61 N 
XRCC5 Yku80 35.61 42.14 Y 
CYP4V2  35.61 58.17 N 
RRM1 Rnr1/3 35.33 9.46 N 
FAM221A  34.73 49.23 N 
ECHDC2  34.49 22.43 N 
RBBP8  33.82 21.42 N 
CCDC81  33.78 22.74 N 
KRBA1  32.89 29.14 N 
PRUNE  32.76 19.24 N 
SCRN3  32.28 63.05 N 
AGR2  31.52 25.80 N 
SMG5 Ebs1/Est1 31.03 27.66 N 
LAPTM5  30.61 32.18 N 
DBNDD1  30.51 10.27 N 
RFC1  30.18 46.61 Y 
IFT88  30.16 57.16 N 
C9orf142  29.86 29.73 N 
SGOL1  29.67 16.63 N 
EBF3  29.63 36.33 N 
MCM6 Mcm6 29.60 54.59 Y 
OSBP2 Hes1/Kes1 29.58 14.65 N 
PRAM1  29.56 14.07 N 
GCNT2  29.56 34.99 N 
ZNF219  29.31 45.34 N 
LDB1  29.25 50.16 N 
FAM58A  29.22 22.15 N 
LIG3  29.07 40.91 Y 
SNX21  29.02 25.45 N 
GLTP  28.95 20.74 N 
GZF1  28.93 47.20 Y 
MAP4K5  28.92 27.53 N 
SLC26A7  28.77 61.21 N 
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TARS2 Mst1 28.66 36.20 N 
ABCE1 Rli1 28.57 25.65 Y 
LCORL 
TYMP 
 28.28 21.07 N 
TYMP  28.06 72.51 N 
MRPL52  27.86 36.04 N 
RIMS3 Tcb3 27.82 10.82 Y 
WBSCR27  27.79 33.22 N 
H1-10 Hho1 27.78 31.61 Y 
ZNF678  27.75 19.58 Y 
RACGAP1 Bem2/Rga1/2/Rgd1 27.62 15.60 N 
STK24 Kic1/Pbs2 27.53 13.92 Y 
SLC2A12 Stl1 27.49 71.34 N 
NGRN Rrg9 27.47 25.68 N 
LUC7L Luc7 27.15 25.86 N 
YIPF7 Yip1 27.11 5.29 N 
WRAP53 Swt21 27.10 9.48 N 
DYNC1H1 Dyn1 26.87 19.67 Y 
GEN1  26.82 51.87 N 
NR0B2  26.79 37.50 N 
ANKEF1  26.73 22.43 Y 
KTN1  26.70 14.57 N 
FGD4 Cdc24/Rom1/2 26.65 28.85 N 
MIA  26.64 39.43 N 
CCN4  26.52 46.48 N 
GOLGA8EP  26.48 20.11 N 
TOPBP1 Dpb11 26.37 10.58 Y 
SMAP2 Glo3/Gts1 26.24 33.90 N 
OXNAD1 Aim33/Pga3 26.16 60.29 N 
HSD11B2  26.09 21.32 N 
MARCH9 Ssm4 26.06 68.46 N 
TM2D1  26.04 19.78 N 
PCOLCE2  26.02 19.56 N 
CAMK2N1  25.99 26.33 N 
RAPH1  25.95 6.16 N 
MPV17L2 Mpv17 25.65 13.92 N 
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FAM98A  25.60 10.13 N 
SUV39H1  25.56 32.30 N 
TAF1D  25.54 27.66 Y 
NFYB Hap3 25.50 41.60 N 
MASTL Pkh3/Rim15 25.41 32.46 N 
GTF2IRD1  25.38 24.82 N 
SCN2B  25.29 15.56 N 
MLL3  25.28 73.70 N 
DDAH1  25.27 55.36 Y 
NLRC5 Gip3/Her1 25.12 46.44 N 











Cell cycle analysis of screen hits selected for validation by oligonucleotide 
deconvolution. Each siRNA in the pool of 4 was tested independently (n=3). Controls, 
siRISC-free and the siKIF11 pool, were also assayed (n=48). The column with the 
number (No.) of cells is the total sum of nuclei analyzed in all replicates and is number of 
cells used to generate the cumulative histograms in Figure 2-5.  Significance is listed in 
parentheses below the mean ± SD and was determined by unpaired t-tests relative to 
siRISC-free and a False Discovery Rate approach using the two-stage step-up method of 
Benjamini, Krieger and Yekutieli (n=3 or 48; q<0.01=*; q<0.001=**; q<0.0001=***; 
ns=not significant). A column that includes the ≥5 nucleoli per nucleus normalized 































siRISC-free 498,155 48.3 ± 2.0 10.2 ± 1.1 20.3 ± 0.8 2.7 ± 0.5 0 
siKIF11 (pool) 93,027 12.2 ± 1.2 
(q<0.0001
) 
7.5 ± 0.8 
(q<0.0001
) 
60.6 ± 1.7 
(q<0.0001
) 




siKIF11 -05 3426 16.5 ± 1.9 
(q<0.0001
)  
9.1 ± 1.2 
(ns) 
56.1 ± 2.5 
(q<0.0001
) 




siKIF11 -06 6816 15.8 ± 1.0 
(q<0.0001
) 
8.7 ± 0.3 
(q<0.01) 
56.7 ± 0.8 
(q<0.0001
) 




siKIF11 -07 2154 23.8 ± 4.5 
(q<0.0001
) 
10.8 ± 2.1 
(ns) 
42.1 ± 1.6 
(q<0.0001
) 






siKIF11 -08 2721 20.6 ± 2.3 
(q<0.0001
) 
10.5 ± 1.0 
(ns) 
50.7 ± 3.5 
(q<0.0001
) 




siABCE1 -01 12653 30.6 ± 0.7 
(q<0.0001
) 
20.0 ± 0.3 
(q<0.0001
) 
33.6 ± 1.0 
(q<0.0001
) 




siABCE1 -02 22023 42.7 ± 1.0 
(q<0.0001
) 
15.4 ± 0.7 
(q<0.0001
) 
25.9 ± 0.6 
(q<0.0001
) 




siABCE1 -04 19958 49.9 ± 1.5 
(ns) 
23.3 ± 0.4 
(q<0.0001
) 
15.9 ± 0.9 
(q<0.0001
) 
1.8 ± 0.2 
(q<0.01) 
26.31 
siABCE1 -17 21264 50.2 ± 2.9 
(ns) 
12.9 ± 0.8 
(q<0.0001
) 
21.7 ± 1.6 
(q<0.001) 
1.9 ± 0.2 
(q<0.01) 
9.86 








24.1 ± 1.6 
(q<0.0001
) 





siATAD5 -02 17992 49.9 ± 3.5 
(ns) 
19.4 ± 2.0 
(q<0.0001
) 
22.3 ± 1.2 
(q<0.0001
) 
1.5 ± 0.4 
(q<0.001) 
16.49 
siATAD5 -03 21010 45.1 ± 1.9 
(q<0.01) 
17.2 ± 0.9 
(q<0.0001
) 
25.7 ± 1.1 
(q<0.0001
) 
2.7 ± 0.2 
(ns) 
25.01 
siATAD5 -04 14337 37.0 ± 5.6 
(q<0.0001
) 
19.8 ± 3.9 
(q<0.0001
) 
27.8 ± 2.2 
(q<0.0001
) 




siCCN4 -01 24641 45.9 ± 0.9 
(q<0.01) 
20.3 ± 1.8 
(q<0.0001
) 
15.4 ± 0.4 
(q<0.0001
) 
2.6 ± 0.2 
(ns) 
17.85 
siCCN4 -02 4868 40.6 ± 4.3 
(q<0.0001
) 
14.6 ± 2.0 
(q<0.0001
) 
30.8 ± 3.3 
(q<0.0001
) 
2.5 ± 0.6 
(ns) 
18.51 
siCCN4 -03 7630 44.5 ± 1.7 
(q<0.01) 
13.7 ± 1.0 
(q<0.0001
) 
27.8 ± 0.3 
(q<0.0001
) 
2.0 ± 0.4 
(ns) 
23.89 










siCDCA8 -01 6261 10.6 ± 0.4 
(q<0.0001
) 
7.9 ± 0.8 
(q<0.001) 
26.6 ± 0.6 
(q<0.0001
) 




siCDCA8 -02 5595 10.4 ± 0.7 
(q<0.0001
) 
8.7 ± 0.3 
(ns) 
23.8 ± 1.1 
(q<0.0001
) 




siCDCA8 -03 5073 30.5 ± 1.0 
(q<0.0001
) 
14.6 ± 0.9 
(q<0.0001
) 
27.0 ± 0.8 
(q<0.0001
) 




siCDCA8 -04 8186 23.7 ± 0.4 
(q<0.0001
) 
12.0 ± 0.8 
(q<0.01) 
28.7 ± 0.5 
(q<0.0001
) 




siCIAO2B -01 16932 42.3 ± 2.1 
(q<0.0001
) 
32.0 ± 4.2 
(q<0.0001
) 
16.3 ± 0.8 
(q<0.0001
) 
1.7 ± 0.0 
(q<0.001) 
24.41 











siCIAO2B -04 19264 41.6 ± 1.5 
(q<0.0001
) 
24.0 ± 1.8 
(q<0.0001
) 
21.9 ± 0.8 
(q<0.001) 




siCIAO2B -18 14660 41.3 ± 3.7 
(q<0.0001
) 
37.7 ± 3.5 
(q<0.0001
) 
10.1 ± 0.3 
(q<0.0001
) 






15255 32.0 ± 0.3 
(q<0.0001
) 
25.3 ± 0.9 
(q<0.0001
) 
33.1 ± 1.0 
(q<0.0001
) 





16855 33.3 ± 0.2 
(q<0.0001
) 
21.1 ± 0.8 
(q<0.0001
) 
26.3 ± 0.2 
(q<0.0001
) 






10371 23.0 ± 0.7 
(q<0.0001
) 
22.4 ± 1.1 
(q<0.0001
) 
39.2 ± 0.1 
(q<0.0001
) 

















siENY2 -01 18169 39.6 ± 0.7 
(q<0.0001
) 
25.0 ± 0.8 
(q<0.0001
) 
19.3 ± 0.3 
(q<0.01) 




siENY2 -02 10196 43.1 ± 1.4 
(q<0.0001
) 
15.5 ± 0.7 
(q<0.0001
) 
26.4 ± 1.3 
(q<0.0001
) 




siENY2 -03 21547 35.8 ± 0.5 
(q<0.0001
) 
24.5 ± 0.9 
(q<0.0001
) 
21.2 ± 0.9 
(ns) 




siENY2 -04 14896 43.8 ± 1.6 
(q<0.0001
) 
28.6 ± 0.9 
(q<0.0001
) 
16.5 ± 0.4 
(q<0.0001
) 
2.1 ± 0.5 
(ns) 
16.54 
siFAM98A -01 7481 38.5 ± 1.5 
(q<0.0001
) 
24.4 ± 1.0 
(q<0.0001
) 
23.8 ± 0.5 
(q<0.0001
) 
3.1 ± 0.4 
(ns) 
23.43 











siFAM98A -03 31999 47.9 ± 0.8 
(ns) 
11.2 ± 0.6 
(ns) 
20.0 ± 0.4 
(ns) 




siFAM98A -04 12092 33.1 ± 3.6 
(q<0.0001
) 
35.2 ± 3.1 
(q<0.0001
) 
18.8 ± 0.7 
(q<0.001) 




siH1-10 -01 19495 40.2 ± 7.0 
(q<0.0001
) 
17.5 ± 5.7 
(q<0.0001
) 
27.4 ± 1.0 
(q<0.0001
) 




siH1-10 -02 3095 26.7 ± 1.4 
(q<0.0001
) 
10.9 ± 1.3 
(ns) 
37.6 ± 4.7 
(q<0.0001
) 




siH1-10 -03 20063 54.2 ± 0.6 
(q<0.0001
) 
10.3 ± 1.4 
(ns) 
19.8 ± 0.7 
(ns) 
2.1 ± 0.2 
(ns) 
16.89 











siINCENP -01 5191 14.1 ± 0.5 
(q<0.0001
) 
9.3 ± 1.0 
(ns) 
29.6 ± 0.7 
(q<0.0001
) 




siINCENP -02 6073 13.1 ± 1.2 
(q<0.0001
) 
7.9 ± 0.3 
(q<0.001) 
43.1 ± 2.0 
(q<0.0001
) 




siINCENP -03 5151 14.6 ± 1.9 
(q<0.0001
) 
9.5 ± 0.3 
(ns) 
42.4 ± 2.7 
(q<0.0001
) 




siINCENP -04 7989 19.9 ± 0.6 
(q<0.0001
) 
9.1 ± 0.3 
(ns) 
38.4 ± 0.4 
(q<0.0001
) 




siINKA1 -01 8245 24.3 ± 0.6 
(q<0.0001
) 
13.0 ± 1.4 
(q<0.0001
) 
50.4 ± 0.5 
(q<0.0001
) 















siINKA1 -03 20994 56.5 ± 1.3 
(q<0.0001
) 
21.2 ± 1.2 
(q<0.0001
) 
14.5 ± 0.1 
(q<0.0001
) 




siINKA1 -04 7543 30.0 ± 3.2 
(q<0.0001
) 
16.8 ± 2.7 
(q<0.0001
) 
38.3 ± 1.2 
(q<0.0001
) 




siKTN1 -17 15844 43.6 ± 1.3 
(q<0.0001
) 
26.6 ± 1.7 
(q<0.0001
) 
16.9 ± 0.8 
(q<0.0001
) 
3.5 ± 0.4 
(q<0.01) 
41.87 
siKTN1 -18 2762 22.7 ± 2.1 
(q<0.0001
) 
10.0 ± 0.7 
(ns) 
47.8 ± 1.8 
(q<0.0001
) 




siKTN1 -19 29473 55.4 ± 2.1 
(q<0.0001
) 
10.9 ± 0.7 
(ns) 
19.2 ± 0.9 
(ns) 
2.7 ± 0.3 
(ns) 
4.61 
siKTN1 -20 22507 46.0 ± 0.4 
(ns) 









siLUC7L -01 1855 30.5 ± 2.8 
(q<0.0001
) 
11.6 ± 1.4 
(q<0.01) 
34.1 ± 3.0 
(q<0.0001
) 




siLUC7L -02 9450 39.6 ± 2.7 
(q<0.0001
) 
30.3 ± 3.8 
(q<0.0001
) 
15.7 ± 0.2 
(q<0.0001
) 
2.4 ± 0.6 
(ns) 
6.67 
siLUC7L -03 24023 51.5 ± 0.7 
(q<0.01) 
25.4 ± 1.1 
(q<0.0001
) 
14.2 ± 0.6 
(q<0.0001
) 
1.6 ± 0.2 
(q<0.001) 
7.84 
siLUC7L -04 15445 38.4 ± 1.5 
(q<0.0001
) 
28.5 ± 2.5 
(q<0.0001
) 
21.1 ± 0.7 
(q<0.01) 
2.2 ± 0.0 
(ns) 
22.01 
siMDN1 -03 22383 61.8 ± 4.5 
(q<0.0001
) 
17.6 ± 4.3 
(ns) 
11.6 ± 0.5 
(q<0.0001
) 
1.5 ± 0.2 
(q<0.001) 
16.23 
siMDN1 -17 10682 64.0 ± 0.2 10.7 ± 0.9 
(ns) 









siMDN1 -18 18302 52.2 ± 0.9 
(q<0.001) 
24.3 ± 3.0 
(q<0.0001
) 
14.6 ± 0.6 
(q<0.0001
) 
1.4 ± 0.2 
(q<0.001) 
8.92 
siMDN1 -19 16924 51.6 ± 1.8 
(q<0.01) 
15.7 ± 1.3 
(q<0.0001
) 
18.9 ± 1.2 
(q<0.001) 





10345 28.6 ± 1.8 
(q<0.0001
) 
19.5 ± 1.6 
(q<0.0001
) 
31.1 ± 0.8 
(q<0.0001
) 






14099 33.4 ± 1.3 
(q<0.0001
) 
15.0 ± 0.3 
(q<0.0001
) 
27.8 ± 0.6 
(q<0.0001
) 






9246 20.7 ± 2.0 
(q<0.0001
) 
14.2 ± 0.6 
(q<0.0001
) 
37.3 ± 1.6 
(q<0.0001
) 

















siRFC1 -01 22242 36.7 ± 1.0 
(q<0.0001
) 
21.5 ± 1.7 
(q<0.0001
) 
28.7 ± 0.9 
(q<0.0001
) 




siRFC1 -02 18739 35.2 ± 2.3 
(q<0.0001
) 
24.5 ± 0.3 
(q<0.0001
) 
27.6 ± 0.9 
(q<0.0001
) 
3.7 ± 0.4 
(q<0.01) 
15.79 
siRFC1 -03 18566 38.5 ± 2.1 
(q<0.0001
) 
24.6 ± 1.4 
(q<0.0001
) 
26.9 ± 0.6 
(q<0.0001
) 
2.6 ± 0.2 
(ns) 
20.99 
siRFC1 -04 32219 46.9 ± 0.6 
(ns) 
10.8 ± 1.0 
(ns) 
21.8 ± 0.2 
(q<0.001) 




siSTK24 -05 13758 41.3 ± 2.1 
(q<0.0001
) 
34.8 ± 1.9 
(q<0.0001
) 
15.0 ± 0.6 
(q<0.0001
) 
2.0 ± 0.3 
(q<0.01) 
7.04 
siSTK24 -21 30865 52.6 ± 2.3 11.5 ± 1.7 
(ns) 
19.3 ± 0.4 
(q<0.01) 







siSTK24 -22 15617 37.4 ± 3.9 
(q<0.0001
) 
25.7 ± 2.9 
(q<0.0001
) 
23.6 ± 0.6 
(q<0.0001
) 
3.6 ± 0.4 
(q<0.01) 
17.66 
siSTK24 -23 11330 43.4 ± 3.4 
(q<0.0001
) 
37.5 ± 2.9 
(q<0.0001
) 
12.0 ± 0.8 
(q<0.0001
) 




siTPX2 -01 3189 18.7 ± 2.6 
(q<0.0001
) 
12.4 ± 2.2 
(q<0.001) 
49.8 ± 2.8 
(q<0.0001
) 




siTPX2 -02 6023 16.5 ± 1.3 
(q<0.0001
) 
10.6 ± 1.1 
(ns) 
50.9 ± 0.6 
(q<0.0001
) 




siTPX2 -03 10750 47.2 ± 3.5 
(ns) 
22.9 ± 2.6 
(q<0.0001
) 
15.9 ± 0.4 
(q<0.0001
) 
2.8 ± 0.4 
(ns) 
39.05 
siTPX2 -04 7667 34.5 ± 2.3 18.3 ± 0.6 
(ns) 









siWRAP53 -19 31592 49.2 ± 1.4 
(ns) 
12.6 ± 1.0 
(q<0.001) 
21.4 ± 0.9 
(q<0.01) 




siWRAP53 -20 17584 38.1 ± 1.9 
(q<0.0001
) 
33.2 ± 0.6 
(q<0.0001
) 
16.5 ± 1.4 
(q<0.0001
) 
2.4 ± 0.3 
(ns) 
28.11 
siWRAP53 -21 18888 41.2 ± 0.6 
(q<0.0001
) 
26.9 ± 0.5 
(q<0.0001
) 
20.9 ± 0.7 
(ns) 
3.3 ± 0.3 
(ns) 
18.45 
siWRAP53 -22 17244 41.0 ± 1.0 
(q<0.0001
) 
29.8 ± 0.9 
(q<0.0001
) 
18.6 ± 0.2 
(q<0.001) 
2.4 ± 0.2 
(ns) 
38.53 
siXRCC5 -01 24899 50.9 ± 2.0 
(q<0.01) 
21.5 ± 1.4 
(q<0.0001
) 
18.8 ± 0.5 
(q<0.01) 
1.9 ± 0.3 
(q<0.01) 
8.08 
siXRCC5 -02 25424 49.4 ± 1.2 
(ns) 









siXRCC5 -03 24903 48.2 ± 2.0 
(ns) 
15.0 ± 0.7 
(q<0.0001
) 
25.8 ± 0.8 
(q<0.0001
) 
2.2 ± 0.4 
(ns) 
-1.50 
siXRCC5 -04 31137 53.9 ± 0.8 
(ns) 
10.2 ± 0.3 
(ns) 
19.3 ± 0.2 
(q<0.01) 




Effect on nucleolar number of 25 candidate compounds screened in positive control 
search for a high-throughput screen. 25 compounds were tested at 8 different 
concentrations. Mean percent effect (PE) from 3 replicates relative to DMSO (0.1%; 
DMSO=100 PE), seeded at 2,000 cells per well and incubated for 48 hrs, are shown for 
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per nucleus PE 
(mean ± SD) 
≥5 nucleoli per 
nucleus PE 
(mean ± SD) 
Percent 
viability 
(mean ± SD) 
5-Fluorouracil 20 106.7 ± 46.8 139.1 ± 103.5 20.2 ± 13.1 
5-Fluorouracil 6.7 81.3 ± 12.7 292.7 ± 55.5 27.4 ± 0.8 
5-Fluorouracil 2.2 80.3 ± 15.1 251.2 ± 19 29.1 ± 1.8 
5-Fluorouracil 0.7 74 ± 6.5 219.7 ± 30.3 27 ± 8.5 
5-Fluorouracil 0.2 73.1 ± 9.7 283.9 ± 7.3 41.3 ± 3.1 
5-Fluorouracil 0.08 68.7 ± 8.1 222.5 ± 41.7 89.5 ± 2.5 
5-Fluorouracil 0.03 77.4 ± 5.4 178.2 ± 28 109.3 ± 8.2 
5-Fluorouracil 0.009 78 ± 7.7 177.3 ± 4.4 116.2 ± 6.4 
Actinomycin D 20 13.5 ± 6.5 9.2 ± 8.3 3.4 ± 0.7 
Actinomycin D 6.7 19.6 ± 12.4 69.3 ± 78.2 3.6 ± 2.3 
Actinomycin D 2.2 18 ± 5.5 70.5 ± 96 2.5 ± 0.8 
Actinomycin D 0.7 18 ± 9 32.7 ± 26.9 2.8 ± 0.8 
Actinomycin D 0.2 22.1 ± 7.6 22.4 ± 19.7 4.2 ± 0.8 
Actinomycin D 0.08 29.8 ± 5.6 156.2 ± 119 1.9 ± 0.4 
Actinomycin D 0.03 48.9 ± 23.3 58.9 ± 62.6 2.3 ± 1.1 
Actinomycin D 0.009 17.2 ± 13.8 10 ± 13.6 5.4 ± 2.6 
Amperozide 20 86.2 ± 3.3 54.4 ± 10.5 66.1 ± 8.6 
Amperozide 6.7 86.6 ± 7.6 86.1 ± 11.8 82 ± 5.5 
Amperozide 2.2 87 ± 3.7 139.4 ± 4.4 86.1 ± 0.9 
Amperozide 0.7 91.6 ± 4.6 106.2 ± 25.1 73.1 ± 1.6 
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Amperozide 0.2 70.5 ± 7.1 83.8 ± 8.4 77.8 ± 10.1 
Amperozide 0.08 85.8 ± 4.9 124.2 ± 21.8 70 ± 1.5 
Amperozide 0.03 92.7 ± 10.5 101.8 ± 21.6 77 ± 3.6 
Amperozide 0.009 103.8 ± 4.8 100.5 ± 23.1 68.6 ± 2.9 
BMH-21 20 26.8 ± 22.3 31 ± 23 5 ± 0.2 
BMH-21 6.7 215.2 ± 135.6 40 ± 24.3 7.6 ± 3.5 
BMH-21 2.2 331.1 ± 22.1 5.1 ± 1.1 15.8 ± 0.5 
BMH-21 0.7 314.5 ± 34 7.6 ± 1.9 17.2 ± 3.2 
BMH-21 0.2 89.6 ± 9.6 111.7 ± 46.2 50.8 ± 3 
BMH-21 0.08 73.9 ± 7.1 155.2 ± 25 114.8 ± 17.1 
BMH-21 0.03 76.5 ± 12.1 169.1 ± 12 120.1 ± 7.4 
BMH-21 0.009 59.8 ± 15.4 153.9 ± 26.5 103.1 ± 19.2 
C646 20 102.6 ± 11.5 127.4 ± 30.3 44.7 ± 23.8 
C646 6.7 96.2 ± 22.8 107 ± 12.3 83.6 ± 6.2 
C646 2.2 92.8 ± 22.1 104.1 ± 37.6 89.8 ± 5.8 
C646 0.7 91.9 ± 10.1 115.2 ± 20.5 96.7 ± 9.5 
C646 0.2 89.4 ± 3.5 124.2 ± 30 90.1 ± 1.6 
C646 0.08 82.7 ± 9.3 99.4 ± 17 93.5 ± 4.3 
C646 0.03 92.4 ± 2.5 123 ± 4.3 87.2 ± 10.8 
C646 0.009 87.4 ± 15 108 ± 23.1 83.6 ± 5.1 
CDK9 Inhibitor 20 70.2 ± 3.2 342.4 ± 16 47.5 ± 4.5 
CDK9 Inhibitor 6.7 78.1 ± 13.5 179.1 ± 1.9 89.4 ± 10.2 
CDK9 Inhibitor 2.2 88 ± 7.6 151.4 ± 15.4 94 ± 14.6 
 
293 
CDK9 Inhibitor 0.7 75.8 ± 24.2 133.1 ± 38.7 97.6 ± 11.4 
CDK9 Inhibitor 0.2 63.4 ± 48.5 96 ± 75.7 62.6 ± 52.1 
CDK9 Inhibitor 0.08 73.9 ± 13.2 122.5 ± 11.4 96.4 ± 9.7 
CDK9 Inhibitor 0.03 61.3 ± 19.8 78.6 ± 57.4 61.2 ± 49.2 
CDK9 Inhibitor 0.009 81.5 ± 21 119.7 ± 31.8 90.1 ± 13.4 
Cisplatin 20 77.2 ± 15.2 281.8 ± 47.1 23.9 ± 2.9 
Cisplatin 6.7 53.6 ± 29.9 157.9 ± 71 40 ± 9.1 
Cisplatin 2.2 92.7 ± 10.6 162.4 ± 15.1 69.1 ± 10.2 
Cisplatin 0.7 116.4 ± 7.3 96.6 ± 16.3 101.4 ± 0.2 
Cisplatin 0.2 75.7 ± 7.6 108.1 ± 5.4 95.3 ± 3.1 
Cisplatin 0.08 77.3 ± 23.4 94.5 ± 34 97.5 ± 6 
Cisplatin 0.03 108.8 ± 7.1 100.3 ± 14.7 81.9 ± 12.1 
Cisplatin 0.009 100 ± 22.5 67.7 ± 53.5 57.7 ± 44.5 
CX-5461 20 173.9 ± 6.4 91.2 ± 13 26.8 ± 2.6 
CX-5461 6.7 133 ± 3.3 115 ± 14.2 26.2 ± 4.5 
CX-5461 2.2 107.1 ± 11.8 164.5 ± 10.7 33.2 ± 7.9 
CX-5461 0.7 92.2 ± 29.1 131.7 ± 42.5 25.5 ± 18.8 
CX-5461 0.2 100.5 ± 5.5 182.1 ± 5.6 36.4 ± 11 
CX-5461 0.08 75.9 ± 6.1 193.1 ± 29.9 60.7 ± 7.5 
CX-5461 0.03 67.1 ± 13 186.2 ± 28.4 86.5 ± 4.2 
CX-5461 0.009 79.1 ± 1.2 183.9 ± 22 113.3 ± 8.6 
Doxorubicin 20 99.5 ± 19.1 36.3 ± 51.5 7.9 ± 1 
Doxorubicin 6.7 91.5 ± 21.3 37.2 ± 32.5 10.1 ± 1 
 
294 
Doxorubicin 2.2 91.2 ± 9.8 2.6 ± 2.7 9.8 ± 0.6 
Doxorubicin 0.7 235.8 ± 58.8 42.3 ± 28.4 2.3 ± 1.2 
Doxorubicin 0.2 300 ± 35.1 8.6 ± 7.6 7.6 ± 2.5 
Doxorubicin 0.08 232.9 ± 28.3 22.9 ± 1.4 7.3 ± 1.5 
Doxorubicin 0.03 121.6 ± 5.6 162.7 ± 46.6 10.4 ± 1.7 
Doxorubicin 0.009 71.7 ± 25.5 88.3 ± 30 38.5 ± 5.4 
Etoposide 20 173.7 ± 21.4 125.6 ± 20.2 14.7 ± 1.6 
Etoposide 6.7 111.2 ± 15.5 275 ± 43.2 15.1 ± 0.8 
Etoposide 2.2 88.1 ± 7 415.8 ± 36.8 15.9 ± 1.7 
Etoposide 0.7 95.5 ± 4.3 365.2 ± 36.4 21.7 ± 2.3 
Etoposide 0.2 89.1 ± 10.4 258.6 ± 26.5 46.3 ± 4.1 
Etoposide 0.08 82.7 ± 23 185.1 ± 43.3 73.6 ± 5.3 
Etoposide 0.03 85.7 ± 14.6 179.5 ± 19.4 96.6 ± 4.6 
Etoposide 0.009 91.4 ± 10.2 138.6 ± 2.3 110.6 ± 12 
Fenbendazole 20 143.1 ± 20.2 251.4 ± 45.7 4.8 ± 0.8 
Fenbendazole 6.7 136.5 ± 12.7 185.8 ± 114.7 5 ± 0.4 
Fenbendazole 2.2 113.2 ± 16.8 261.2 ± 35.4 5.2 ± 2.8 
Fenbendazole 0.7 161.8 ± 17.4 138.2 ± 9.3 13.4 ± 1.8 
Fenbendazole 0.2 89.7 ± 11.7 107 ± 5.7 86.4 ± 5.1 
Fenbendazole 0.08 73.8 ± 22.9 85.8 ± 51.8 64 ± 49.8 
Fenbendazole 0.03 89.2 ± 4.8 112.1 ± 19.7 85.2 ± 7.8 
Fenbendazole 0.009 98.6 ± 18.5 94.4 ± 19.6 77.6 ± 6 
Flavopiridol 20 133.5 ± 39 215.7 ± 50.6 1.9 ± 0.6 
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Flavopiridol 6.7 125.3 ± 83.7 130 ± 65.6 2.2 ± 0.9 
Flavopiridol 2.2 163.9 ± 44.5 104.7 ± 59.7 1.6 ± 0.9 
Flavopiridol 0.7 87.1 ± 44.6 163 ± 115.8 1.4 ± 1 
Flavopiridol 0.2 114.6 ± 74.2 88.7 ± 67 3.8 ± 1.6 
Flavopiridol 0.08 97.5 ± 6.2 241.7 ± 80.6 7.9 ± 1.2 
Flavopiridol 0.03 73.1 ± 8.9 194.3 ± 56.1 73.7 ± 4.7 
Flavopiridol 0.009 79.3 ± 9.7 127.3 ± 13.1 93.5 ± 3.9 
Hesperadin 20 230.3 ± 11.8 55.2 ± 25.1 3.2 ± 0.9 
Hesperadin 6.7 211.3 ± 17.4 92.2 ± 29.1 9.4 ± 1 
Hesperadin 2.2 200.4 ± 2.9 130.9 ± 16.4 10 ± 0.5 
Hesperadin 0.7 152.1 ± 29.9 192.5 ± 45.4 10.4 ± 1.5 
Hesperadin 0.2 120 ± 3.7 374 ± 37.6 12.4 ± 1.8 
Hesperadin 0.08 96.9 ± 4.9 459.7 ± 38 16.1 ± 3.4 
Hesperadin 0.03 73.3 ± 10.3 242.2 ± 52.5 44.3 ± 5.9 
Hesperadin 0.009 90.5 ± 4.2 154.4 ± 28.4 89.9 ± 9.5 
Ispinesib 20 6 ± 1.7 2 ± 3.5 5.8 ± 0.9 
Ispinesib 6.7 201.6 ± 19.3 121.6 ± 24.2 3.2 ± 0.7 
Ispinesib 2.2 93.4 ± 16.4 332.8 ± 51.2 3.7 ± 0.4 
Ispinesib 0.7 94.6 ± 10.1 296.5 ± 58.2 3.6 ± 0.9 
Ispinesib 0.2 105.7 ± 22.5 266.9 ± 80.4 4.7 ± 1.7 
Ispinesib 0.08 114 ± 18.8 316.7 ± 12 4.1 ± 0.8 
Ispinesib 0.03 83.5 ± 43.4 152 ± 130.3 5 ± 1.4 
Ispinesib 0.009 79.7 ± 41.9 197.9 ± 159.6 6.6 ± 0.7 
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IWP-2 20 77.9 ± 31.9 71.6 ± 44.7 48.3 ± 35 
IWP-2 6.7 89.6 ± 14.4 96.9 ± 13.8 80.9 ± 2.8 
IWP-2 2.2 80 ± 20 91.3 ± 21.6 72.5 ± 10 
IWP-2 0.7 104.2 ± 9.6 85 ± 7 75.8 ± 1.1 
IWP-2 0.2 87.5 ± 22.3 85 ± 30.8 53.8 ± 41.6 
IWP-2 0.08 99.6 ± 9.1 89.4 ± 5.9 76.7 ± 3.6 
IWP-2 0.03 97.3 ± 11.7 85.8 ± 16 54.3 ± 15.1 
IWP-2 0.009 109.3 ± 11.6 74.2 ± 27 57.1 ± 18.9 
LY411575 20 70.9 ± 4.2 121.7 ± 26.9 79.6 ± 3.8 
LY411575 6.7 85.6 ± 10 123.7 ± 16.2 78.1 ± 5 
LY411575 2.2 86.4 ± 7.9 139.1 ± 10.5 85.1 ± 1.8 
LY411575 0.7 84.1 ± 2 143.8 ± 18.1 93.5 ± 6.8 
LY411575 0.2 79.6 ± 7.2 127.1 ± 19.8 85.4 ± 2.6 
LY411575 0.08 83.7 ± 13.6 136.9 ± 5.3 90.1 ± 1.8 
LY411575 0.03 67.8 ± 18.3 112.3 ± 28.2 85.1 ± 6.3 
LY411575 0.009 68.7 ± 18.3 124.9 ± 29.8 90.6 ± 6.8 
Metarrestin 20 201.9 ± 35 12 ± 3.4 26.5 ± 3.3 
Metarrestin 6.7 86.2 ± 26.9 46.4 ± 14 48.2 ± 36.1 
Metarrestin 2.2 87.6 ± 4.6 83.9 ± 10.4 76.6 ± 5.8 
Metarrestin 0.7 101 ± 7.9 74.5 ± 3.5 74 ± 20.8 
Metarrestin 0.2 95.3 ± 3.7 125.8 ± 10.3 79.4 ± 6 
Metarrestin 0.08 91.2 ± 3.4 105 ± 12.8 77.5 ± 9.9 
Metarrestin 0.03 85.4 ± 22.9 66.8 ± 42.7 54.5 ± 40.2 
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Metarrestin 0.009 97.2 ± 19.4 72.4 ± 4.4 69.4 ± 1.8 
Metformin 20 121.5 ± 8.5 78.3 ± 27.7 66.2 ± 51.4 
Metformin 6.7 111.9 ± 8 99.6 ± 5.1 85.7 ± 10.7 
Metformin 2.2 104.1 ± 9.5 108 ± 11.4 92.5 ± 3.9 
Metformin 0.7 93.4 ± 12.9 115.1 ± 16.3 98.2 ± 7.9 
Metformin 0.2 82.1 ± 14.5 98.3 ± 24.2 95.5 ± 6.5 
Metformin 0.08 85.1 ± 6.4 136.6 ± 12.3 87.8 ± 19.5 
Metformin 0.03 67.1 ± 29.4 95.2 ± 59.2 60.4 ± 46 
Metformin 0.009 80.9 ± 13.5 135.9 ± 22.8 96 ± 0.6 
Mitomycin C 20 237 ± 135.9 18.2 ± 16.2 1 ± 0.3 
Mitomycin C 6.7 213.3 ± 142 13.1 ± 6.6 9.6 ± 2.8 
Mitomycin C 2.2 155 ± 95.8 36.7 ± 14.4 10.4 ± 5.4 
Mitomycin C 0.7 117.4 ± 5 219.2 ± 20.8 18 ± 1 
Mitomycin C 0.2 78.4 ± 15.9 346 ± 65.7 26 ± 3.8 
Mitomycin C 0.08 78.7 ± 11.1 297.5 ± 51.7 42.1 ± 8.6 
Mitomycin C 0.03 77 ± 2.9 236.7 ± 11.7 67.7 ± 8.3 
Mitomycin C 0.009 76.5 ± 8.9 180.2 ± 30.5 85.5 ± 2.2 
Paclitaxel 20 123.7 ± 18.8 372 ± 49.3 3.2 ± 0.2 
Paclitaxel 6.7 112.5 ± 65 171.7 ± 161.3 4.1 ± 3.5 
Paclitaxel 2.2 121.5 ± 11.2 359.4 ± 60.8 2 ± 0.3 
Paclitaxel 0.7 154.6 ± 4.7 306.7 ± 24 2.2 ± 0.5 
Paclitaxel 0.2 90.1 ± 22.4 268.4 ± 55.3 1.8 ± 0.4 
Paclitaxel 0.08 143.4 ± 6.3 227 ± 40.5 2.3 ± 1 
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Paclitaxel 0.03 113.2 ± 35.3 374.5 ± 88.2 2.3 ± 0.1 
Paclitaxel 0.009 152.6 ± 15.9 250 ± 60.9 7.9 ± 1.4 
SBE 13 20 54.6 ± 37.4 100.7 ± 73.9 69.7 ± 55.8 
SBE 13 6.7 81 ± 7 163.5 ± 22.7 108 ± 2.9 
SBE 13 2.2 79.6 ± 14.7 157.7 ± 13.4 106.3 ± 5.3 
SBE 13 0.7 78.5 ± 9.6 160.3 ± 12.8 109.2 ± 1 
SBE 13 0.2 82.8 ± 8.2 151.7 ± 10.5 105.2 ± 5.2 
SBE 13 0.08 43.3 ± 28.9 47.6 ± 78.7 39 ± 56.9 
SBE 13 0.03 78.8 ± 18.6 122.4 ± 21.3 84.7 ± 24.7 
SBE 13 0.009 90.3 ± 4.1 114.8 ± 26.1 97.1 ± 8 
Temsirolimus 20 116 ± 14.5 81 ± 24 25.5 ± 1.9 
Temsirolimus 6.7 62 ± 9.9 159.6 ± 34.3 54.4 ± 4.6 
Temsirolimus 2.2 77.4 ± 8.2 181 ± 9 54.4 ± 3.9 
Temsirolimus 0.7 69.1 ± 8.2 213.4 ± 11.4 52.5 ± 3.8 
Temsirolimus 0.2 57.6 ± 1.6 181.5 ± 53.6 43.1 ± 23.2 
Temsirolimus 0.08 67.7 ± 3.1 198.5 ± 21.8 55.1 ± 6.6 
Temsirolimus 0.03 65 ± 14.6 199 ± 31.9 58.1 ± 1.9 
Temsirolimus 0.009 63 ± 7.6 206.3 ± 37.5 65.3 ± 2.6 
Topotecan 20 263.1 ± 42.7 10.2 ± 17.7 1.2 ± 0.6 
Topotecan 6.7 351.9 ± 31.8 3.4 ± 5.9 3.1 ± 0.3 
Topotecan 2.2 247.9 ± 41.4 52.3 ± 10.7 8.1 ± 1.2 
Topotecan 0.7 214.6 ± 24.3 69.3 ± 10.4 8.3 ± 1.5 
Topotecan 0.2 156.7 ± 25.4 101 ± 9 11 ± 0.8 
 
299 
Topotecan 0.08 129.3 ± 27.1 150.6 ± 26.2 12.2 ± 1.1 
Topotecan 0.03 95.5 ± 16.1 223.4 ± 41.2 12.8 ± 0.5 
Topotecan 0.009 87.9 ± 11.2 302.7 ± 37.4 17.6 ± 1.6 
Trichostatin A 20 148.7 ± 37.2 10.3 ± 8 7.4 ± 1.5 
Trichostatin A 6.7 136.6 ± 34.2 5.6 ± 1.7 7.4 ± 0.6 
Trichostatin A 2.2 186.6 ± 86 26.7 ± 10.5 3.8 ± 3 
Trichostatin A 0.7 187.9 ± 4 49.8 ± 11.2 9.4 ± 0.6 
Trichostatin A 0.2 88.6 ± 7.5 129.9 ± 30 48.3 ± 3.1 
Trichostatin A 0.08 96.7 ± 7.2 133.7 ± 33.5 56.1 ± 4.5 
Trichostatin A 0.03 95.4 ± 5.3 126.5 ± 15.2 66.6 ± 3.5 
Trichostatin A 0.009 99.4 ± 21.7 91 ± 26.7 67.7 ± 3.8 
XAV939 20 92.4 ± 3.9 107.6 ± 28 78.7 ± 9.3 
XAV939 6.7 64 ± 6.5 101.3 ± 14.3 80.6 ± 2.6 
XAV939 2.2 80.7 ± 8.8 136.4 ± 21.2 83.2 ± 8.9 
XAV939 0.7 74.4 ± 9.7 139.7 ± 21 89 ± 11.4 
XAV939 0.2 78.8 ± 11.9 144 ± 12.8 84.1 ± 9.9 
XAV939 0.08 81.5 ± 5.7 141 ± 6.1 100.4 ± 5 
XAV939 0.03 79.1 ± 11.2 137.4 ± 29.5 91.6 ± 10.1 










The 110 FDA-approved drugs that caused a decrease in nucleolar number. Drug 
name, Chemical Abstracts Service (CAS) registry number, the one nucleolus normalized 
percent effect (NPE), percent (%) viability relative DMSO, medical use, and molecular 




Drug Name CAS No. NPE % 
Viab-
ility 









57-09-0 208.9 1.1 Antiseptic Plasma 
membrane 
Mitoxantrone 65271-80-9 188.7 5.9 Antineoplastic Topo-
isomerase 








548-62-9 139.2 4.2 Antiseptic Unknown 
Vindesine sulfate 59917-39-4 138.1 6.6 Antineoplastic Tubulin 
Mitoxantrone 
hydrochloride 
70476-82-3 131.9 5.9 Antineoplastic Topo-
isomerase 










Vinblastine 865-21-4 125.7 6.3 Antineoplastic Tubulin 




Ispinesib 336113-53-2 122.7 1.6 Antineoplastic Kinesin 
(KIF11) 
Vincristine sulfate 2068-78-2 122.5 7.1 Antineoplastic Tubulin 
Povan (pyrvinium 
pamoate) 
3546-41-6 121.1 14.3 Antiparasitic Unknown 




Topotecan 123948-87-8 120.5 13.0 Antineoplastic Topo-
isomerase 
Aclarubicin 57576-44-0 118.6 4.6 Antineoplastic Topo-
isomerase 
Vinblastine sulfate 143-67-9 117.6 6.7 Antineoplastic Tubulin 











Vinorelbine 71486-22-1 114.8 6.5 Antineoplastic Tubulin 
Crystodigin 
(digitoxin) 








143-67-9 111.5 7.5 Antineoplastic Tubulin 
Vinorelbine 71486-22-1 111.4 7.4 Antineoplastic Tubulin 
Vincristine 57-22-7 109.8 6.3 Antineoplastic Tubulin 






2068-78-2 105.8 6.3 Antineoplastic Tubulin 
Dacinostat 404951-53-7 104.7 6.1 Antineoplastic Histone 
deacetylases 
Vinleurosine 54081-68-4 104.4 8.2 Antineoplastic Tubulin 
Zinc omadine 
(pyrithione zinc) 










1320-44-1 102.9 21.9 Antiseptic Plasma 
membrane 




Plicamycin 18378-89-7 100.9 2.7 Antineoplastic DNA 
Maitansine 35846-53-8 100.5 6.8 Antineoplastic Tubulin 
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Miripirium 2748-88-1 99.0 18.2 Antiseptic Plasma 
membrane 
Dasatinib 863127-77-9 99.0 20.1 Antineoplastic Tyrosine 
kinases 
Podophyllin 900-55-9 97.3 6.2 Antiviral  Tubulin 
Velban 
(vinblastine) 
865-21-4 96.8 5.7 Antineoplastic Tubulin 









59917-39-4 96.5 6.2 Antineoplastic Tubulin 






68890-66-4 94.1 19.1 Antifungal Unknown 
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Piroctone 50650-76-5 94.0 17.3 Antifungal Unknown 






71486-22-1 91.7 6.6 Antineoplastic Tubulin 
Soblidotin 149606-27-9 91.3 6.7 Antineoplastic Tubulin 
Emetine 
dihydrochloride 
316-42-7 90.1 8.2 Antiparasitic Ribosome 
Vumon (teniposide) 29767-20-2 89.9 8.2 Antineoplastic Topo-
isomerase 
Colchicine 64-86-8 88.1 8.9 Anti-
inflammatory 
Tubulin 

























41621-49-2 85.5 18.0 Antifungal Plasma 
membrane 
Plicamycin 18378-89-7 84.0 2.3 Antineoplastic DNA 
Ciclopirox 29342-05-0 83.7 15.3 Antifungal Plasma 
membrane 
Azacitidine 320-67-2 83.0 10.8 Antineoplastic DNA methyl-
transferase 





115007-34-6 82.9 20.5 Immuno-
modulator 
IMPDH 
Vinformide 54022-49-0 82.6 6.8 Antineoplastic Tubulin 
Docusate sodium 577-11-7 81.6 2.5 Gastrointestina
l agent 
Unknown 
Mepacrine 83-89-6 81.1 24.5 Antiparasitic DNA 
Condylox 
(podofilox) 
518-28-5 81.0 6.3 Antiviral Tubulin 
Sertindole 106516-24-9 80.1 22.0 Antipsychotic Dopamine 
receptor 






22573-93-9 78.4 25.4 Antiseptic Plasma 
membrane 
Vinblastine 865-21-4 78.2 5.8 Antineoplastic Tubulin 
Mitomycin C 50-07-7 77.3 21.4 Antineoplastic DNA 
Albendazole 54965-21-8 76.4 15.5 Antiparasitic Fumarate 
reductase 
Gemcitabine 95058-81-4 76.1 13.5 Antineoplastic Ribonucleotide 
reductase 













18378-89-7 73.6 2.1 Antineoplastic DNA 
Hexachlorophene 70-30-4 73.1 20.9 Antiseptic D-lactate 
dehydrogenase 
BI-2536 755038-02-9 72.4 14.5 Antineoplastic Polo-like 
kinase 







Lestaurtinib 111358-88-4 71.6 6.7 Antineoplastic Tyrosine 
kinases 
Nocodazole 31430-18-9 71.4 8.1 Antineoplastic Tubulin 
Gramicidin 1405-97-6 70.7 24.7 Antibacterial Plasma 
membrane 
Albendazole 54965-21-8 70.4 19.4 Antiparasitic Fumarate 
reductase 
Edoxudine 15176-29-1 68.8 28.3 Antiviral DNA 
polymerase 
Idarubicin 58957-92-9 68.2 1.2 Antineoplastic Topo-
isomerase 
Ixabepilone 219989-84-1 68.2 2.9 Antineoplastic Tubulin 
Clofarabine 123318-82-1 68.0 18.3 Antineoplastic Ribonucleotide 
reductase 
Cambendazole 26097-80-3 67.0 12.1 Antiparasitic Fumarate 
reductase 
Parbendazole 14255-87-9 65.4 5.7 Antiparasitic Tubulin 
Mebendazole 31431-39-7 65.2 6.0 Antiparasitic Tubulin 









Mycophenolic acid 24280-93-1 63.8 20.9 Immuno-
modulator 
IMPDH 
Riboprine 7724-76-7 62.3 16.4 Antineoplastic Unknown 
Daunorubicin 20830-81-3 62.2 1.4 Antineoplastic Topo-
isomerase 






1393-48-2 61.3 23.8 Antibacterial Ribosome 
Gefitinib 184475-35-2 58.4 16.0 Antineoplastic Tyrosine 
kinases 
Fenbendazole 43210-67-9 58.1 14.1 Antiparasitic Tubulin 





Vorinostat 149647-78-9 57.7 16.9 Antineoplastic Histone 
deacetylases 
Oxibendazole 20559-55-1 55.5 32.4 Antiparasitic Tubulin 
Cosmegen 
(Dactinomycin) 
50-76-0 55.4 1.3 Antineoplastic DNA 
Vermox 
(mebendazole) 
31431-39-7 55.0 14.5 Antiparasitic Tubulin 
Niclofolan 10331-57-4 54.5 20.1 Antiparasitic Unknown 
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Patupilone 152044-54-7 53.4 7.6 Antineoplastic Tubulin 
Cicloheximide 
(cycloheximide) 













The 30 FDA-approved drugs that caused an increase in nucleolar number. Drug 
name, Chemical Abstracts Service (CAS) registry number, the ≥5 nucleoli normalized 
percent effect (NPE), percent (%) viability relative DMSO, medical use, and molecular 




Drug Name CAS No. NPE % 
Viab-
ility 




90-45-9 364.3 16.5 Antiseptic DNA 
Melphalan 148-82-3 353.1 29.9 Antineoplastic DNA 
Merimepodib 198821-22-6 271.6 24.7 Antiparasitic; 
Antiviral 
IMPDH 
Docetaxel 114977-28-5 260.7 9.1 Antineoplastic Tubulin 
Acrisorcin 7527-91-5 236.6 18.6 Antifungal DNA 
Jevtana 
(cabazitaxel) 




62-38-4 201.4 2.1 Pharmaceutical 
preservative 
Unknown 
Taxol 33069-62-6 199.7 7.0 Antineoplastic Tubulin 
Fungizone 
(amphotericin B) 
1397-89-3 183.6 6.2 Antifungal Ergosterol 




148408-66-6 173.3 9.6 Antineoplastic Tubulin 
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Alvocidib 131740-09-5 169.0 4.9 Antineoplastic Cyclin-
dependent 
kianses 









55-86-7 140.8 19.9 Antineoplastic DNA 
Butoconazole 64872-77-1 135.2 72.6 Antifungal Ergosterol 





33419-42-0 133.3 32.3 Antineoplastic Topo-
isomerase 







8063-24-9 129.1 20.5 Antiseptic; 
Antiparasitic 
DNA 










Bortezomib 179324-69-7 125.9 0.8 Antineoplastic Proteasome 
Tegafur 17902-23-7 124.5 66.7 Antineoplastic Thymidylate 
synthase 
Sertaconazole 99592-32-2 124.2 90.0 Antifungal Ergosterol 
Mebendazole 31431-39-7 119.8 6.0 Antiparasitic Tubulin 
Tioconazole 65899-73-2 118.7 83.9 Antifungal Ergosterol 






















The 234 synthetic, drug-like compounds that yielded either an increase or decrease 
in nucleolar number. Unique compound ID, the designated phenotype (one nucleolus 
per nucleus or ≥5 nucleoli per nucleus), the normalized percent effect (NPE) for each 







1 nucleolus per 
nucleus NPE  
≥5 nucleoli per 
nucleus NPE  
Percent viability 
YU275173 1 82.1 -55.4 30.8 
YU275624 1 79.5 -41.7 21.5 
YU258006 1 78.8 -500.4 13.7 
YU257337 1 74.0 -190.9 25.7 
YU268831 1 73.0 -116.0 28.8 
YU263255 1 68.4 -12.4 22.3 
YU268218 1 67.4 -4.7 6.7 
YU262883 1 62.1 -41.0 40.2 
YU257828 1 61.1 -415.4 14.1 
YU270835 1 61.1 18.7 6.3 
YU271333 1 61.0 -40.2 36.2 
YU258701 1 58.3 -114.4 7.2 
YU256667 1 57.3 -61.7 10.0 
YU256773 1 55.5 -189.4 30.1 
YU270716 1 53.8 -22.4 22.2 
YU256771 1 53.4 -91.2 8.1 
YU265245 1 53.3 -45.3 19.9 
YU269527 1 48.6 -170.4 215.2 
YU275232 1 48.2 -29.5 56.2 
YU256691 1 47.2 -213.2 17.8 
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YU280992 1 47.1 -14.4 28.7 
YU263854 1 46.8 -62.1 20.8 
YU275534 1 46.8 52.3 38.3 
YU256776 1 46.5 -229.8 6.2 
YU265474 1 46.4 -458.2 354.7 
YU263078 1 44.5 -27.0 51.7 
YU276852 1 44.5 -58.5 41.7 
YU276881 1 43.6 -43.5 55.4 
YU277406 1 42.8 -38.1 63.1 
YU276803 1 40.8 -51.7 67.9 
YU262873 1 40.3 -34.1 61.6 
YU276687 1 39.5 -28.6 76.5 
YU276750 1 39.1 -45.7 68.2 
YU267724 1 38.4 -86.9 253.4 
YU276831 1 38.1 -47.0 60.7 
YU271407 1 37.8 -37.9 26.3 
YU257883 1 37.8 -20.3 22.9 
YU257642 1 37.7 -246.5 26.7 
YU257875 1 37.4 -384.4 35.0 
YU276844 1 37.3 -40.0 74.6 
YU275974 1 37.0 -41.4 56.2 
YU258712 1 36.9 -208.1 27.1 
YU279797 1 36.0 -34.0 53.4 
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YU270641 1 35.9 -151.4 214.0 
YU279821 1 35.9 -24.6 63.4 
YU270819 1 35.0 -34.3 31.2 
YU279801 1 34.9 -33.3 60.7 
YU279798 1 34.5 -29.6 52.1 
YU276816 1 34.3 -29.2 39.5 
YU276861 1 34.2 -35.0 91.5 
YU276806 1 33.8 -28.0 63.8 
YU256505 1 33.6 -253.8 18.9 
YU275610 1 33.1 -26.9 60.1 
YU277605 1 33.0 -26.9 67.1 
YU276867 1 32.9 -31.1 93.6 
YU279851 1 32.6 -28.5 56.7 
YU276814 1 32.4 -36.7 85.8 
YU279858 1 32.3 -44.4 62.8 
YU276856 1 32.2 -22.2 63.0 
YU268641 1 31.8 -39.9 47.1 
YU279803 1 31.7 -18.8 46.7 
YU265485 1 31.3 -266.2 19.5 
YU276596 1 31.2 -28.7 93.2 
YU256775 1 31.1 -91.9 6.6 
YU275397 1 31.0 -23.3 41.2 
YU260066 1 30.9 -21.6 133.6 
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YU276691 1 30.7 -36.2 57.4 
YU258900 1 30.5 -210.9 19.9 
YU266928 1 30.2 -52.6 58.2 
YU276870 1 30.0 -13.3 86.6 
YU276846 1 29.5 -27.0 74.0 
YU279785 1 29.2 -24.7 55.1 
YU279802 1 28.9 -26.9 55.2 
YU275603 1 28.8 -23.3 33.2 
YU270104 1 28.7 -33.9 56.9 
YU276888 1 28.2 -29.4 118.1 
YU276865 1 28.2 -27.5 72.7 
YU276810 1 27.6 -27.1 76.2 
YU277549 1 27.6 -15.8 43.1 
YU275618 1 27.0 -22.6 49.7 
YU276862 1 26.8 -18.6 100.4 
YU263845 1 26.8 -50.8 21.2 
YU278496 1 26.6 -21.9 63.9 
YU277450 1 26.3 -23.3 70.7 
YU275602 1 26.0 -21.0 36.1 
YU268869 1 25.8 -57.5 31.3 
YU279792 1 25.8 -46.3 57.1 
YU274699 1 25.8 -35.2 111.2 
YU258859 1 25.7 -245.0 46.4 
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YU270744 1 25.4 -31.0 57.2 
YU276833 1 25.4 -30.8 86.2 
YU270748 1 25.3 -36.4 51.2 
YU258715 1 25.3 -209.7 72.7 
YU277932 1 25.1 -17.8 74.7 
YU275374 1 24.8 -19.4 54.3 
YU277614 1 24.8 -13.3 78.7 
YU279789 1 24.8 -10.5 82.1 
YU261429 1 24.6 -26.3 62.7 
YU260850 1 24.5 -8.8 107.6 
YU276808 1 24.3 -16.5 59.4 
YU276595 1 24.2 -41.5 70.9 
YU279799 1 24.2 -16.1 69.9 
YU270752 1 24.1 -37.1 53.3 
YU276618 1 23.8 -16.2 92.4 
YU259823 1 23.8 -31.0 152.1 
YU273348 1 23.6 -31.1 50.7 
YU275607 1 23.5 -26.8 34.5 
YU277613 1 23.1 -12.4 71.8 
YU276837 1 22.9 -5.1 83.0 
YU279819 1 22.6 -25.2 60.6 
YU276738 1 22.6 -30.1 79.7 
YU276901 1 22.5 2.0 94.0 
 
321 
YU279793 1 22.5 -37.3 39.4 
YU275612 1 22.5 -31.3 53.2 
YU275775 1 22.4 -17.9 71.3 
YU275402 1 22.4 -23.6 70.0 
YU276727 1 22.3 -24.8 64.9 
YU276807 1 22.2 -41.7 73.2 
YU275398 1 22.2 -30.5 64.8 
YU275243 1 22.2 -16.3 78.4 
YU260480 1 22.1 -17.0 56.1 
YU276764 1 22.0 -31.0 118.4 
YU268679 1 22.0 -36.1 69.0 
YU272087 1 21.9 -37.7 50.7 
YU276879 1 21.6 -40.8 116.0 
YU276305 1 21.6 -26.4 67.6 
YU275286 1 21.6 -19.6 79.5 
YU276871 1 21.5 -40.3 96.2 
YU277943 1 21.4 -17.3 86.3 
YU274118 1 21.4 -20.0 41.2 
YU260026 1 21.1 -15.6 123.2 
YU278495 1 21.1 -12.0 64.0 
YU275632 1 21.1 -27.8 42.9 
YU276809 1 20.9 -37.9 93.7 
YU263335 1 20.9 -14.9 55.8 
 
322 
YU276863 1 20.8 -25.1 111.0 
YU276576 1 20.7 -16.5 37.9 
YU271638 1 20.4 -38.7 54.2 
YU271833 1 20.2 -27.6 58.0 
YU276827 1 20.2 -28.8 114.5 
YU278475 1 20.2 -24.6 71.7 
YU274377 1 20.1 -19.3 121.0 
YU276789 1 20.0 -29.5 120.5 
YU258334 1 19.8 -132.3 52.9 
YU276594 1 19.8 -25.4 60.2 
YU276905 1 19.7 -26.0 104.8 
YU273331 1 19.7 -26.0 40.1 
YU276798 1 19.6 -27.8 112.0 
YU279309 1 19.6 -24.7 101.4 
YU268935 1 19.5 -129.5 68.3 
YU276773 1 19.4 -23.2 119.4 
YU275819 1 19.4 -26.7 60.5 
YU259930 1 19.4 -10.5 110.6 
YU276703 1 19.3 -14.4 102.0 
YU273238 1 19.3 -29.2 40.1 
YU275604 1 19.3 -18.1 39.2 
YU268938 1 19.3 -151.8 57.0 
YU275440 1 19.3 -16.9 54.8 
 
323 
YU275570 1 19.2 -18.3 70.0 
YU279838 1 19.2 -11.5 93.0 
YU261750 1 19.2 -14.6 64.7 
YU266010 1 19.0 -55.5 68.1 
YU275588 1 19.0 -20.5 59.5 
YU276699 1 18.9 -23.3 87.7 
YU261190 1 18.8 -9.3 70.2 
YU277461 1 18.8 -17.2 52.1 
YU275987 1 18.7 -23.4 71.2 
YU275628 1 18.7 -18.1 79.2 
YU278050 1 18.6 -10.9 83.1 
YU276848 1 18.6 -16.6 94.8 
YU276689 1 18.6 -14.3 95.8 
YU275300 1 18.5 -15.5 71.2 
YU276836 1 18.5 -32.0 111.8 
YU275609 1 18.5 -15.8 55.7 
YU263612 1 18.5 -10.2 65.7 
YU276568 1 18.4 -11.0 152.2 
YU276712 1 18.4 -0.9 116.9 
YU273533 1 18.3 -114.7 51.2 
YU273745 1 18.3 -13.7 70.1 
YU275623 1 18.3 -18.2 38.7 
YU272308 1 18.3 -39.8 45.1 
 
324 
YU276688 1 18.3 -9.1 95.1 
YU276746 1 18.1 -17.8 79.2 
YU260673 1 18.1 3.6 57.8 
YU268759 1 17.9 -44.5 67.1 
YU276740 1 17.8 -11.8 106.0 
YU268672 1 17.8 -33.0 54.1 
YU278492 1 17.8 -9.9 57.3 
YU269499 1 17.8 -46.7 44.5 
YU274537 1 17.7 -31.6 111.9 
YU256863 1 17.7 -216.2 65.3 
YU271635 1 17.4 -38.1 58.8 
YU259866 1 17.3 -16.6 110.9 
YU274162 1 17.3 -20.1 59.9 
YU279413 1 17.2 -23.4 102.2 
YU259962 1 17.1 -9.7 85.1 
YU278301 1 17.1 -16.1 92.2 
YU275406 1 17.1 -17.9 82.3 
YU275611 1 17.0 -20.1 53.2 
YU275294 1 17.0 -10.5 102.8 
YU261389 1 16.9 -27.9 83.0 
YU276885 1 16.8 -11.0 120.5 
YU265558 ≥5 -4.2 347.2 51.2 
YU265327 ≥5 -3.5 319.8 86.2 
 
325 
YU265551 ≥5 -3.1 315.9 55.9 
YU258014 ≥5 0.3 302.1 30.8 
YU265571 ≥5 -4.7 297.5 64.2 
YU265323 ≥5 -1.5 264.8 108.5 
YU258011 ≥5 -2.2 259.1 28.1 
YU265585 ≥5 -2.0 254.2 93.9 
YU265315 ≥5 0.9 250.4 77.7 
YU265601 ≥5 -6.1 243.1 86.7 
YU265296 ≥5 -4.2 240.8 122.7 
YU258019 ≥5 -6.2 240.7 24.3 
YU258017 ≥5 -4.6 236.2 39.4 
YU265799 ≥5 -0.7 228.0 133.0 
YU266442 ≥5 -0.3 225.3 155.0 
YU265306 ≥5 1.1 218.5 60.7 
YU258013 ≥5 -1.0 217.8 39.0 
YU265301 ≥5 2.2 210.2 98.7 
YU258012 ≥5 -4.7 208.9 39.8 
YU265307 ≥5 -3.2 208.6 42.4 
YU265319 ≥5 -3.9 188.2 88.9 
YU265310 ≥5 -8.4 178.8 85.6 
YU265595 ≥5 -0.2 174.5 88.0 
YU265311 ≥5 -2.9 161.9 83.3 
YU265579 ≥5 -0.9 156.3 74.6 
 
326 
YU265560 ≥5 -11.6 153.2 66.8 
YU265484 ≥5 1.0 152.0 120.9 
YU265332 ≥5 2.7 150.2 116.3 
YU280559 ≥5 -0.2 148.2 103.8 
YU265475 ≥5 3.2 146.5 115.2 
YU265473 ≥5 0.7 142.6 132.6 











The 185 high confidence compounds that regulate nucleolar number from both the 
FDA-approved drug screen and screen of synthetic, drug-like compounds. Drug 
name or unique compound ID, the designated phenotype in initial screen (one nucleolus 
per nucleus or ≥5 nucleoli per nucleus), percent effect for each phenotype relative to 
DMSO, and the mean percent viability relative to DMSO are shown. The designated 









1 nucleolus per 
nucleus PE 
(Rep1, Rep2) 










≥5 -17.4, 1.3 150.3, 97 17.9 1 
Actosin 
(bucladesine) 
≥5 -10.9, -5 124.5, 100.9 43.0 2 
Tegafur ≥5 -12.5, -8.4 61.6, 98.1 51.3 2 
Docetaxel ≥5 4.2, -1.4 116.4, -8.6 59.9 2 
Ouabain 1 54.4, 1.5 -53.7, 7.2 55.4 2 
Mitomycin C 1 40.7, -4.4 -55.4, 26.4 62.4 2 
Gemcitabine 1 21.6, 3.8 -11.4, 3.7 57.8 2 
Clofarabine 1 30.5, 22.9 -23, 16.7 14.7 2 
Taxol ≥5 37.5, 7.9 54.1, -26.2 56.3 2 
Mutamycin 
(mitomycin) 
1 49.5, 107.9 -60.4, -97.8 11.6 2 
Edoxudine 1 47.7, 47.7 13.3, -12.1 22.6 2 
Vepesid (etoposide) ≥5 -13.1, 0.4 53.2, 89.2 32.4 2 
Riboprine 1 22.5, 60.5 -22.6, -64.7 17.2 2 
Lasalocid 1 46.6, 53.4 -64.4, -96 28.2 2 
Vinorelbine 1 27.6, 50.4 -48.1, -91.8 25.8 3 
Octopirox (piroctone 
olamine) 





1 64.7, 86.4 -64.1, -92.4 22.2 3 
BI-2536 1 -8.8, 14.8 44.8, -35.8 12.4 3 
Ciclopirox 1 53.2, 95.2 -66.2, -96.9 19.7 3 
Piroctone 1 60.3, 98.9 -58, -78.7 24.0 3 
BI-831266 ≥5 8.4, 22.5 334, 180.9 30.4 3 
YU256773 1 22.8, 45.8 82.7, 34.9 12.9 3 
YU256863 1 18, 8.9 -38.7, -128.9 61.3 3 
YU257337 1 71.4, 96.9 -63, -175.4 21.7 3 
YU257828 1 1.5, 67.3 2.6, -153.7 53.1 3 
YU257875 1 0.6, 44.9 4.7, -129.4 76.7 3 
YU257883 1 36.4, 57.8 -43.5, -115.1 21.2 3 
YU258006 1 -5.1, 104.8 -3.8, -170.9 70.1 3 
YU258712 1 52.8, 68 -47.8, -149.1 20.7 3 
YU258715 1 17.8, 10.5 -39.3, -110.2 46.6 3 
YU258859 1 12.8, 13 -45.5, -111.3 51.1 3 
YU260480 1 9.3, 11.2 -25.5, -92.5 58.3 3 
YU260673 1 8.4, 10.7 -32.9, -100.3 64.2 3 
YU261429 1 10.7, 10.1 -38.3, -100.8 73.0 3 
YU261750 1 14.5, 13.4 -31.2, -119.1 63.0 3 
YU262873 1 30.1, 34.2 -38.6, -115 82.9 3 
YU262883 1 58.8, 74.2 -54, -174.9 31.8 3 
YU263335 1 16.1, 18.4 -31.2, -106.1 43.4 3 
 
330 
YU263845 1 42.2, 113.5 -61.1, -176.2 21.1 3 
YU263912 1 12.3, 13.2 -30, -116.2 48.2 3 
YU264306 1 15.5, 18.1 -26.1, -77.8 84.9 3 
YU265142 1 12.3, 15 -43.8, -113.5 60.9 3 
YU265245 1 62.3, 64.8 -42.4, -129.6 30.6 3 
YU266010 1 20.9, 13.7 -32.9, -116.3 52.4 3 
YU266138 1 2.8, 10.3 -9.8, -21.7 60.5 3 
YU266595 1 16.4, 8.4 -12, -26.5 77.8 3 
YU266868 1 17.4, 20.4 -31.9, -99.1 77.2 3 
YU266926 1 14.9, 6.2 -35.7, -110.5 64.6 3 
YU268257 1 15.3, 4.2 -34.2, -137.8 62.8 3 
YU268641 1 17.1, 30.4 -27.2, -149.3 41.7 3 
YU268672 1 25.7, 16.5 -52.1, -127.4 55.9 3 
YU268679 1 14, 17.9 -36.2, -121.6 62.2 3 
YU268680 1 18.4, 11.4 -43, -108 48.9 3 
YU268831 1 70.3, 107.2 -56.4, -125.1 22.9 3 
YU268869 1 43, 74.7 -56.5, -165.9 30.5 3 
YU268935 1 20, 18.3 -35.4, -70.7 41.5 3 
YU268938 1 15.6, 18.8 -36.8, -78.5 51.1 3 
YU270716 1 55, 64.5 -41.4, -128.8 24.9 3 
YU270744 1 18, 8 -45.1, -132.8 77.8 3 
YU270748 1 17.8, 7.9 -39.4, -123 69.9 3 
YU270751 1 22.3, 9.1 -36.4, -96 84.2 3 
 
331 
YU270819 1 23.9, 66.2 -55.9, -169.6 30.8 3 
YU271407 1 34.3, 26.8 -33.3, -103.9 62.6 3 
YU272087 1 13.6, 13.1 -47.6, -93 64.7 3 
YU272289 1 13.4, 14.3 -36.6, -63.5 63.4 3 
YU272308 1 38.8, 13.5 -46.5, -98.8 39.1 3 
YU273466 1 23.6, 22.2 -42.6, -75.3 56.2 3 
YU273533 1 10.6, 13.7 -20.3, -56 62.6 3 
YU273668 1 -6.7, 18.8 -40.7, -82.8 52.8 3 
YU273758 1 27, 19.6 -32.6, -69 62.4 3 
YU274118 1 17.4, 15.8 -27.6, -68.4 57.0 3 
YU275232 1 19.9, 14.6 -34.8, -60.6 61.8 3 
YU275243 1 13.2, 11.2 -16.4, -53.6 88.0 3 
YU275374 1 8.2, 14.4 -23.2, -91.9 52.6 3 
YU275397 1 14.8, 10.1 -35.9, -73.3 57.3 3 
YU275398 1 13.9, 10.9 -25.4, -63.9 63.1 3 
YU275402 1 7, 15 -28.6, -59.6 75.9 3 
YU275534 1 24.4, 36.8 76.7, 48.4 10.4 3 
YU275602 1 36.1, 15.5 -49.9, -105.8 30.9 3 
YU275603 1 21.5, 46.6 -42.4, -118.2 34.2 3 
YU275607 1 12.6, 22.9 -37.4, -81.3 67.3 3 
YU275610 1 16.3, 17.5 -34.6, -76.2 39.4 3 
YU275612 1 12.3, 12.9 -34.9, -77.4 46.3 3 
YU275618 1 8.9, 16.3 -33.7, -72 62.9 3 
 
332 
YU275624 1 51.2, 105.2 -56.4, -125.2 25.5 3 
YU275632 1 0.7, 12.2 -39.5, -65.4 63.4 3 
YU276576 1 8.4, 20.1 -36.1, -73 58.8 3 
YU276595 1 13.6, 22.7 -33.7, -76 60.8 3 
YU276618 1 18, 9.7 -21.6, -45 65.7 3 
YU276691 1 14.3, 14.4 -29.4, -58.3 50.6 3 
YU276750 1 23.8, 18.4 -35.7, -68.4 62.8 3 
YU277549 1 5.5, 14.7 -31.1, -96.3 47.2 3 
YU277605 1 16.3, 18.5 -23, -66.8 63.0 3 
YU280408 1 18.5, 26.2 -30.3, -80.8 69.4 3 
Monacrin 
(aminacrine) 
≥5 27.8, 5.2 65.1, 243.1 16.9 4 
Zinc omadine 
(pyrithione zinc) 
1 14.3, 15.6 -31.3, 12.5 18.2 5 
YU264477 1 0.5, 17.9 -44.7, -112.9 53.7 5 
YU277406 1 12.2, 19.9 -42.5, -77 43.8 5 
YU277450 1 7.6, 12.3 -35.2, -76.1 75.3 5 
YU280992 1 63, 51.5 -3.3, -73.9 26.5 5 
Albendazole 1 48.7, 52 -29.1, -53.9 15.5 6 
YU256419 1 18.6, 8.9 -32.1, -84.2 64.6 7 
YU266928 1 15.2, 17.9 -34.6, -108.5 61.4 7 
YU268759 1 13.3, 13.5 -35.4, -88.2 77.2 7 
YU269011 1 13, 14.2 -30.4, -91.7 78.0 7 
 
333 
YU269499 1 13.1, 11.9 -34.1, -85.1 33.4 7 
YU270104 1 12.7, 15.2 -29.7, -92.3 68.0 7 
YU270941 1 21.7, 11.3 -36.9, -103.6 72.2 7 
YU275775 1 10.3, 12.5 -39.3, -58.5 78.8 7 
Melphalan ≥5 -20.5, -11.6 243.3, 222.6 27.7 8 
Vorinostat 1 22.8, 0.5 -30, -43.2 17.5 9 
YU263612 1 16.4, 17.3 -39.3, -109.5 63.2 10 
YU265745 1 9.9, 16.3 -37.1, -98.6 60.6 10 
YU273238 1 14.3, 12.1 -33.5, -71.6 58.8 10 
YU273331 1 22.7, 12.8 -29.7, -74.7 49.2 10 
YU275173 1 56.4, 103 -53.6, -117 19.3 10 
YU275974 1 17.9, 16.2 -24.6, -61 59.3 10 
Cicloheximide 
(cycloheximide) 
1 17.8, 42.4 -30, -71.5 22.5 11 
YU268779 1 3.5, 15.3 -29, -73.4 57.2 11 
YU273745 1 14.7, 11.2 -25.2, -52.4 78.0 11 
YU278496 1 9.1, 15.4 -38.2, -60 55.8 11 
Hexachlorophene 1 49.2, 71.9 -50.5, -87 13.1 12 









1 5.4, 130.5 -7.1, -97.8 57.8 14 
YU261190 1 17.4, 16.3 -34.7, -93.3 81.3 15 
YU271333 1 44.1, 64.4 -55.6, -170.9 31.3 15 
YU271635 1 13.2, 18.4 -33.7, -100.6 78.1 15 
YU271638 1 10, 17.2 -43.9, -108.8 69.6 15 
Miripirium 1 62.1, 66.5 -54.1, -88 18.5 16 
Niclofolan 1 17.8, 25 -29.1, -75 56.3 17 
Mycophenolic acid 1 85.3, 111.4 -45.4, -88.1 21.1 18 
Mycophenolic acid 1 80.6, 0.4 -52.1, 8 56.6 18 
Mycophenolate 
mofetil 




1 90.6, 119.1 -64.8, -92.6 22.4 18 
YU276687 1 17.3, 18.6 -30.7, -60 59.1 19 
YU276803 1 22.2, 15.9 -31.5, -66.1 62.2 19 
YU276806 1 16.1, 10.7 -32.3, -72.2 65.8 19 
YU276814 1 23, 19.2 -32.8, -74.3 66.0 19 
YU276816 1 1.8, 9.1 -28, -61.2 63.1 19 
YU276831 1 13.1, 13.1 -34, -68.6 58.2 19 
YU276833 1 18.4, 13.1 -23.3, -53.7 54.0 19 
YU276844 1 13.9, 12 -35, -63.7 51.2 19 
 
335 
YU276846 1 17.7, 11.6 -26.9, -54.6 62.4 19 
YU276852 1 15, 13.8 -31.2, -62.5 51.0 19 
YU276856 1 4.5, 19.1 -32.8, -62.8 68.7 19 
YU276862 1 16.7, 11.7 -28.3, -66.8 63.3 19 
YU276865 1 31.6, 18.4 -38.4, -83.2 50.7 19 
YU276867 1 10.8, 18.7 -34.5, -77.5 68.4 19 
YU276870 1 15.6, 12.2 -46.3, -73.6 58.4 19 
YU276881 1 20, 16.4 -38.6, -74.8 41.7 19 
YU279785 1 18.5, 16.8 -29, -69.3 61.4 19 
YU279789 1 18, 3 -22.8, -54.9 66.0 19 
YU279792 1 11.4, 17.6 -28.3, -66.9 53.9 19 
YU279793 1 7.2, 18.3 -38, -86.4 55.2 19 
YU279797 1 23.7, 12.2 -37.5, -64.4 51.9 19 
YU279798 1 17.6, 2.1 -46.2, -87.1 45.0 19 
YU279799 1 18.8, 13.5 -32.9, -75.5 54.6 19 
YU279801 1 20.7, 12.1 -31.1, -63.4 57.4 19 
YU279802 1 16, 18.9 -34.9, -74.4 55.3 19 
YU279803 1 20.7, 5.1 -36.3, -77.1 57.4 19 
YU279821 1 2.4, 15.9 -16.4, -74.4 58.8 19 
YU279851 1 15.3, 12.8 -31.5, -80.3 60.2 19 
Mitoxantrone 
hydrochloride 





1 90.7, 149.1 -64, -96.3 12.9 20 
YU271832 1 21.4, 19.6 -39.4, -109.6 42.3 21 
YU271833 1 13.3, 18.1 -34.9, -106.7 65.1 21 
Gefitinib 1 53.9, 78.1 -57.5, -88.3 25.8 22 
Methylbenzetho-
nium chloride 
1 45.3, 37.7 -49.5, -92.8 27.5 22 
YU256505 1 27.5, 69.1 -46.3, -163.6 20.4 22 
Istaroxime ≥5 -6.6, -10.1 57.4, 6.8 70.9 23 
YU256254 1 15, 8.7 -50, -119.5 49.8 24 
YU257642 1 34.2, 45.1 -37.1, -133.9 23.7 24 
YU258900 1 44.5, 32.4 -28.2, -119.4 17.7 24 
YU273265 1 19.5, 10.6 -21.8, -58.8 58.0 24 
YU273348 1 21.2, 10.8 -33.6, -58.7 71.7 24 
YU279858 1 21.2, 20 -32.3, -84.7 56.5 24 
Mepacrine 1 63.1, 117.2 -58.5, -97 26.3 25 
Sertindole 1 35.6, 50.2 -56.5, -84.7 29.2 26 
YU263078 1 31.1, 52.8 -54, -156.6 34.7 26 
Cerivastatin 1 48.3, -5 -47.9, 6.6 52.1 29 
Pranidipine 1 70.3, 78.7 -66.6, -97.8 25.0 30 
Alexidine 
hydrochloride 





1 36.7, 84.8 -55.6, -89.1 13.1 32 
Bryamycin 
(thiostrepton) 
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